


**CUMULATIVE
SUPPLEMENT 7
JULY 2016**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2016

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Cumulative Supplement 7

July 2016

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	viii
1.5 Availability of the Edition	ix
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend.....	x
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

36th EDITION

CUMULATIVE SUPPLEMENT 07
July 2016

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 36th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
 Office of Generic Drugs
 7620 Standish Place
 Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
BD RX INC (BD RX)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
CITRON PHARMA LLC (CITRON PHARMA LLC)	CASPER PHARMA LLC (CASPER PHARMA LLC)
PROSAM LABS LLC (PROSAM LABS)	OXFORD PHARMACEUTICALS LLC (OXFORD PHARMS)
HIKMA MAPLE LTD (HIKMA MAPLE)	EUROHEALTH INTERNATIONAL SARL (EUROHLTH INTL SARL)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2015</u>	<u>MAR 2016</u>	<u>JUN 2016</u>	<u>SEP 2016</u>	<u>DEC 2016</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	17151 2664 (15.5%)	17251 2693 (15.6%)	17528 2664 (15.2%)		
MULTISOURCE	14487 (84.5%)	14558 (84.4%)	14864 (84.8%)		
THERAPEUTICALLY EQUIVALENT	14366 (83.8%)	14434 (83.7%)	14731 (84%)		
NOT THERAPEUTICALLY EQUIVALENT	121 (0.7%)	124 (0.7%)	133 (0.8%)		
EXCEPTIONS ¹	73 (0.4%)	73 (0.4%)	73 (0.4%)		
NEW MOLECULAR ENTITIES APPROVED	28	9	20		
NUMBER OF APPLICANTS	1011	1007	1023		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action.

The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL
ACAMPROSATE CALCIUM
AB + GLENMARK GENERICS 333MG A202229 001 Jul 16, 2013 May CRLD

ACETAMINOPHEN

SOLUTION;IV (INFUSION)
ACETAMINOPHEN
AP PADDOCK LLC 1GM/100ML (10MG/ML) A202605 001 Jun 13, 2016 May NEWA
AP SANDOZ INC 1GM/100ML (10MG/ML) A204052 001 Mar 22, 2016 Mar NEWA
OFIRMEV
AP + MALLINCKRODT IP 1GM/100ML (10MG/ML) N022450 001 Nov 02, 2010 Mar CFTG

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
@ INGENUS PHARMS NJ 325MG;50MG;40MG A040864 001 Dec 01, 2008 Jan CAHN
@ SUN PHARM INDS 325MG;50MG;40MG A040601 001 Jul 29, 2005 Jan CAHN
FIORICET
AA ACTAVIS LABS UT INC 325MG;50MG;40MG A088616 001 Nov 09, 1984 May CMFD

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL
FIORICET W/ CODEINE
>A> AB + ACTAVIS LABS UT INC 325MG;50MG;40MG;30MG N020232 001 Jul 30, 1992 Jul CAHN
>D> AB + ALLERGAN SALES LLC 325MG;50MG;40MG;30MG N020232 001 Jul 30, 1992 Jul CAHN
AB + 325MG;50MG;40MG;30MG N020232 001 Jul 30, 1992 Apr CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
>A> @ FRONTIDA BIOPHARM 300MG;60MG A089673 001 Feb 10, 1988 Jul CAHN
>D> @ SUN PHARM INDS 300MG;60MG A089673 001 Feb 10, 1988 Jul CAHN
@ 300MG;60MG A089673 001 Feb 10, 1988 Mar CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL
ZYFREL
AA CYPRESS PHARM INC 325MG/15ML;7.5MG/15ML A090468 001 Apr 14, 2016 Apr NEWA

TABLET;ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN
AA ACTAVIS LABS FL INC 300MG;5MG A206470 001 Jun 02, 2016 May NEWA
AA 300MG;7.5MG A206470 002 Jun 02, 2016 May NEWA
AA 300MG;10MG A206470 003 Jun 02, 2016 May NEWA
@ ALLERGAN SALES LLC 500MG;10MG A040148 002 Feb 14, 1997 Jun CAHN
AA AMNEAL PHARMS NY 325MG;7.5MG A040746 002 May 10, 2016 Apr NEWA
AA LARKEN LABS INC 325MG;5MG A202935 002 Jun 15, 2016 Jun NEWA
AA 325MG;7.5MG A202935 003 Jun 15, 2016 Jun NEWA
AA 325MG;10MG A202935 004 Jun 15, 2016 Jun NEWA
AA PAR PHARM 300MG;5MG A205001 001 Jul 05, 2016 Jun NEWA
AA 300MG;7.5MG A205001 002 Jul 05, 2016 Jun NEWA
AA 300MG;10MG A205001 003 Jul 05, 2016 Jun NEWA
AA RHODES PHARMS 325MG;5MG A202991 001 Apr 12, 2016 Mar NEWA
AA 325MG;7.5MG A202991 002 Apr 12, 2016 Mar NEWA
AA 325MG;10MG A202991 003 Apr 12, 2016 Mar NEWA
AA TRIS PHARMA INC 300MG;5MG A202214 004 Mar 15, 2016 Jun NEWA
AA 300MG;7.5MG A202214 005 Mar 15, 2016 Jun NEWA
AA 300MG;10MG A202214 006 Mar 15, 2016 Jun NEWA

NORCO
AA ALLERGAN SALES LLC 325MG;2.5MG A040148 004 Jul 07, 2014 Jun CAHN
AA + 325MG;5MG A040099 001 Jun 25, 1997 Jun CAHN
AA 325MG;5MG A040148 005 Jul 07, 2014 Jun CAHN
AA + 325MG;7.5MG A040148 003 Sep 12, 2000 Jun CAHN
AA + 325MG;10MG A040148 001 Feb 14, 1997 Jun CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL		OXYCODONE AND ACETAMINOPHEN					
AA	MALLINCKRODT INC	325MG/5ML; 5MG/5ML		A 040680	001	Sep 29, 2006	May CMFD
TABLET; ORAL		OXYCODONE AND ACETAMINOPHEN					
AA	ALVOGEN MALTA	325MG; 5MG		A 202677	003	Mar 08, 2016	Feb NEWA
AA		325MG; 7.5MG		A 202677	001	Jul 26, 2012	Jan CAHN
AA		325MG; 10MG		A 202677	002	Jul 26, 2012	Jan CAHN
AA	AMNEAL PHARMS NY	325MG; 7.5MG		A 040778	002	Jun 27, 2014	Apr NEWA
AA	MAYNE PHARMA INC	325MG; 2.5MG		A 090177	001	Oct 20, 2008	Feb CAHN
AA		325MG; 5MG		A 090177	002	Oct 20, 2008	Feb CAHN
AA		325MG; 7.5MG		A 090177	003	Oct 20, 2008	Feb CAHN
AA		325MG; 10MG		A 090177	004	Oct 20, 2008	Feb CAHN
	@	500MG; 7.5MG		A 090177	005	Oct 20, 2008	Feb CAHN
	@	650MG; 10MG		A 090177	006	Oct 20, 2008	Feb CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL		TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN					
AB	ATLAS PHARMS LLC	325MG; 37.5MG		A 202076	001	Mar 30, 2012	May CAHN

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL		ACETAZOLAMIDE					
AB	NOSTRUM LABS INC	500MG		A 204691	001	Mar 29, 2016	Mar NEWA

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS		ACETYLCYSTEINE					
AP	AUROBINDO PHARMA LTD	6GM/30ML (200MG/ML)		A 207358	001	Feb 29, 2016	Feb NEWA
TABLET, EFFERVESCENT; ORAL		CETYLEV					
	ARBOR PHARMS LLC	500MG		N 207916	001	Jan 29, 2016	Jan NEWA
+		2.5GM		N 207916	002	Jan 29, 2016	Jan NEWA

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL		SEMPREX-D					
+	AUXILIUM PHARMS INC	8MG; 60MG		N 019806	001	Mar 25, 1994	Mar CAHN

ACYCLOVIR

CAPSULE; ORAL		ACYCLOVIR					
	@ RANBAXY	200MG		A 074975	001	Sep 30, 1998	Feb DISC
AB	ZYDUS PHARMS USA INC	200MG		A 204313	001	Mar 25, 2016	Mar NEWA
OINTMENT; TOPICAL		ACYCLOVIR					
AB	FOUGERA PHARMS INC	5%		A 206633	001	May 11, 2016	Apr NEWA
TABLET; BUCCAL		SITAVIG					
+	CIPHER PHARMS US	50MG		N 203791	001	Apr 12, 2013	Jan CAHN
TABLET; ORAL		ACYCLOVIR					
	@ SUN PHARM INDS LTD	400MG		A 074980	001	Sep 30, 1998	Feb DISC
	@	800MG		A 074980	002	Sep 30, 1998	Feb DISC

ACYCLOVIR SODIUM

INJECTABLE; INJECTION		ACYCLOVIR SODIUM					
	@ AMPHASTAR PHARMS INC	EQ 500MG BASE/VIAL		A 074596	002	Apr 22, 1997	Jun CAHN
	@	EQ 1GM BASE/VIAL		A 074596	001	Apr 22, 1997	Jun CAHN
	@ BEDFORD	EQ 500MG BASE/VIAL		A 074596	002	Apr 22, 1997	Feb DISC
	@	EQ 1GM BASE/VIAL		A 074596	001	Apr 22, 1997	Feb DISC
AP	+	EQ 1GM BASE/VIAL		A 074596	001	Apr 22, 1997	Feb CTEC
	@ EUROHLTH INTL SARL	EQ 500MG BASE/VIAL		A 074596	002	Apr 22, 1997	Apr CAHN
	@	EQ 1GM BASE/VIAL		A 074596	001	Apr 22, 1997	Apr CAHN
AP	HIKMA PHARMS LLC	EQ 500MG BASE/VIAL		A 205771	001	Feb 29, 2016	Feb NEWA
+		EQ 1GM BASE/VIAL		A 205771	002	Feb 29, 2016	Feb CRLD
AP		EQ 1GM BASE/VIAL		A 205771	002	Feb 29, 2016	Feb NEWA

ADAPALENE

	GEL; TOPICAL						
	ADAPALENE						
AB	TARO	0.3%		A208322	001	Jun 23, 2016	Jun NEWA

ADENOSINE

	INJECTABLE; INJECTION						
	ADENOSINE						
AP	EUROHLTH INTL SARL	3MG/ML		A076404	001	Jun 16, 2004	Apr CAHN
	SOLUTION; IV (INFUSION)						
	ADENOSCAN						
	@ ASTELLAS	60MG/20ML (3MG/ML)		N020059	001	May 18, 1995	Apr DISC
	@	90MG/30ML (3MG/ML)		N020059	002	May 18, 1995	Apr DISC
	ADENOSINE						
AP	+ TEVA PHARMS USA	60MG/20ML (3MG/ML)		A077425	001	Aug 29, 2013	Apr CRLD
AP	+	90MG/30ML (3MG/ML)		A077425	002	Aug 29, 2013	Apr CRLD

ALBUTEROL SULFATE

	SOLUTION; INHALATION						
	ALBUTEROL SULFATE						
	@ HI TECH PHARMA	EQ 0.083% BASE		A075063	001	Feb 09, 1999	Mar DISC
	@ LANDELA PHARM	EQ 0.083% BASE		A077569	001	Apr 04, 2006	Mar DISC
	@ MYLAN SPECLT	EQ 0.083% BASE		A072652	001	Feb 21, 1992	Mar DISC
AN	+ NEPHRON	EQ 0.083% BASE		A074880	001	Sep 17, 1997	Mar CRLD
	@ TEVA PHARMS	EQ 0.083% BASE		A075343	001	Nov 09, 1999	Mar DISC
	@ WATSON LABS INC	EQ 0.083% BASE		A076370	001	Nov 24, 2003	Mar DISC
	TABLET; ORAL						
	ALBUTEROL SULFATE						
AB	SUN PHARM INDS	EQ 2MG BASE		A072637	002	Dec 05, 1989	Mar CAHN
AB		EQ 4MG BASE		A072637	001	Dec 05, 1989	Mar CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

	SOLUTION; INHALATION						
	DUONEB						
	@ MYLAN SPECLT	EQ 0.083% BASE; 0.017%		N020950	001	Mar 21, 2001	Jun DISC

ALENDRONATE SODIUM

	TABLET; ORAL						
	ALENDRONATE SODIUM						
AB	JUBILANT CADISTA	EQ 5MG BASE		A090557	001	Feb 18, 2010	Jun CAHN
AB		EQ 10MG BASE		A090557	002	Feb 18, 2010	Jun CAHN
AB		EQ 35MG BASE		A090557	003	Feb 18, 2010	Jun CAHN
AB		EQ 70MG BASE		A090557	004	Feb 18, 2010	Jun CAHN

ALFUZOSIN HYDROCHLORIDE

	TABLET, EXTENDED RELEASE; ORAL						
	ALFUZOSIN HYDROCHLORIDE						
AB	UNICHEM LABS LTD	10MG		A203192	001	Jan 28, 2016	Jan NEWA

ALLOPURINOL

	TABLET; ORAL						
	ALLOPURINOL						
>A>	AB INDOCO REMEDIES	100MG		A204467	001	Jul 28, 2016	Jul NEWA
>A>	AB	300MG		A204467	002	Jul 28, 2016	Jul NEWA
	AB SUN PHARM INDS	300MG		A071450	001	Jan 09, 1987	Mar CAHN
	ZYLOPRIM						
	AB SEBELA IRELAND LTD	100MG		N016084	001		Jan CAHN
	AB +	300MG		N016084	002		Jan CAHN

ALMOTRIPTAN MALATE

	TABLET; ORAL						
	ALMOTRIPTAN MALATE						
AB	AJANTA PHARMA LTD	EQ 6.25MG BASE		A205523	001	Mar 03, 2016	Feb NEWA
AB		EQ 12.5MG BASE		A205523	002	Mar 03, 2016	Feb NEWA

ALOSETRON HYDROCHLORIDETABLET; ORAL
LOTRONEX

AB	SEBELA IRELAND LTD	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Feb	CAHN
AB	+	EQ 1MG BASE	N021107	001	Feb 09, 2000	Feb	CAHN

ALPRAZOLAMTABLET, EXTENDED RELEASE; ORAL
ALPRAZOLAM

@	ACTAVIS LABS FL INC	0.5MG	A077198	001	May 13, 2010	Jan	DISC
@		1MG	A077198	002	May 13, 2010	Jan	DISC
@		2MG	A077198	003	May 13, 2010	Jan	DISC
@		3MG	A077198	004	May 13, 2010	Jan	DISC
@	COREPHARMA	0.5MG	A077996	001	Jan 31, 2007	Mar	DISC
@		1MG	A077996	002	Jan 31, 2007	Mar	DISC
@		2MG	A077996	003	Jan 31, 2007	Mar	DISC
@		3MG	A077996	004	Jan 31, 2007	Mar	DISC
@	IMPAX LABS	0.5MG	A077968	004	May 24, 2007	Jan	DISC
@		1MG	A077968	003	May 24, 2007	Jan	DISC
@		2MG	A077968	002	May 24, 2007	Jan	DISC
@		3MG	A077968	001	May 24, 2007	Jan	DISC

ALPROSTADILINJECTABLE; INJECTION
EDEX

@	AUXILIUM PHARMS INC	0.005MG/VIAL	N020649	001	Jun 12, 1997	Mar	CAHN
AP		0.01MG/VIAL	N020649	002	Jun 12, 1997	Mar	CAHN
+		0.01MG/VIAL	N020649	005	Jul 30, 1998	Mar	CAHN
AP		0.02MG/VIAL	N020649	003	Jun 12, 1997	Mar	CAHN
+		0.02MG/VIAL	N020649	006	Jul 30, 1998	Mar	CAHN
AP		0.04MG/VIAL	N020649	004	Jun 12, 1997	Mar	CAHN
+		0.04MG/VIAL	N020649	007	Jul 30, 1998	Mar	CAHN

SUPPOSITORY; URETHRAL
MUSE

+	MEDA PHARMS	0.125MG	N020700	001	Nov 19, 1996	Jan	CRLD
+		0.25MG	N020700	002	Nov 19, 1996	Jan	CRLD
+		0.5MG	N020700	003	Nov 19, 1996	Jan	CRLD

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB	BIONPHARMA INC	100MG	A078720	001	May 29, 2008	Jan	CAHN
AB	ZYDUS PHARMS USA INC	100MG	A208278	001	May 31, 2016	May	NEWA

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

AP	+	EMCURE PHARMS LTD	EQ 250MG BASE/ML	A204040	001	Dec 12, 2013	May	CRLD
AP		EUROHLTH INTL SARL	EQ 250MG BASE/ML	A063315	001	Apr 11, 1994	May	CRLD
AP		SAGENT PHARMS	EQ 250MG BASE/ML	A203323	001	May 12, 2016	Apr	NEWA

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	002	Mar 26, 1997	Mar	CMS1
---	-----------------	--	---------	-----	--------------	-----	------

CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	005	Mar 26, 1997	Mar	CMS1
---	-----------------	--	---------	-----	--------------	-----	------

CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 5GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	001	Mar 26, 1997	Mar	CMS1
---	-----------------	---	---------	-----	--------------	-----	------

CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	4.25%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020678	009	Mar 26, 1997	Mar	CMS1
---	-----------------	---	---------	-----	--------------	-----	------

CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	4.25%; 33MG/100ML; 20GM/100ML; 51MG/100ML; 261MG/100ML	N020678	011	Mar 26, 1997	Mar	CMS1
---	-----------------	--	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

	CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER							
	297MG/100ML; 77MG/100ML							
	CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	4.25%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020678	012	Mar 26, 1997			Mar CMS1
	CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	4.25%; 33MG/100ML; 5GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020678	008	Mar 26, 1997			Mar CMS1
	CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	5%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678	016	Mar 26, 1997			Mar CMS1
	CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	5%; 33MG/100ML; 15GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678	017	Mar 26, 1997			Mar CMS1
	CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	5%; 33MG/100ML; 20GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678	018	Mar 26, 1997			Mar CMS1
	CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	5%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678	019	Mar 26, 1997			Mar CMS1
	CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	5%; 33MG/100ML; 35GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678	021	Mar 26, 1997			Mar CMS1

AMINOLEVULINIC ACID HYDROCHLORIDE

GEL; TOPICAL

AMELUZ

+	BIOFRONTERA	10%			N208081	001	May 10, 2016	May NEWA
---	-------------	-----	--	--	---------	-----	--------------	----------

AMINOPHYLLINE

TABLET; ORAL

AMINOPHYLLINE

@ IDT AUSTRALIA LTD

100MG

A085261 003

May CAHN

@

100MG

A085262 002

May CAHN

@

200MG

A085261 002

May CAHN

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	200MG			A204742	001	Jun 03, 2016	May NEWA
----	----------------------	-------	--	--	---------	-----	--------------	----------

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

	@ SUN PHARM INDS INC	10MG			A040816	002	Jun 27, 2008	Mar DISC
	@	10MG			A089399	002	Jul 14, 1987	Mar DISC
AB	@	10MG			A089399	002	Jul 14, 1987	Mar CAHN
	@	25MG			A040816	001	Jun 27, 2008	Mar DISC
	@	25MG			A089399	001	Jul 14, 1987	Mar DISC
AB	@	25MG			A089399	001	Jul 14, 1987	Mar CAHN
	@	50MG			A040816	003	Jun 27, 2008	Mar DISC
	@	50MG			A089399	003	Jul 14, 1987	Mar DISC
AB	@	50MG			A089399	003	Jul 14, 1987	Mar CAHN
	@	75MG			A040816	004	Jun 27, 2008	Mar DISC
	@	75MG			A089399	004	Jul 14, 1987	Mar DISC
AB	@	75MG			A089399	004	Jul 14, 1987	Mar CAHN
	@	100MG			A040816	005	Jun 27, 2008	Mar DISC
	@	100MG			A089399	005	Jul 14, 1987	Mar DISC
AB	@	100MG			A089399	005	Jul 14, 1987	Mar CAHN
	@	150MG			A040816	006	Jun 27, 2008	Mar DISC
	@	150MG			A089399	006	Jul 14, 1987	Mar DISC
AB	@	150MG			A089399	006	Jul 14, 1987	Mar CAHN

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

>A>	@ FRONTIDA BIOPHARM	EQ 12.5MG BASE;5MG	A 070765	001	Dec 10, 1986	Jul CAHN
>A>	@	EQ 25MG BASE;10MG	A 070766	001	Dec 10, 1986	Jul CAHN
>D>	@ SUN PHARM INDS	EQ 12.5MG BASE;5MG	A 070765	001	Dec 10, 1986	Jul CAHN
	@	EQ 12.5MG BASE;5MG	A 070765	001	Dec 10, 1986	Mar CAHN
>D>	@	EQ 25MG BASE;10MG	A 070766	001	Dec 10, 1986	Jul CAHN
	@	EQ 25MG BASE;10MG	A 070766	001	Dec 10, 1986	Mar CAHN

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	@ SUN PHARM INDS	10MG;2MG	A 071077	001	Nov 12, 1986	Mar CAHN
	@	10MG;4MG	A 071078	001	Nov 12, 1986	Mar CAHN
	@	25MG;2MG	A 070297	001	Nov 12, 1986	Mar CAHN
	@	25MG;4MG	A 071079	001	Nov 12, 1986	Mar CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	CHINA RESOURCES	EQ 2.5MG BASE	A 090752	003	May 16, 2016	May NEWA
AB	INVAGEN PHARMS	EQ 2.5MG BASE	A 206367	001	Dec 10, 2015	Feb CAHN
AB		EQ 5MG BASE	A 206367	002	Dec 10, 2015	Feb CAHN
AB		EQ 10MG BASE	A 206367	003	Dec 10, 2015	Feb CAHN
AB	POLYGEN PHARMS	EQ 2.5MG BASE	A 207821	001	Jul 11, 2016	Jun NEWA
AB		EQ 5MG BASE	A 207821	002	Jul 11, 2016	Jun NEWA
AB		EQ 10MG BASE	A 207821	003	Jul 11, 2016	Jun NEWA
	@ SUN PHARM INDS	EQ 2.5MG BASE	A 078081	001	Jan 31, 2008	Mar CAHN
	@	EQ 5MG BASE	A 078081	002	Jan 31, 2008	Mar CAHN
	@	EQ 10MG BASE	A 078081	003	Jan 31, 2008	Mar CAHN

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	AUROBINDO PHARMA LTD	EQ 5MG BASE;160MG	A 206512	001	Apr 22, 2016	Apr NEWA
AB		EQ 5MG BASE;320MG	A 206512	002	Apr 22, 2016	Apr NEWA
AB		EQ 10MG BASE;160MG	A 206512	003	Apr 22, 2016	Apr NEWA
AB		EQ 10MG BASE;320MG	A 206512	004	Apr 22, 2016	Apr NEWA

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	MA GENERAL HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A 207025	001	Feb 03, 2016	Jan NEWA
AP	MIDWEST MEDCL	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A 204457	001	Nov 18, 2015	Jan NEWA

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB	+ PERRIGO NEW YORK	EQ 12% BASE	A 075774	001	May 01, 2002	Apr CRLD
	LAC-HYDRIN					
	@ RANBAXY	EQ 12% BASE	N 020508	001	Aug 29, 1996	Apr DISC
	LOTION; TOPICAL					
	AMMONIUM LACTATE					
AB	+ PERRIGO NEW YORK	EQ 12% BASE	A 075570	001	Jun 23, 2004	Apr CRLD
	LAC-HYDRIN					
	@ RANBAXY	EQ 12% BASE	N 019155	001	Apr 24, 1985	Apr DISC

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

	@ SUN PHARM INDS LTD	250MG	A 065016	001	Apr 08, 1999	Feb DISC
	@	500MG	A 065016	002	Apr 08, 1999	Feb DISC

TABLET; ORAL

AMOXICILLIN

	@ SUN PHARM INDS LTD	500MG	A 065059	001	Nov 24, 2000	Feb DISC
	@	875MG	A 065059	002	Nov 24, 2000	Feb DISC

TABLET, CHEWABLE; ORAL

AMOXICILLIN

	@ SUN PHARM INDS LTD	125MG	A 065021	001	Dec 23, 1999	Feb DISC
	@	250MG	A 065021	002	Dec 23, 1999	Feb DISC

TABLET, EXTENDED RELEASE;ORAL
MOXATAG

+ VERNALIS R AND D LTD 775MG N050813 001 Jan 23, 2008 Jan CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A201090	001	Dec 20, 2011	Feb	CDFR
AB		400MG/5ML;EQ 57MG BASE/5ML	A201090	002	Dec 20, 2011	Feb	CDFR
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A201091	001	Dec 20, 2011	Feb	CDFR
	@ SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Feb	DISC
	@	400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Feb	DISC
	@	600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Feb	DISC

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@ SUN PHARM INDS LTD 875MG;EQ 125MG BASE A065102 001 Sep 17, 2002 Feb DISC

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>D>	AB	SANDOZ	200MG;EQ 28.5MG BASE	A065065	001	Apr 18, 2002	Jul	DISC
>A>		@	200MG;EQ 28.5MG BASE	A065065	001	Apr 18, 2002	Jul	DISC
>D>	AB		400MG;EQ 57MG BASE	A065065	002	Apr 18, 2002	Jul	DISC
>A>		@	400MG;EQ 57MG BASE	A065065	002	Apr 18, 2002	Jul	DISC
		@ SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Feb	DISC
		@	400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003	Feb	DISC
AUGMENTIN '125'								
>D>		DR REDDYS LABS INC	125MG;EQ 31.25MG BASE	N050597	001	Jul 22, 1985	Jul	DISC
>A>		@	125MG;EQ 31.25MG BASE	N050597	001	Jul 22, 1985	Jul	DISC
			125MG;EQ 31.25MG BASE	N050597	001	Jul 22, 1985	Mar	CTEC
AUGMENTIN '250'								
>D>	+	DR REDDYS LABS INC	250MG;EQ 62.5MG BASE	N050597	002	Jul 22, 1985	Jul	DISC
>A>		@	250MG;EQ 62.5MG BASE	N050597	002	Jul 22, 1985	Jul	DISC
		+	250MG;EQ 62.5MG BASE	N050597	002	Jul 22, 1985	Mar	CRLD

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

ADZENYS XR-ODT

NEOS THERAPS

		EQ 3.1MG BASE	N204326	001	Jan 27, 2016	Jan	NEWA
		EQ 6.3MG BASE	N204326	002	Jan 27, 2016	Jan	NEWA
		EQ 9.4MG BASE	N204326	003	Jan 27, 2016	Jan	NEWA
		EQ 12.5MG BASE	N204326	004	Jan 27, 2016	Jan	NEWA
		EQ 15.7MG BASE	N204326	005	Jan 27, 2016	Jan	NEWA
	+	EQ 18.8MG BASE	N204326	006	Jan 27, 2016	May	CRLD
		EQ 18.8MG BASE	N204326	006	Jan 27, 2016	Jan	NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	IMPAX LABS	1.25MG;1.25MG;1.25MG;1.25MG	A076852	001	Feb 16, 2016	Feb	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A076852	002	Feb 16, 2016	Feb	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A076852	003	Feb 16, 2016	Feb	NEWA
AB		5MG;5MG;5MG;5MG	A076852	004	Feb 16, 2016	Feb	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A076852	005	Feb 16, 2016	Feb	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A076852	006	Feb 16, 2016	Feb	NEWA
AB	TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488	001	Apr 29, 2013	Feb	CTNA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A077488	002	Apr 29, 2013	Feb	CTNA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A077488	003	Apr 29, 2013	Feb	CTNA
AB		5MG;5MG;5MG;5MG	A077488	004	Apr 29, 2013	Feb	CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A077488	005	Apr 29, 2013	Feb	CTNA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A077488	006	Apr 29, 2013	Feb	CTNA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A206340	001	Feb 05, 2016	Jan	NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A206340	002	Feb 05, 2016	Jan	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206340	003	Feb 05, 2016	Jan	NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A206340	004	Feb 05, 2016	Jan	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206340	005	Feb 05, 2016	Jan	NEWA
AB		5MG;5MG;5MG;5MG	A206340	006	Feb 05, 2016	Jan	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206340	007	Feb 05, 2016	Jan	NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION
AMPHOTEC

@ ALKOPHARMA USA 50MG/VIAL N050729 001 Nov 22, 1996 Apr DISC
@ 100MG/VIAL N050729 002 Nov 22, 1996 Apr DISC

ARIPIPIRAZOLE

INJECTABLE; INTRAMUSCULAR
ABILIFY

@ OTSUKA 9.75MG/1.3ML (7.5MG/ML) N021866 001 Sep 20, 2006 Jun DISC

SOLUTION; ORAL
ARIPIPIRAZOLE

AA + AMNEAL PHARMS 1MG/ML A203906 001 Aug 14, 2015 Feb CRLD

TABLET; ORAL

ARIPIPIRAZOLE

AB AMNEAL PHARMS 2MG A204838 001 Jun 17, 2016 Jun NEWA

AB 5MG A204838 002 Jun 17, 2016 Jun NEWA

AB 10MG A204838 003 Jun 17, 2016 Jun NEWA

AB 15MG A204838 004 Jun 17, 2016 Jun NEWA

AB 20MG A204838 005 Jun 17, 2016 Jun NEWA

AB 30MG A204838 006 Jun 17, 2016 Jun NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

ABILIFY

@ OTSUKA 10MG N021729 002 Jun 07, 2006 May DISC

@ 15MG N021729 003 Jun 07, 2006 May DISC

ARIPIPIRAZOLE

+ ALEMbic PHARMS LTD 10MG A202102 001 Apr 28, 2015 May CRLD

15MG A202102 002 Apr 28, 2015 May CTEC

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

AB MYLAN PHARMS INC 50MG A200043 001 Jun 01, 2012 Apr CMFD

AB 150MG A200043 002 Jun 01, 2012 Apr CMFD

AB 250MG A200043 003 Jun 01, 2012 Apr CMFD

NUVIGIL

AB CEPHALON 50MG N021875 001 Jun 15, 2007 Apr CTEC

AB 150MG N021875 003 Jun 15, 2007 Apr CTEC

AB + 250MG N021875 004 Jun 15, 2007 Apr CTEC

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 LYOPHILIZED

@ TELIGENT PHARMA INC 100MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15MG/VIAL; 5MCG/VIAL; 0.4MG/VIAL; 40MG/VIAL; 4MG/VIAL; 3.6MG/VIAL; 3MG/VIAL; 1MG/VIAL; 10MG/VIAL N018933 002 Aug 08, 1985 Jan CAHN

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

FOREST LABS LLC EQ 2.5 BASE N022117 003 Mar 12, 2015 Mar NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

@ NOSTRUM LABS INC 325MG; 50MG; 40MG A078149 001 Jun 13, 2007 Jan CAHN

FIORINAL

AA + ALLERGAN SALES LLC 325MG; 50MG; 40MG N017534 005 Apr 16, 1986 Apr CAHN

TABLET; ORAL

FIORINAL

@ ALLERGAN SALES LLC 325MG; 50MG; 40MG N017534 003 Apr 16, 1986 Apr CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

FIORINAL W/CODEINE

AB + ALLERGAN SALES LLC 325MG; 50MG; 40MG; 30MG N019429 003 Oct 26, 1990 Apr CAHN

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB	+	HERITAGE PHARMS INC	325MG;200MG	A 089594	001	Mar 31, 1989	Jun	CRLD
AB		INGENUS PHARMS NJ	325MG;200MG	A 040832	001	Jan 07, 2010	Jan	CAHN
		SOMA COMPOUND						
		@ MEDA PHARMS	325MG;200MG	N 012365	005	Jul 11, 1983	Jun	DISC

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB		INGENUS PHARMS NJ	325MG;200MG;16MG	A 040860	001	Jan 07, 2010	Mar	CMFD
		@	325MG;200MG;16MG	A 040860	001	Jan 07, 2010	Jan	CAHN
AB	+	SANDOZ	325MG;200MG;16MG	A 040118	001	Apr 16, 1996	Mar	CTEC
	+		325MG;200MG;16MG	A 040118	001	Apr 16, 1996	Jan	CRLD
		SOMA COMPOUND W/ CODEINE						
		@ MEDA PHARMS	325MG;200MG;16MG	N 012366	002	Jul 11, 1983	Jan	DISC

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

ASPIRIN AND DIPYRIDAMOLE

		@ AMNEAL PHARMS	25MG;200MG	A 206392	001	Mar 08, 2016	Apr	DISC
AB			25MG;200MG	A 206392	001	Mar 08, 2016	Feb	NEWA

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

		@ SUN PHARM INDS	325MG;4.5MG;0.38MG	A 040260	001	Jul 17, 1998	Mar	CAHN
		@	325MG;4.5MG;0.38MG	A 087794	001	May 26, 1982	Mar	CAHN

ATENOLOL

TABLET; ORAL

ATENOLOL

AB		ALVOGEN MALTA	25MG	A 073646	001	Jul 31, 1992	Jan	CAHN
AB			50MG	A 072303	001	Jul 15, 1988	Jan	CAHN
AB			100MG	A 072304	001	Jul 15, 1988	Jan	CAHN
		TENORMIN						
AB		ALVOGEN MALTA	25MG	N 018240	004	Apr 09, 1990	Jan	CAHN
AB			50MG	N 018240	001		Jan	CAHN
AB	+		100MG	N 018240	002		Jan	CAHN

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

AB		ALVOGEN MALTA	50MG;25MG	A 072301	001	May 31, 1990	Jan	CAHN
AB			100MG;25MG	A 072302	001	May 31, 1990	Jan	CAHN
AB		SUN PHARM INDS	100MG;25MG	A 073582	001	Apr 29, 1993	Mar	CAHN
		TENORETIC 100						
AB	+	ALVOGEN MALTA	100MG;25MG	N 018760	001	Jun 08, 1984	Jan	CAHN
		TENORETIC 50						
AB		ALVOGEN MALTA	50MG;25MG	N 018760	002	Jun 08, 1984	Jan	CAHN

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB		SCIEGEN PHARMS INC	EQ 10MG BASE	A 205519	001	May 19, 2016	May	NEWA
AB			EQ 20MG BASE	A 205519	002	May 19, 2016	May	NEWA
AB			EQ 40MG BASE	A 205519	003	May 19, 2016	May	NEWA
AB			EQ 80MG BASE	A 205519	004	May 19, 2016	May	NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

		@ SUN PHARM INDS	0.025MG;2.5MG	A 085506	001		Mar	CAHN
--	--	------------------	---------------	----------	-----	--	-----	------

<u>AURANOFIN</u>									
CAPSULE;ORAL									
RIDAURA									
	+	SEBELA IRELAND LTD	3MG		N018689	001	May 24, 1985	Jan	CAHN
<u>AXITINIB</u>									
TABLET;ORAL									
INLYTA									
		PF PRISM CV	1MG		N202324	001	Jan 27, 2012	Apr	CAHN
	+		5MG		N202324	002	Jan 27, 2012	Apr	CAHN
<u>AZACITIDINE</u>									
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS									
AZACITIDINE									
AP		MYLAN INSTITUTIONAL	100MG/VIAL		A204949	001	Apr 28, 2016	Apr	NEWA
POWDER;IV (INFUSION), SUBCUTANEOUS									
AZACITIDINE									
		ACTAVIS LLC	100MG/VIAL		N208216	001	Apr 29, 2016	Apr	NEWA
<u>AZATHIOPRINE</u>									
TABLET;ORAL									
IMURAN									
		@ SEBELA IRELAND LTD	25MG		N016324	002		Jan	CAHN
AB	+		50MG		N016324	001		Jan	CAHN
<u>AZATHIOPRINE SODIUM</u>									
INJECTABLE;INJECTION									
IMURAN									
		@ SEBELA IRELAND LTD	EQ 100MG BASE/VIAL		N017391	001		Jan	CAHN
<u>AZILSARTAN KAMEDOXOMIL</u>									
TABLET;ORAL									
EDARBI									
		ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL		N200796	001	Feb 25, 2011	Jan	CAHN
	+		EQ 80MG MEDOXOMIL		N200796	002	Feb 25, 2011	Jan	CAHN
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE</u>									
TABLET;ORAL									
EDARBYCLOL									
		ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL;12.5MG		N202331	001	Dec 20, 2011	Jan	CAHN
	+		EQ 40MG MEDOXOMIL;25MG		N202331	002	Dec 20, 2011	Jan	CAHN
<u>AZITHROMYCIN</u>									
FOR SUSPENSION;ORAL									
AZITHROMYCIN									
BX		LUPIN LTD	EQ 100MG BASE/5ML		A065488	001	May 15, 2015	Apr	CTEC
BX			EQ 200MG BASE/5ML		A065488	002	May 15, 2015	Apr	CTEC
<u>AZTREONAM</u>									
INJECTABLE;INJECTION									
AZTREONAM									
		@ EUROHLTH INTL SARL	1GM/VIAL		A065286	001	Mar 23, 2011	Mar	DISC
		@	2GM/VIAL		A065286	002	Mar 23, 2011	Mar	DISC
<u>BACLOFEN</u>									
INJECTABLE;INTRATHECAL									
BACLOFEN									
AP		SINETTICA SA	0.05MG/ML		A091193	001	May 03, 2016	Apr	NEWA
AP			0.5MG/ML		A091193	002	May 03, 2016	Apr	NEWA
AP			2MG/ML		A091193	003	May 03, 2016	Apr	NEWA
LIORESAL									
AP	+	SAOL THERAPS RES LTD	0.05MG/ML		N020075	003	Nov 07, 1996	May	CAHN
AP	+		0.5MG/ML		N020075	001	Jun 17, 1992	May	CAHN
AP	+		2MG/ML		N020075	002	Jun 17, 1992	May	CAHN
TABLET;ORAL									
BACLOFEN									
AB		NORTHSTAR HLTHCARE	10MG		A078401	002	Sep 18, 2009	Jan	NEWA

BARIUM SULFATEFOR SUSPENSION; ORAL
E-Z-HD

+	BRACCO	334GM/BOTTLE	N208036	001	Jan 11, 2016	Jan	NEWA
SUSPENSION; ORAL READI-CAT 2							
+	BRACCO	2% (9GM/450ML)	N208143	001	Jan 15, 2016	Jan	NEWA
READI-CAT 2 SMOOTHIES							
	BRACCO	2% (9GM/450ML)	N208143	002	Jan 15, 2016	Jan	NEWA

BENZAEPRIIL HYDROCHLORIDE

TABLET; ORAL

BENZAEPRIIL HYDROCHLORIDE

@	ACTAVIS LABS FL INC	5MG	A076267	001	Feb 11, 2004	Jan	DISC
@		10MG	A076267	002	Feb 11, 2004	Jan	DISC
@		20MG	A076267	003	Feb 11, 2004	Jan	DISC
@		40MG	A076267	004	Feb 11, 2004	Jan	DISC

BENZAEPRIIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENZAEPRIIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	ACTAVIS LABS FL INC	5MG; 6.25MG	A076342	001	Feb 11, 2004	Jan	DISC
@		10MG; 12.5MG	A076342	002	Feb 11, 2004	Jan	DISC
@		20MG; 12.5MG	A076342	003	Feb 11, 2004	Jan	DISC
@		20MG; 25MG	A076342	004	Feb 11, 2004	Jan	DISC
@	IVAX SUB TEVA PHARMS	5MG; 6.25MG	A076348	001	Feb 11, 2004	Mar	DISC
@		10MG; 12.5MG	A076348	002	Feb 11, 2004	Mar	DISC
@		20MG; 12.5MG	A076348	003	Feb 11, 2004	Mar	DISC
@		20MG; 25MG	A076348	004	Feb 11, 2004	Mar	DISC
@	SUN PHARM INDS LTD	5MG; 6.25MG	A077483	001	Sep 08, 2005	Mar	DISC
@		10MG; 12.5MG	A077483	002	Sep 08, 2005	Mar	DISC
@		20MG; 12.5MG	A077483	003	Sep 08, 2005	Mar	DISC
@		20MG; 25MG	A077483	004	Sep 08, 2005	Mar	DISC

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP	ACCORD HLTHCARE	25MG/VIAL	A205574	001	May 19, 2016	May	NEWA
AP		100MG/VIAL	A205574	002	May 19, 2016	May	NEWA
AP	GLENMARK PHARMS LTD	25MG/VIAL	A204771	001	Mar 24, 2016	Mar	NEWA
AP		100MG/VIAL	A204771	002	Mar 24, 2016	Mar	NEWA
AP	HOSPIRA INC	25MG/VIAL	A204086	001	May 20, 2016	May	NEWA
AP		100MG/VIAL	A204086	002	May 20, 2016	May	NEWA
AP	INNOPHARMA LICENSING	25MG/VIAL	A205476	001	Mar 24, 2016	Mar	NEWA
AP		100MG/VIAL	A205476	002	Mar 24, 2016	Mar	NEWA
TREANDA							
AP	+ CEPHALON	25MG/VIAL	N022249	002	May 01, 2009	Mar	CFTG
AP	+	100MG/VIAL	N022249	001	Mar 20, 2008	Mar	CFTG

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA	BIONPHARMA INC	100MG	A081297	001	Jan 29, 1993	Jan	CAHN
AA		200MG	A081297	002	Oct 30, 2007	Jan	CAHN

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN PAK

+	CUTANEA	5%; 3%	N050769	001	Nov 27, 2000	Feb	CAHN
---	---------	--------	---------	-----	--------------	-----	------

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

@	IMPAX LABS	50MG	A040845	001	Nov 18, 2008	Mar	DISC
---	------------	------	---------	-----	--------------	-----	------

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

>A>	AA	ASPEN GLOBAL INC	0.5MG	A204713	001	Apr 14, 2015	Jul	CAHN
>A>	AA		1MG	A204713	002	Apr 14, 2015	Jul	CAHN
>A>	AA		2MG	A204713	003	Apr 14, 2015	Jul	CAHN

TABLET;ORAL

BENZTROPINE MESYLATE

>A>	@ FRONTIDA BIOPHARM	2MG	A081265	001	Jan 23, 1992	Jul	CAHN
>D>	@ MUTUAL PHARM	2MG	A081265	001	Jan 23, 1992	Jul	CAHN
>D> AA	NUVO PHARM INC	0.5MG	A204713	001	Apr 14, 2015	Jul	CAHN
>D> AA		1MG	A204713	002	Apr 14, 2015	Jul	CAHN
>D> AA		2MG	A204713	003	Apr 14, 2015	Jul	CAHN

BETAMETHASONE DIPROPIONATE

SPRAY;TOPICAL

SERNIVO

+	PROMIUS PHARMA LLC	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Feb	NEWA
---	--------------------	---------------------	---------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	GLENMARK PHARMS	EQ 0.05% BASE;1%	A202894	001	Oct 30, 2015	Mar	CAHN
----	-----------------	------------------	---------	-----	--------------	-----	------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT	TELIGENT PHARMA INC	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Jan	CAHN
----	---------------------	--------------	---------	-----	--------------	-----	------

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

@ IMPAX LABS

5MG

A040739 001 Nov 01, 2006 Mar DISC

@

10MG

A040741 001 Nov 01, 2006 Mar DISC

@

25MG

A040740 001 Nov 01, 2006 Mar DISC

@

50MG

A040721 004 Nov 01, 2006 Mar DISC

DUVOID

>A> AA	BI-COASTAL PHARMA	10MG	A086262	001		Jul	CAHN
>A> AA		25MG	A086263	001		Jul	CAHN
>A> AA		50MG	A085882	003		Jul	CAHN
>D> AA	WELLSPRING PHARM	10MG	A086262	001		Jul	CAHN
>D> AA		25MG	A086263	001		Jul	CAHN
>D> AA		50MG	A085882	003		Jul	CAHN

BIMATOPROST

SOLUTION/DROPS;TOPICAL

BIMATOPROST

AT	SANDOZ INC	0.03%	A202719	001	Apr 19, 2016	Apr	NEWA
----	------------	-------	---------	-----	--------------	-----	------

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL

HELIDAC

@ SEBELA IRELAND LTD

262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,
N/A,500MG

N050719 001 Aug 15, 1996 Jan CAHN

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

>A>	@ FRONTIDA BIOPHARM	5MG	A075474	001	Oct 25, 2002	Jul	CAHN
>A>	@	10MG	A075474	002	Oct 25, 2002	Jul	CAHN
>D>	@ SUN PHARM INDS	5MG	A075474	001	Oct 25, 2002	Jul	CAHN
	@	5MG	A075474	001	Oct 25, 2002	Mar	CAHN
>D>	@	10MG	A075474	002	Oct 25, 2002	Jul	CAHN
	@	10MG	A075474	002	Oct 25, 2002	Mar	CAHN

BOCEPREVIR

CAPSULE;ORAL

VICTRELIS

@ MERCK SHARP DOHME

200MG

N202258 001 May 13, 2011 Jun DISC

BRIVARACETAM

SOLUTION;INTRAVENOUS

BRIVIACT

+ UBC INC

50MG/5ML (10MG/ML)

N205837 001 Feb 18, 2016 Feb NEWA

+ UCB INC

50MG/5ML (10MG/ML)

N205837 001 May 12, 2016 May CMS1

SOLUTION;ORAL

BRIVIACT

+ UCB INC

10MG/ML

N205838 001 May 12, 2016 May CMS1

	SOLUTION;ORAL						
	BRIVIACT						
	+	10MG/ML		N205838	001	Feb 18, 2016	Feb NEWA
	TABLET;ORAL						
	BRIVIACT						
		UCB INC	10MG	N205836	001	May 12, 2016	May CMS1
			10MG	N205836	001	Feb 18, 2016	Feb NEWA
			25MG	N205836	002	May 12, 2016	May CMS1
			25MG	N205836	002	Feb 18, 2016	Feb NEWA
			50MG	N205836	003	May 12, 2016	May CMS1
			50MG	N205836	003	Feb 18, 2016	Feb NEWA
			75MG	N205836	004	May 12, 2016	May CMS1
			75MG	N205836	004	Feb 18, 2016	Feb NEWA
	+	100MG		N205836	005	May 12, 2016	May CMS1
	+	100MG		N205836	005	Feb 18, 2016	Feb NEWA
	<u>BROMFENAC SODIUM</u>						
	SOLUTION/DROPS;OPHTHALMIC						
	BROMSITE						
>D>	+	INSITE VISION INC	EQ 0.075% ACID	N206911	001	Apr 08, 2016	Jul CAHN
	+		EQ 0.075% ACID	N206911	001	Apr 08, 2016	Apr NEWA
>A>	+	SUN PHARMA GLOBAL	EQ 0.075% ACID	N206911	001	Apr 08, 2016	Jul CAHN
	<u>BROMOCRIPTINE MESYLATE</u>						
	CAPSULE;ORAL						
	BROMOCRIPTINE MESYLATE						
AB	+	MYLAN	EQ 5MG BASE	A077226	001	Apr 04, 2005	Jan CRLD
		PARLODEL					
		@ US PHARMS HOLDINGS I	EQ 5MG BASE	N017962	002	Mar 01, 1982	Jan DISC
	TABLET;ORAL						
	BROMOCRIPTINE MESYLATE						
AB	+	PADDOCK LLC	EQ 2.5MG BASE	A077646	001	Oct 01, 2008	Jan CRLD
AB		SANDOZ INC	EQ 2.5MG BASE	A074631	001	Jan 13, 1998	Feb CAHN
		PARLODEL					
AB		US PHARMS HOLDINGS I	EQ 2.5MG BASE	N017962	001		Apr CMFD
		@	EQ 2.5MG BASE	N017962	001		Jan DISC
	<u>BUDESONIDE</u>						
	CAPSULE;ORAL						
	BUDESONIDE						
AB		ACTAVIS ELIZABETH	3MG	A206623	001	Apr 08, 2016	Mar NEWA
		ENTOCORT EC					
AB	+	ELAN PHARMA INTL LTD	3MG	N021324	001	Oct 02, 2001	Jan CAHN
AB	+	PERRIGO PHARMA INTL	3MG	N021324	001	Oct 02, 2001	May CAHN
	SUSPENSION;INHALATION						
	BUDESONIDE						
AN		APOTEX INC	0.25MG/2ML	A078202	001	Mar 30, 2009	Jun CMFD
AN			0.5MG/2ML	A078202	002	Mar 30, 2009	Jun CMFD
AN		TEVA PHARMS USA	1MG/2ML	A204548	001	Mar 08, 2016	Feb NEWA
	<u>BUMETANIDE</u>						
	INJECTABLE;INJECTION						
	BUMETANIDE						
AP	+	AMPHASTAR PHARMS INC	0.25MG/ML	A074441	001	Jan 27, 1995	Jun CAHN
AP	+	EUROHLTH INTL SARL	0.25MG/ML	A074441	001	Jan 27, 1995	Apr CAHN
	<u>BUPIVACAINE HYDROCHLORIDE</u>						
	INJECTABLE;INJECTION						
	BUPIVACAINE HYDROCHLORIDE						
AP		AUROBINDO PHARMA LTD	0.25%	A207183	001	May 13, 2016	May NEWA
AP			0.5%	A207183	002	May 13, 2016	May NEWA
	INJECTABLE;SPINAL						
	BUPIVACAINE HYDROCHLORIDE						
>A>	AP	CLARIS	0.75%	A207266	001	Jul 25, 2016	Jul NEWA
	<u>BUPRENORPHINE HYDROCHLORIDE</u>						
	IMPLANT;IMPLANTATION						
	PROBUPHINE						
	+	BRAEBURN PHARMS INC	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	Jun CAHN
	+	TITAN PHARMS	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	May NEWA

TABLET;SUBLINGUALBUPRENORPHINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 2MG BASE	A201760	001	Jan 29, 2016	Jan NEWA
AB		EQ 8MG BASE	A201760	002	Jan 29, 2016	Jan NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDETABLET;SUBLINGUALBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

>A>	AB	SUN PHARM INDS LTD	EQ 8MG BASE;EQ 2MG BASE	A201633	002	Aug 05, 2016	Jul NEWA
>A>	AB	SUN PHARM INDS LTD	EQ 2MG BASE;EQ 0.5MG BASE	A201633	001	Aug 05, 2016	Jul NEWA
		ZUBSOLV					
>D>		OREXO AB	EQ 1.4MG BASE;EQ 0.36MG BASE	N204242	001	Jul 03, 2013	Jul CAHN
>D>			EQ 2.9MG BASE;EQ 0.71MG BASE	N204242	005	Jun 04, 2015	Jul CAHN
>D>	+		EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jul CAHN
>D>			EQ 8.6MG BASE;EQ 2.1MG BASE	N204242	003	Dec 11, 2014	Jul CAHN
>D>			EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014	Jul CAHN
>A>		OREXO US INC	EQ 1.4MG BASE;EQ 0.36MG BASE	N204242	001	Jul 03, 2013	Jul CAHN
>A>			EQ 2.9MG BASE;EQ 0.71MG BASE	N204242	005	Jun 04, 2015	Jul CAHN
>A>	+		EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jul CAHN
>A>			EQ 8.6MG BASE;EQ 2.1MG BASE	N204242	003	Dec 11, 2014	Jul CAHN
>A>			EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014	Jul CAHN

BUPROPION HYDROCHLORIDETABLET, EXTENDED RELEASE;ORALBUPROPION HYDROCHLORIDE

AB1	INVAGEN PHARMS	100MG	A206674	001	Feb 09, 2016	Jan NEWA
AB1		150MG	A206674	002	Feb 09, 2016	Jan NEWA
AB1		200MG	A206674	003	Feb 09, 2016	Jan NEWA
AB1	SCIEGEN PHARMS INC	100MG	A205794	001	Mar 01, 2016	Feb NEWA
AB1		150MG	A205794	002	Mar 01, 2016	Feb NEWA
AB1		200MG	A205794	003	Mar 01, 2016	Feb NEWA

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDETABLET, EXTENDED RELEASE;ORALCONTRAVE

+	OREXIGEN	90MG;8MG	N200063	001	Sep 10, 2014	Apr CAHN
---	----------	----------	---------	-----	--------------	----------

BUSPIRONE HYDROCHLORIDETABLET;ORALBUSPIRONE HYDROCHLORIDE

AB	HERITAGE PHARMA	5MG	A204582	001	Sep 18, 2015	Jun CAHN
AB		10MG	A204582	002	Sep 18, 2015	Jun CAHN
AB		15MG	A204582	003	Sep 18, 2015	Jun CAHN
AB		30MG	A204582	004	Sep 18, 2015	Jun CAHN

BUSULFANINJECTABLE;INJECTIONBUSULFAN

AP	LUITPOLD PHARMS INC	6MG/ML	A202259	001	Dec 22, 2015	Mar CAHN
----	---------------------	--------	---------	-----	--------------	----------

BUTOCONAZOLE NITRATECREAM;VAGINALBUTOCONAZOLE NITRATE

@	PERRIGO PHARMA INTL	2%	N019881	001	Feb 07, 1997	Jun CAHN
---	---------------------	----	---------	-----	--------------	----------

BUTORPHANOL TARTRATEINJECTABLE;INJECTIONBUTORPHANOL TARTRATE

@	CLARIS	2MG/ML	A075697	001	Oct 23, 2001	Jan CAHN
AP	EUROHLTH INTL SARL	2MG/ML	A075046	001	Aug 12, 1998	Apr CAHN
AP	EUROHLTH INTL SARL	1MG/ML	A075045	001	Aug 12, 1998	Apr CAHN
AP		2MG/ML	A075045	002	Aug 12, 1998	Apr CAHN

CABERGOLINE

TABLET; ORAL

CABERGOLINE

@ IMPAX LABS INC

0.5MG

A077843 001 Jul 03, 2007 Mar DISC

CABOZANTINIB S-MALATE

TABLET; ORAL

CABOMETYX

EXELIXIS INC

EQ 20MG BASE

N208692 001 Apr 25, 2016 Apr NEWA

EQ 40MG BASE

N208692 002 Apr 25, 2016 Apr NEWA

+

EQ 60MG BASE

N208692 003 Apr 25, 2016 Apr NEWA

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

MIGERGOT

+ HORIZON PHARMA

100MG; 2MG

A086557 001 Oct 04, 1983 Jan CAHN

CALCIFEDIOL

CAPSULE, EXTENDED RELEASE; ORAL

RAYALDEE

+ OPKO IRELAND GLOBAL

0.03MG

N208010 001 Jun 17, 2016 Jun NEWA

CALCIPOTRIENE

CREAM; TOPICAL

CALCIPOTRIENE

AB GLENMARK PHARMS

0.005%

A205772 001 Jun 09, 2015 Mar CAHN

CALCITRIOL

CAPSULE; ORAL

CALCITRIOL

AB BIONPHARMA INC

0.25MCG

A091174 001 May 24, 2013 Jan CAHN

AB

0.5MCG

A091174 002 May 24, 2013 Jan CAHN

INJECTABLE; INJECTION

CALCITRIOL

AKORN

0.001MG/ML

A078066 001 Jan 29, 2008 Feb CTEC

@ ROCKWELL MEDCL

0.001MG/ML

A076206 001 Sep 17, 2003 Feb DISC

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

>A> AB LOTUS PHARM CO LTD

EQ 169MG CALCIUM

A203298 001 Jul 26, 2016 Jul NEWA

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL

25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML

N018379 002

Feb DISC

DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL

25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML

N018379 003

Feb DISC

DELFLX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL

25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML

N018379 007

Jun 24, 1988

Feb DISC

DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL

25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML

N018379 001

Feb DISC

DELFLX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL

25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML

N018379 004

Jul 07, 1982

Feb DISC

DELFLX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL

25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML

N018379 005

Jul 07, 1982

Feb DISC

DELFLX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL

25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML

N018379 008

Jun 24, 1988

Feb DISC

DELFLX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL

25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML

N018379 006

Jul 07, 1982

Feb DISC

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE

25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML

N017512 010

Nov 18, 1985

Feb CTEC

SOLUTION;INTRAPERITONEAL

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	011	Nov 18, 1985	Feb	CTEC
-----------------	---	---------	-----	--------------	-----	------

CANGRELOR

POWDER; IV (INFUSION)

KENGREAL

>A>	+	CHIESI USA INC	50MG/VIAL	N204958	001	Jun 22, 2015	Jul	CAHN
>D>	+	THE MEDICINES CO	50MG/VIAL	N204958	001	Jun 22, 2015	Jul	CAHN

CAPECITABINE

TABLET;ORAL

CAPECITABINE

>A>	AB	ROXANE	150MG	A200483	001	Jul 14, 2016	Jul	NEWA
>A>	AB		500MG	A200483	002	Jul 14, 2016	Jul	NEWA

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

		@ APOTEX	12.5MG	A074737	001	Oct 28, 1998	Mar	DISC
		@	25MG	A074737	002	Oct 28, 1998	Mar	DISC
		@	50MG	A074737	003	Oct 28, 1998	Mar	DISC
		@	100MG	A074737	004	Oct 28, 1998	Mar	DISC
	AB	HIKMA INTL PHARMS	12.5MG	A074505	001	Feb 13, 1996	Jun	CAHN
	AB		25MG	A074505	002	Feb 13, 1996	Jun	CAHN
	AB		50MG	A074505	003	Feb 13, 1996	Jun	CAHN
	AB		100MG	A074505	004	Feb 13, 1996	Jun	CAHN
>D>		@ PRINSTON INC	12.5MG	A074477	001	Feb 13, 1996	Jul	CMFD
>A>	AB		12.5MG	A074477	001	Feb 13, 1996	Jul	CMFD
>D>		@	25MG	A074477	002	Feb 13, 1996	Jul	CMFD
>A>	AB		25MG	A074477	002	Feb 13, 1996	Jul	CMFD
>D>		@	50MG	A074477	003	Feb 13, 1996	Jul	CMFD
>A>	AB		50MG	A074477	003	Feb 13, 1996	Jul	CMFD
>D>		@	100MG	A074477	004	Feb 13, 1996	Jul	CMFD
>A>	AB		100MG	A074477	004	Feb 13, 1996	Jul	CMFD
		@ SANDOZ	12.5MG	A074363	001	Nov 09, 1995	Jan	DISC
		@	25MG	A074363	002	Nov 09, 1995	Jan	DISC
		@	50MG	A074363	003	Nov 09, 1995	Jan	DISC
		@	100MG	A074363	004	Nov 09, 1995	Jan	DISC
		@ STASON	12.5MG	A074677	004	May 30, 1997	Mar	DISC
		@	25MG	A074677	002	May 30, 1997	Mar	DISC
		@	50MG	A074677	001	May 30, 1997	Mar	DISC
		@	100MG	A074677	003	May 30, 1997	Mar	DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB		MYLAN IRELAND LTD	100MG	A076697	001	May 20, 2011	Jan	CAHN
AB			200MG	A076697	002	May 20, 2011	Jan	CAHN
AB			300MG	A076697	003	May 20, 2011	Jan	CAHN

CARBIDOPA

TABLET;ORAL

CARBIDOPA

AB		EDENBRIDGE PHARMS	25MG	A205304	001	Feb 17, 2016	Feb	NEWA
----	--	-------------------	------	---------	-----	--------------	-----	------

CARBIDOPA; LEVODOPA

TABLET;ORAL

CARBIDOPA AND LEVODOPA

		@ IDT AUSTRALIA LTD	10MG;100MG	A073586	001	Jun 29, 1995	May	CAHN
		@	25MG;100MG	A073587	001	Jun 29, 1995	May	CAHN
		@	25MG;250MG	A073620	001	Jun 29, 1995	May	CAHN

CARBINOXAMINE MALEATE

TABLET;ORAL

CARBINOXAMINE MALEATE

		MIKART INC	6MG	A207484	001	May 31, 2016	May	NEWA
--	--	------------	-----	---------	-----	--------------	-----	------

CARBOPLATIN

INJECTABLE; IV (INFUSION)		CARBOPLATIN							
	@ ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A 078732	001	Feb 06, 2012	Apr	DISC		
	@	150MG/15ML (10MG/ML)	A 078732	002	Feb 06, 2012	Apr	DISC		
	@	450MG/45ML (10MG/ML)	A 078732	003	Feb 06, 2012	Apr	DISC		
	@	600MG/60ML (10MG/ML)	A 078732	004	Feb 06, 2012	Apr	DISC		
AP	SANDOZ INC	50MG/5ML (10MG/ML)	A 078280	001	May 08, 2008	Feb	CAHN		
AP		150MG/15ML (10MG/ML)	A 078280	002	May 08, 2008	Feb	CAHN		
AP		450MG/45ML (10MG/ML)	A 078280	003	May 08, 2008	Feb	CAHN		
AP	SANJA PHARMS CO	50MG/5ML (10MG/ML)	A 205487	001	Mar 28, 2016	Mar	NEWA		
AP		150MG/15ML (10MG/ML)	A 205487	002	Mar 28, 2016	Mar	NEWA		
AP		450MG/45ML (10MG/ML)	A 205487	003	Mar 28, 2016	Mar	NEWA		

CARFILZOMIB

POWDER; INTRAVENOUS
KYPROLIS

	ONYX THERAP	30MG/VIAL	N 202714	002	Jun 03, 2016	Jun	NEWA		
+		60MG/VIAL	N 202714	001	Jul 20, 2012	Feb	CAHN		

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

AA	INGENUS PHARMS NJ	350MG	A 040823	001	Oct 22, 2008	Jan	CAHN		
AB	STRIDES PHARMA	250MG	A 205513	001	Nov 12, 2015	May	CAHN		
AA		350MG	A 205513	002	Nov 12, 2015	May	CAHN		

CARVEDILOL

TABLET; ORAL
COREG

AB	SMITHKLINE BEECHAM	3.125MG	N 020297	004	May 29, 1997	May	CAHN		
AB		6.25MG	N 020297	003	Sep 14, 1995	May	CAHN		
AB	+	12.5MG	N 020297	002	Sep 14, 1995	May	CAHN		
AB		25MG	N 020297	001	Sep 14, 1995	May	CAHN		

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL
COREG CR

	SMITHKLINE BEECHAM	10MG	N 022012	001	Oct 20, 2006	May	CAHN		
		20MG	N 022012	002	Oct 20, 2006	May	CAHN		
+		40MG	N 022012	003	Oct 20, 2006	May	CAHN		
		80MG	N 022012	004	Oct 20, 2006	May	CAHN		

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL
CEFADROXIL

	@ SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A 065115	001	Mar 26, 2003	Feb	DISC		
	@	EQ 250MG BASE/5ML	A 065115	002	Mar 26, 2003	Feb	DISC		
	@	EQ 500MG BASE/5ML	A 065115	003	Mar 26, 2003	Feb	DISC		

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A 201654	001	Feb 03, 2016	Jan	NEWA		
----	-------------	------------------	----------	-----	--------------	-----	------	--	--

CEFDITOREN PIVOXIL

TABLET; ORAL
SPECTRACEF

	@ VANSER PHARMA	200MG	N 021222	001	Aug 29, 2001	Apr	DISC		
	@	400MG	N 021222	002	Jul 21, 2008	Apr	DISC		

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

AP	QILU PHARM CO LTD	EQ 500MG BASE/VIAL	A 203704	001	Feb 01, 2016	Jan	NEWA		
AP		EQ 1GM BASE/VIAL	A 203704	002	Feb 01, 2016	Jan	NEWA		
AP		EQ 2GM BASE/VIAL	A 203704	003	Feb 01, 2016	Jan	NEWA		

CEFOTAXIME SODIUM

INJECTABLE; INJECTION		CEFOTAXIME SODIUM					
AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016	Feb	NEWA
AP		EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016	Feb	NEWA
CLAFORAN							
AP	+ US PHARM HOLDINGS	EQ 500MG BASE/VIAL	N050547	001		Jan	CAHN
AP	+	EQ 1GM BASE/VIAL	N050547	002		Jan	CAHN
AP	+	EQ 2GM BASE/VIAL	N050547	003		Jan	CAHN
AP	+	EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Jan	CAHN
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER							
	@ US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Jun	DISC
	@	EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jun	DISC
	+	EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jan	CAHN
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
	@ US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Jan	CAHN
	@	EQ 40MG BASE/ML	N050596	003	May 20, 1985	Jan	CAHN

CEFOTETAN DISODIUM

INJECTABLE; INJECTION		CEFOTAN					
	@ TELIGENT PHARMA INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	Jan	CAHN
AP		EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Feb	CMFD
	@	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Jan	CAHN
	@	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	Jan	CAHN
AP		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Feb	CMFD
	@	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Jan	CAHN
	@	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Jan	CAHN
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER							
	+ B BRAUN	EQ 1GM BASE/VIAL	N065430	001	Aug 09, 2007	Jun	CMS2
	+	EQ 2GM BASE/VIAL	N065430	002	Aug 09, 2007	Jun	CMS2

CEFOXITIN SODIUM

INJECTABLE; INJECTION		CEFOXITIN					
AP	ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011	May	CAHN
AP		EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011	May	CAHN
AP		EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011	May	CAHN

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL		CEFPODOXIME PROXETIL					
	@ SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Feb	DISC
	@	EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Feb	DISC
TABLET; ORAL							
	@ SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Feb	DISC
	@	EQ 200MG BASE	A065083	002	Aug 20, 2003	Feb	DISC

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL		CEDAX					
	@ PERNIX THERAP	EQ 400MG BASE	N050685	002	Dec 20, 1995	Jun	DISC
FOR SUSPENSION; ORAL		CEDAX					
	@ PERNIX THERAP	EQ 90MG BASE/5ML	N050686	001	Dec 20, 1995	Jun	DISC
	@	EQ 180MG BASE/5ML	N050686	002	Dec 20, 1995	Jun	DISC

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION		CEFTRIAXONE					
	@ HOSPIRA INC	EQ 1GM BASE/VIAL	A065231	001	Aug 02, 2005	Apr	DISC
	@	EQ 1GM BASE/VIAL	A202563	001	Aug 20, 2012	Apr	DISC
	@	EQ 2GM BASE/VIAL	A065231	002	Aug 02, 2005	Apr	DISC
	@	EQ 2GM BASE/VIAL	A202563	002	Aug 20, 2012	Apr	DISC
ROCEPHIN							
	@ HOFFMANN LA ROCHE	EQ 500MG BASE/VIAL	A063239	002	Aug 13, 1993	Apr	DISC
	@	EQ 1GM BASE/VIAL	A063239	003	Aug 13, 1993	Apr	DISC

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE							
	@ BEDFORD	EQ	250MG BASE/VIAL	A065465	001	Aug 18, 2008	Jun DISC
	@	EQ	500MG BASE/VIAL	A065465	002	Aug 18, 2008	Jun DISC
	@	EQ	1GM BASE/VIAL	A065465	003	Aug 18, 2008	Jun DISC
	@	EQ	2GM BASE/VIAL	A065465	004	Aug 18, 2008	Jun DISC
AP	QILU PHARM CO LTD	EQ	250MG BASE/VIAL	A203702	001	Jun 29, 2016	Jun NEWA
AP		EQ	500MG BASE/VIAL	A203702	002	Jun 29, 2016	Jun NEWA
AP		EQ	1GM BASE/VIAL	A203702	003	Jun 29, 2016	Jun NEWA
AP		EQ	2GM BASE/VIAL	A203702	004	Jun 29, 2016	Jun NEWA

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL

CEFTIN							
	GLAXOSMITHKLINE	EQ	125MG BASE/5ML	N050672	001	Jun 30, 1994	Feb CTEC
+		EQ	250MG BASE/5ML	N050672	002	Apr 29, 1997	Feb CTEC
CEFUROXIME AXETIL							
	@ SUN PHARM INDS LTD	EQ	125MG BASE/5ML	A065323	001	Feb 05, 2008	Feb DISC
	@	EQ	250MG BASE/5ML	A065323	002	Feb 05, 2008	Feb DISC
TABLET; ORAL							
	CEFUROXIME AXETIL						
	@ SUN PHARM INDS LTD	EQ	125MG BASE	A065118	001	Apr 25, 2003	Feb DISC
	@	EQ	250MG BASE	A065118	002	Apr 25, 2003	Feb DISC
	@	EQ	500MG BASE	A065118	003	Apr 25, 2003	Feb DISC

CEFUROXIME SODIUM

INJECTABLE; INJECTION

ZINACEF							
AP	+ IGI LABS INC	EQ	1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jan CAHN
AP	+ IGI LABS INC	EQ	7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jan CAHN
ZINACEF IN PLASTIC CONTAINER							
	@ IGI LABS INC	EQ	15MG BASE/ML	N050643	001	Apr 28, 1989	Jan CAHN
+		EQ	30MG BASE/ML	N050643	002	Apr 28, 1989	Jan CAHN
INJECTABLE; INTRAMUSCULAR, INTRAVENOUS							
	ZINACEF						
AB	+ IGI LABS INC	EQ	750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jan CAHN

CELECOXIB

CAPSULE; ORAL

CELECOXIB							
AB	AUROBINDO PHARMA LTD	50MG		A206827	001	Feb 01, 2016	Jan NEWA
AB		100MG		A206827	002	Feb 01, 2016	Jan NEWA
AB		200MG		A206827	003	Feb 01, 2016	Jan NEWA
AB		400MG		A206827	004	Feb 01, 2016	Jan NEWA
AB	MACLEODS PHARMS LTD	50MG		A204590	001	Mar 16, 2016	Feb NEWA
AB		100MG		A204590	002	Mar 16, 2016	Feb NEWA
AB		200MG		A204590	003	Mar 16, 2016	Feb NEWA
AB		400MG		A204590	004	Mar 16, 2016	Feb NEWA

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN							
	@ SUN PHARM INDS LTD	EQ	250MG BASE	A065007	001	Sep 16, 1999	Feb DISC
	@	EQ	500MG BASE	A065007	002	Sep 16, 1999	Feb DISC
KEFLEX							
>A>	AB PRAGMA PHARMS LLC	EQ	250MG BASE	N050405	002		Jul CAHN
>A>	@	EQ	333MG BASE	N050405	004	May 12, 2006	Jul CAHN
>A>	AB	EQ	500MG BASE	N050405	003		Jul CAHN
>A>	AB +	EQ	750MG BASE	N050405	005	May 12, 2006	Jul CAHN
>D>	AB SHIONOGI INC	EQ	250MG BASE	N050405	002		Jul CAHN
>D>	@	EQ	333MG BASE	N050405	004	May 12, 2006	Jul CAHN
>D>	AB	EQ	500MG BASE	N050405	003		Jul CAHN
>D>	AB +	EQ	750MG BASE	N050405	005	May 12, 2006	Jul CAHN
FOR SUSPENSION; ORAL							
	KEFLEX						
	@ PRAGMA PHARMS LLC	EQ	100MG BASE/ML	N050406	003		Mar CAHN
	@	EQ	125MG BASE/5ML	N050406	001		Mar CAHN
	@	EQ	250MG BASE/5ML	N050406	002		Mar CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL
 CETIRIZINE HYDROCHLORIDE
 AA NOSTRUM LABS INC 5MG/5ML A090191 001 Nov 12, 2009 Mar CAHN
 @ WOCHKHARDT 5MG/5ML A078757 001 Aug 28, 2009 Apr DISC

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL
 LIBRAX
 >A>
 >A> + VALEANT PHARMS 5MG;2.5MG N012750 001 Jul NEWA

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL
 PERIOGARD
 AT COLGATE-PALMOLIVE CO 0.12% A203212 001 Jan 28, 2016 Jan NEWA

CHLOROQUINE PHOSPHATE

TABLET;ORAL
 CHLOROQUINE PHOSPHATE
 @ IMPAX LABS EQ 150MG BASE A080880 001 Mar DISC
 @ EQ 300MG BASE A040516 001 Aug 29, 2003 Mar DISC

CHLORPHENIRAMINE MALEATE

TABLET;ORAL
 CHLORPHENIRAMINE MALEATE
 @ AUROLIFE PHARMA LLC 4MG A080961 001 Mar CAHN
 @ SUN PHARM INDS 4MG A080700 001 Jun CAHN

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

TABLET, EXTENDED RELEASE;ORAL
 CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE
 @ SPRIASO LLC 8MG;54.3MG N206323 001 Jun 22, 2015 Jun DISC

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL
 HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE
 AA MAYNE PHARMA INC 4MG/5ML;5MG/5ML;60MG/5ML A205657 001 Aug 03, 2015 Feb CAHN

CHLORPROPAMIDE

TABLET;ORAL
 CHLORPROPAMIDE
 @ AUROLIFE PHARMA LLC 100MG A088725 001 Aug 31, 1984 Mar CAHN
 @ 250MG A088726 001 Aug 31, 1984 Mar CAHN

CHLOROTHALIDONE

TABLET;ORAL
 CHLOROTHALIDONE
 AB MYLAN 25MG A086831 002 Jan CTEC
 AB SUN PHARM INDS 25MG A089286 002 Jul 21, 1986 Jan NEWA

CHLORZOXAZONE

TABLET;ORAL
 CHLORZOXAZONE
 @ AUROLIFE PHARMA LLC 250MG A089852 001 May 04, 1988 Feb CAHN
 @ 500MG A089853 001 May 04, 1988 Feb CAHN
 + MIKART 750MG A040861 002 Jun 01, 2010 Apr CRLD
 + MIKART INC 250MG A207483 001 Jun 24, 2016 Jun NEWA
 @ SUN PHARM INDS 500MG A089970 001 Sep 27, 1990 Mar CAHN
 >D> AA WATSON LABS 500MG A089859 001 May 04, 1988 Jul CRLD
 >A> AA + 500MG A089859 001 May 04, 1988 Jul CRLD

CICLESONIDE

AEROSOL, METERED;INHALATION
 ALVESCO
 + TAKEDA GMBH 0.08MG/INH N021658 002 Jan 10, 2008 Jan CRLD

CILASTATIN SODIUM; IMIPENEMPOWDER; INTRAMUSCULAR
PRIMAXIN

@	MERCK	EQ 500MG BASE/VIAL;500MG/VIAL	N050630	001	Dec 14, 1990	May	DISC
---	-------	-------------------------------	---------	-----	--------------	-----	------

CILOSTAZOLTABLET; ORAL
CILOSTAZOL

>A>	@	FRONTIDA BIOPHARM	50MG	A077208	002	Mar 29, 2006	Jul	CAHN
>A>	@		100MG	A077208	001	Mar 29, 2006	Jul	CAHN
>D>	@	SUN PHARM INDS	50MG	A077208	002	Mar 29, 2006	Jul	CAHN
	@		50MG	A077208	002	Mar 29, 2006	Jun	CAHN
>D>	@		100MG	A077208	001	Mar 29, 2006	Jul	CAHN
	@		100MG	A077208	001	Mar 29, 2006	Jun	CAHN
AB	+	TEVA	50MG	A077027	001	Nov 24, 2004	Jun	CRLD
AB	+		100MG	A077027	002	Nov 24, 2004	Jun	CRLD
		PLETAL						
	@	OTSUKA	50MG	N020863	001	Jan 15, 1999	Jun	DISC
	@		100MG	N020863	002	Jan 15, 1999	Jun	DISC

CIPROFLOXACIN HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
CIPROFLOXACIN HYDROCHLORIDE

>D>	AT	IGI LABS INC	EQ 0.3% BASE	A076754	001	Jun 09, 2004	Jul	CAHN
>A>	AT	TELIGENT PHARMA INC	EQ 0.3% BASE	A076754	001	Jun 09, 2004	Jul	CAHN

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

@	IDT AUSTRALIA LTD	EQ 100MG BASE	A075939	001	Mar 03, 2005	May	CAHN
@		EQ 250MG BASE	A075939	002	Jun 09, 2004	May	CAHN
@		EQ 500MG BASE	A075939	003	Jun 09, 2004	May	CAHN
@		EQ 750MG BASE	A075939	004	Jun 09, 2004	May	CAHN

CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

SOLUTION/DROPS; OTIC

OTOVEL

+	LABORATORIOS SALVAT	EQ 0.3% BASE;0.025%	N208251	001	Apr 29, 2016	Apr	NEWA
---	---------------------	---------------------	---------	-----	--------------	-----	------

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

@	ACTAVIS LABS FL INC	212.6MG;EQ 287.5MG BASE	A077417	001	Nov 30, 2010	Jan	DISC
@		425.2MG;EQ 574.9MG BASE	A077809	001	Nov 30, 2010	Jan	DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

@	SUN PHARM INDS	EQ 10MG BASE	A077052	001	Jul 03, 2006	Mar	CAHN
@		EQ 20MG BASE	A077052	002	Jul 03, 2006	Mar	CAHN
@		EQ 40MG BASE	A077052	003	Jul 03, 2006	Mar	CAHN

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

AB		ALLIED PHARMA INC	500MG	A203243	001	Feb 29, 2016	Feb	NEWA	
		@	IDT AUSTRALIA LTD	500MG	A065250	001	Aug 25, 2005	May	CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA		MYLAN PHARMS INC	EQ 75MG BASE/5ML	A203063	001	May 25, 2016	May	NEWA
----	--	------------------	------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLINDESSE

+	PERRIGO PHARMA INTL	EQ 2% BASE	N050793	001	Nov 30, 2004	Jun	CAHN
---	---------------------	------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

AP		EUROHLTH INTL SARL	EQ 150MG BASE/ML	A065206	001	Sep 24, 2004	Apr	CAHN
----	--	--------------------	------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE; TRETINOINGEL;TOPICAL
VELTIN

BX	+	AQUA PHARMS LLC	1.2%;0.025%	N050803	001	Jul 16, 2010	Jan	CAHN
----	---	-----------------	-------------	---------	-----	--------------	-----	------

CLOBETASOL PROPIONATEOINTMENT;TOPICAL
CLOBETASOL PROPIONATE

AB	+	FOUGERA PHARMS	0.05%	A074407	001	Feb 23, 1996	Mar	CRLD
		TEMOVATE						
		@ FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Mar	DISC

CLOMIPRAMINE HYDROCHLORIDECAPSULE;ORAL
ANAFRANIL

AB	+	MALLINCKRODT LLC	25MG	N019906	001	Dec 29, 1989	Jan	CRLD
AB			50MG	N019906	002	Dec 29, 1989	Jan	CRLD

CLONIDINE HYDROCHLORIDETABLET;ORAL
CLONIDINE HYDROCHLORIDE

		@ AUROLIFE PHARMA LLC	0.1MG	A070887	001	Aug 31, 1988	Feb	CAHN
		@	0.2MG	A070886	001	Aug 31, 1988	Feb	CAHN
		@	0.3MG	A071294	001	Aug 31, 1988	Feb	CAHN
>A>	AB	FRONTIDA BIOPHARM	0.1MG	A070925	001	Sep 04, 1987	Jul	CAHN
>A>	AB		0.2MG	A070924	001	Sep 04, 1987	Jul	CAHN
>A>	AB		0.3MG	A070923	001	Sep 04, 1987	Jul	CAHN
>D>	AB	SUN PHARM INDS	0.1MG	A070925	001	Sep 04, 1987	Jul	CAHN
>D>	AB		0.2MG	A070924	001	Sep 04, 1987	Jul	CAHN
>D>	AB		0.3MG	A070923	001	Sep 04, 1987	Jul	CAHN

CLOPIDOGREL BISULFATETABLET;ORAL
CLOPIDOGREL BISULFATE

		@ ACTAVIS TOTOWA	EQ 75MG BASE	A090307	001	May 28, 2013	Jun	DISC
AB		SUN PHARM INDS	EQ 75MG BASE	A078133	001	Jun 10, 2013	Mar	CAHN

CLORAZEPATE DIPOTASSIUMCAPSULE;ORAL
CLORAZEPATE DIPOTASSIUM

		@ AUROLIFE PHARMA LLC	3.75MG	A072219	001	Aug 26, 1988	Apr	CAHN
		@	7.5MG	A072220	001	Aug 26, 1988	Feb	CAHN
		@	15MG	A072112	001	Aug 26, 1988	Feb	CAHN

TABLET;ORAL
CLORAZEPATE DIPOTASSIUM

		@ AUROLIFE PHARMA LLC	3.75MG	A072512	001	May 11, 1990	Mar	CAHN
		@	7.5MG	A072513	001	May 11, 1990	Mar	CAHN
		@	15MG	A072514	001	May 11, 1990	Feb	CAHN
		TRANXENE						
		@ RECORDATI RARE	3.75MG	N017105	006		Jun	DISC

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDESYRUP;ORAL
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA		NOSTRUM LABS INC	10MG/5ML;6.25MG/5ML	A090180	001	Mar 17, 2010	Feb	CAHN
----	--	------------------	---------------------	---------	-----	--------------	-----	------

COLCHICINECAPSULE;ORAL
MITIGARE

	+	HIKMA INTL PHARMS	0.6MG	N204820	001	Sep 26, 2014	Mar	CRLD
--	---	-------------------	-------	---------	-----	--------------	-----	------

COLCHICINE; PROBENECIDTABLET;ORAL
PROBENECID AND COLCHICINE

AB		INGENUS PHARMS NJ	0.5MG;500MG	A040618	001	May 13, 2008	Jan	CAHN
----	--	-------------------	-------------	---------	-----	--------------	-----	------

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDESUSPENSION/DROPS;OTIC
COLY-MYCIN S

+	ENDO PHARMS INC	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML	N050356	001			Feb	CAHN
---	-----------------	---	---------	-----	--	--	-----	------

CORTICOTROPININJECTABLE;INJECTION
PURIFIED CORTROPHIN GEL

@	ANI PHARMS	40 UNITS/ML	N008975	001			Feb	CAHN
@		80 UNITS/ML	N008975	002			Feb	CAHN

CORTICOTROPIN-ZINC HYDROXIDEINJECTABLE;INJECTION
CORTROPHIN-ZINC

@	ANI PHARMS	40 UNITS/ML	N009854	001			Feb	CAHN
---	------------	-------------	---------	-----	--	--	-----	------

CROFELEMERTABLET, DELAYED RELEASE;ORAL
FULYZAQ

+	NAPO PHARMS INC	125MG	N202292	001	Dec 31, 2012		Jun	CAHN
---	-----------------	-------	---------	-----	--------------	--	-----	------

CYANOCOBALAMININJECTABLE;INJECTION
CYANOCOBALAMIN

AP	SOMERSET THERAPS LLC	1MG/ML	A206503	001	Dec 11, 2015		Mar	CAHN
----	----------------------	--------	---------	-----	--------------	--	-----	------

SPRAY, METERED;NASAL
NASCOBAL

+	ENDO PHARMS INC	0.5MG/SPRAY	N021642	001	Jan 31, 2005		Feb	CAHN
---	-----------------	-------------	---------	-----	--------------	--	-----	------

CYCLOBENZAPRINE HYDROCHLORIDETABLET;ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

>A>	AB	FRONTIDA BIOPHARM	5MG	A073541	002	Apr 06, 2006	Jul	CAHN
>A>	AB		10MG	A073541	001	May 23, 1995	Jul	CAHN
>D>	AB	SUN PHARM INDS	5MG	A073541	002	Apr 06, 2006	Jul	CAHN
>D>	AB		10MG	A073541	001	May 23, 1995	Jul	CAHN

CYCLOPHOSPHAMIDEINJECTABLE;INJECTION
CYTOXAN (LYOPHILIZED)

@	BAXTER HLTHCARE	500MG/VIAL	N012142	003			Mar	DISC
@		1GM/VIAL	N012142	004	Aug 30, 1982		Mar	DISC
@		2GM/VIAL	N012142	005	Aug 30, 1982		Mar	DISC

CYPROHEPTADINE HYDROCHLORIDETABLET;ORAL
CYPROHEPTADINE HYDROCHLORIDE

AA	INGENUS PHARMS NJ	4MG	A205087	001	Sep 23, 2015		Jan	CAHN
----	-------------------	-----	---------	-----	--------------	--	-----	------

CYTARABINEINJECTABLE;INJECTION
CYTARABINE

AP	MYLAN PHARMS INC	20MG/ML	A200915	001	Dec 13, 2011		Mar	CAHN
AP		20MG/ML	A200916	001	Dec 13, 2011		Mar	CAHN

DACLATASVIR DIHYDROCHLORIDETABLET;ORAL
DAKLINZA

	BRISTOL-MYERS SQUIBB	EQ 90MG BASE	N206843	003	Apr 13, 2016		Apr	NEWA
--	----------------------	--------------	---------	-----	--------------	--	-----	------

DACTINOMYCININJECTABLE;INJECTION
DACTINOMYCIN

@	EUROHLTH INTL SARL	0.5MG/VIAL	A090304	001	Mar 16, 2010		Feb	DISC
---	--------------------	------------	---------	-----	--------------	--	-----	------

DALBAVANCIN HYDROCHLORIDEPOWDER; IV (INFUSION)
DALVANCE

+ DURATA THERAPS INTL EQ 500MG BASE/VIAL N021883 001 May 23, 2014 Jan CDFR

DANTROLENE SODIUMFOR SUSPENSION; INTRAVENOUS
RYANODEX

+ EAGLE PHARMS 250MG/VIAL N205579 001 Jul 22, 2014 Jun CRLD

INJECTABLE; INJECTION
DANTROLENE SODIUM

AP MYLAN INSTITUTIONAL 20MG/VIAL A205239 001 Feb 18, 2016 Feb NEWA

DAPSONEGEL; TOPICAL
ACZONE

+ ALLERGAN INC 7.5% N207154 001 Feb 24, 2016 Feb NEWA

TABLET; ORAL
DAPSONE

AB ALVOGEN 25MG A205429 001 Jan 07, 2016 Mar CAHN

AB 100MG A205429 002 Jan 07, 2016 Mar CAHN

AB NORTH CREEK PHARMS 25MG A204074 001 May 10, 2016 Apr NEWA

AB 100MG A204074 002 May 10, 2016 Apr NEWA

AB NOSTRUM LABS INC 25MG A203887 001 May 06, 2016 Apr NEWA

AB 100MG A203887 002 May 06, 2016 Apr NEWA

DAPTOMYCINPOWDER; INTRAVENOUS
CUBICIN

AP + CUBIST 500MG/VIAL N021572 002 Sep 12, 2003 Jan CDFR

DAPTOMYCIN

AP CRANE PHARMS LLC 500MG/VIAL A206005 001 Jun 15, 2016 Jun NEWA

AP HOSPIRA INC 500MG/VIAL A202857 001 Sep 12, 2014 Jan CDFR

AP TEVA PARENTERAL 500MG/VIAL A091039 001 Mar 25, 2016 Mar NEWA

POWDER; IV (INFUSION)
CUBICIN

@ CUBIST 250MG/VIAL N021572 001 Sep 12, 2003 Jan CDFR

DARIFENACIN HYDROBROMIDETABLET, EXTENDED RELEASE; ORAL
ENABLEX

AB APIL EQ 7.5MG BASE N021513 001 Dec 22, 2004 Jan CAHN

AB + EQ 15MG BASE N021513 002 Dec 22, 2004 Jan CAHN

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

>A> TABLET, EXTENDED RELEASE; ORAL

>A> VIEKIRA XR

>A> + ABBVIE INC EQ 200MG BASE; 8.33MG; 50MG; 33.33MG N208624 001 Jul 22, 2016 Jul NEWA

DASATINIBTABLET; ORAL
DASATINIB

AB APOTEX INC 20MG A202103 001 Jun 10, 2016 May NEWA

AB 50MG A202103 002 Jun 10, 2016 May NEWA

AB 70MG A202103 003 Jun 10, 2016 May NEWA

AB 100MG A202103 004 Jun 10, 2016 May NEWA

SPRYCEL

AB BRISTOL MYERS SQUIBB 20MG N021986 001 Jun 28, 2006 May CFTG

AB 50MG N021986 002 Jun 28, 2006 May CFTG

AB 70MG N021986 003 Jun 28, 2006 May CFTG

AB + 100MG N021986 004 May 30, 2008 May CFTG

DAUNORUBICIN CITRATEINJECTABLE, LIPOSOMAL; INJECTION
DAUNOXOME

@ GALEN (UK) EQ 2MG BASE/ML N050704 002 Apr 08, 1996 May DISC

DEFERASIROX

TABLET, FOR SUSPENSION;ORAL
DEFERASIROX

AB	ACTAVIS ELIZABETH	125MG	A203560	001	Jan 26, 2016	Jan NEWA
AB		250MG	A203560	002	Jan 26, 2016	Jan NEWA
AB		500MG	A203560	003	Jan 26, 2016	Jan NEWA
	EXJADE					
AB	NOVARTIS	125MG	N021882	001	Nov 02, 2005	Jan CFTG
AB		250MG	N021882	002	Nov 02, 2005	Jan CFTG
AB	+	500MG	N021882	003	Nov 02, 2005	Jan CFTG

DEFIBROTIDE SODIUM

SOLUTION;IV (INFUSION)
DEFITELIO

+	GENTIUM SPA	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016	Mar NEWA
---	-------------	-----------------------	---------	-----	--------------	----------

DEMECLOCYCLINE HYDROCHLORIDE

TABLET;ORAL

DEMECLOCYCLINE HYDROCHLORIDE

@	IMPAX LABS	150MG	A065094	001	Mar 22, 2004	Mar DISC
@		300MG	A065094	002	Mar 22, 2004	Mar DISC

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	10MG	A208105	001	Mar 17, 2016	Mar NEWA
AB		25MG	A208105	002	Mar 17, 2016	Mar NEWA
AB		50MG	A208105	003	Mar 17, 2016	Mar NEWA
AB		75MG	A208105	004	Mar 17, 2016	Mar NEWA
AB		100MG	A208105	005	Mar 17, 2016	Mar NEWA
AB		150MG	A208105	006	Mar 17, 2016	Mar NEWA
AB	HERITAGE PHARMS INC	10MG	A207433	001	May 05, 2016	Jun CAHN
AB		25MG	A207433	002	May 05, 2016	Jun CAHN
AB		50MG	A207433	003	May 05, 2016	Jun CAHN
AB		75MG	A207433	004	May 05, 2016	Jun CAHN
AB		100MG	A207433	005	May 05, 2016	Jun CAHN
AB		150MG	A207433	006	May 05, 2016	Jun CAHN
AB	INDICUS PHARMA	10MG	A207433	001	May 05, 2016	Apr NEWA
AB		25MG	A207433	002	May 05, 2016	Apr NEWA
AB		50MG	A207433	003	May 05, 2016	Apr NEWA
AB		75MG	A207433	004	May 05, 2016	Apr NEWA
AB		100MG	A207433	005	May 05, 2016	Apr NEWA
AB		150MG	A207433	006	May 05, 2016	Apr NEWA
	NORPRAMIN					
AB	US PHARM HOLDINGS	10MG	N014399	007	Feb 11, 1982	Jan CAHN
AB		25MG	N014399	001		Jan CAHN
AB		50MG	N014399	003		Jan CAHN
AB		75MG	N014399	004		Jan CAHN
AB	+	100MG	N014399	005		Jan CAHN
AB		150MG	N014399	006		Jan CAHN

DESLORATADINE

SOLUTION;ORAL

DESLORATADINE

AA	TARO	0.5MG/ML	A202936	001	May 26, 2016	May NEWA
----	------	----------	---------	-----	--------------	----------

DESMOPRESSIN ACETATE

TABLET;ORAL

DESMOPRESSIN ACETATE

@	FERRING	0.1MG	N021795	001	May 08, 2008	Jun DISC
@		0.2MG	N021795	002	May 08, 2008	Jun DISC

DESONIDE

CREAM;TOPICAL

DESONIDE

AB	G AND W LABS INC	0.05%	A074027	001	Sep 28, 1992	Jan CAHN
----	------------------	-------	---------	-----	--------------	----------

DESOXIMETASONE

OINTMENT;TOPICAL

DESOXIMETASONE

AB	NOVEL LABS INC	0.25%	A206792	001	May 10, 2016	Apr	NEWA
AB	PERRIGO ISRAEL	0.25%	A077770	001	Apr 20, 2015	May	CAHN
AB	TELLIGENT PHARMA INC	0.25%	A208101	001	Feb 25, 2016	Feb	NEWA

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

>A>	AB	ACTAVIS LABS FL INC	EQ 25MG BASE	A204065	001	Jul 29, 2016	Jul	NEWA
>A>	AB		EQ 50MG BASE	A204065	002	Jul 29, 2016	Jul	NEWA
>A>	AB		EQ 100MG BASE	A204065	003	Jul 29, 2016	Jul	NEWA
	AB	ROXANE	EQ 50MG BASE	A204082	001	Feb 16, 2016	Feb	NEWA
	AB		EQ 100MG BASE	A204083	001	Feb 16, 2016	Feb	NEWA
		PRISTIQ						
>D>	AB	WYETH PHARMS INC	EQ 25MG BASE	N021992	003	Aug 20, 2014	Jul	CFTG
>A>	AB		EQ 25MG BASE	N021992	003	Aug 20, 2014	Jul	CFTG

DEXAMETHASONE

TABLET;ORAL

DEXAMETHASONE

@	IDT AUSTRALIA LTD	0.75MG	A080399	001			May	CAHN
@	SUN PHARM INDS	0.25MG	A084013	001			Mar	CAHN
@		0.25MG	A084764	001			Mar	CAHN
@		0.5MG	A084084	001			Mar	CAHN
@		0.5MG	A084766	001			Mar	CAHN
@		0.75MG	A084081	001			Mar	CAHN
@		0.75MG	A084765	001			Mar	CAHN
@		1.5MG	A084086	001			Mar	CAHN
@		1.5MG	A084763	001			Mar	CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE

AP	+	FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A040491	001	Apr 11, 2003	Mar	CTNA
----	---	--------------------	----------------------	---------	-----	--------------	-----	------

DEXLANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

DEXILANT SOLUTAB

+	TAKEDA PHARMS USA	30MG	N208056	001	Jan 26, 2016	Jan	NEWA
---	-------------------	------	---------	-----	--------------	-----	------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP		ACCORD HLTHCARE INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204023	001	Feb 09, 2016	Jan	NEWA
AP		AUROBINDO PHARMA LTD	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205867	001	Mar 17, 2016	Mar	NEWA
AP		SANDOZ INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A091465	001	Jun 14, 2016	May	NEWA
		PRECEDEX						
+	HOSPIRA		EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Feb	CRLD

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		SUN PHARM INDS	2.5MG	A201231	001	Sep 24, 2015	Feb	CAHN
AB			5MG	A201231	002	Sep 24, 2015	Feb	CAHN
AB			10MG	A201231	003	Sep 24, 2015	Feb	CAHN

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION

TOTECT

+	CLINIGEN HLTHCARE		EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	Mar	CAHN
---	-------------------	--	--------------------	---------	-----	--------------	-----	------

DEXTROAMPHETAMINE SULFATECAPSULE, EXTENDED RELEASE;ORAL
DEXTROAMPHETAMINE SULFATE

AB	MYLAN PHARMS INC	5MG	A206735	001	Jan 27, 2016	Jan	NEWA
AB		10MG	A206735	002	Jan 27, 2016	Jan	NEWA
AB		15MG	A206735	003	Jan 27, 2016	Jan	NEWA

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA	NESHER PHARMS	5MG	A206588	001	Mar 28, 2016	Mar	NEWA
AA		10MG	A206588	002	Mar 28, 2016	Mar	NEWA
AA	NOVEL LABS INC	5MG	A204330	001	Mar 16, 2016	Feb	NEWA
AA		10MG	A204330	002	Mar 16, 2016	Feb	NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

@ ANI PHARMS	15MG/5ML;6.25MG/5ML	N011265	002	Apr 02, 1984	Feb	CMS1
--------------	---------------------	---------	-----	--------------	-----	------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;31MG/100ML;141MG/100ML;20MG/100ML;12MG/100ML;260MG/100ML	N017484	001		Feb	CMS1
-----------------	--	---------	-----	--	-----	------

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	5GM/100ML;205MG/100ML;100MG/100ML;120MG/100ML;220MG/100ML	N018840	001	Jun 29, 1983	Feb	CMS1
-------------------	---	---------	-----	--------------	-----	------

DIAZEPAM

INJECTABLE;INJECTION

DIAZEPAM

@ EUROHLTH INTL SARL	5MG/ML	A070313	001	Dec 16, 1985	Jan	CAHN
----------------------	--------	---------	-----	--------------	-----	------

SOLUTION;ORAL

DIAZEPAM

AA	LANNETT HOLDINGS INC	5MG/5ML	A206477	001	Jun 24, 2016	Jun	NEWA
AA	+ ROXANE	5MG/5ML	A070928	001	Apr 03, 1987	Jun	CFTG

TABLET;ORAL

DIAZEPAM

DAVA PHARMS INC	2MG	A070228	002	Sep 26, 1985	Jan	NEWA
	5MG	A070228	003	Sep 26, 1985	Jan	NEWA

DICLOFENAC POTASSIUM

CAPSULE;ORAL

DICLOFENAC POTASSIUM

AB	BIONPHARMA INC	25MG	A204648	001	Feb 23, 2016	Feb	NEWA
----	----------------	------	---------	-----	--------------	-----	------

ZIPSOR

AB	+ DEPOMED INC	25MG	N022202	001	Jun 16, 2009	Feb	CFTG
----	---------------	------	---------	-----	--------------	-----	------

FOR SOLUTION;ORAL

CAMBIA

AB	+ DEPOMED INC	50MG	N022165	001	Jun 17, 2009	Apr	CFTG
----	---------------	------	---------	-----	--------------	-----	------

DICLOFENAC POTASSIUM

AB	PAR FORM	50MG	A202964	001	May 02, 2016	Apr	NEWA
----	----------	------	---------	-----	--------------	-----	------

TABLET;ORAL

CATAFLAM

@ NOVARTIS	50MG	N020142	002	Nov 24, 1993	Mar	DISC
------------	------	---------	-----	--------------	-----	------

DICLOFENAC POTASSIUM

AB	+ MYLAN	50MG	A075463	001	Jul 26, 1999	Mar	CRLD
----	---------	------	---------	-----	--------------	-----	------

@ SUN PHARM INDS	50MG	A075470	001	Feb 21, 2002	Jun	CAHN
------------------	------	---------	-----	--------------	-----	------

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

AB	AMNEAL PHARMS	1%	A208077	001	Mar 18, 2016	Mar	NEWA
----	---------------	----	---------	-----	--------------	-----	------

AB	TARO	3%	A206298	001	Apr 28, 2016	Apr	NEWA
----	------	----	---------	-----	--------------	-----	------

VOLTAREN

AB	+ GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007	Mar	CFTG
----	------------------------	----	---------	-----	--------------	-----	------

	SOLUTION;TOPICAL								
	DICLOFENAC SODIUM								
AT	TELIGENT PHARMA INC	1.5%	A202769	001	Jul 08, 2015	May	CAHN		
	SOLUTION/DROPS;OPHTHALMIC								
	DICLOFENAC SODIUM								
AT	RISING PHARMS INC	0.1%	A078553	001	Dec 28, 2007	Jan	CAHN		
	TABLET, EXTENDED RELEASE;ORAL								
	DICLOFENAC SODIUM								
AB	+ ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002	Feb	CRLD		
	VOLTAREN-XR								
	@ NOVARTIS	100MG	N020254	001	Mar 08, 1996	Feb	DISC		
	<u>DICLOFENAC SODIUM; MISOPROSTOL</u>								
	TABLET, DELAYED RELEASE;ORAL								
	DICLOFENAC SODIUM AND MISOPROSTOL								
AB	EXELA PHARMA SCS LLC	50MG;0.2MG	A200540	001	Mar 14, 2014	Mar	CAHN		
AB		75MG;0.2MG	A200540	002	Mar 14, 2014	Mar	CAHN		
	<u>DICYCLOMINE HYDROCHLORIDE</u>								
	CAPSULE;ORAL								
	DICYCLOMINE HYDROCHLORIDE								
	@ SUN PHARM INDS	10MG	A084505	001	Oct 21, 1986	Mar	CAHN		
	INJECTABLE;INJECTION								
	DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)								
AP	EUROHLTH INTL SARL	10MG/ML	A040465	001	Jun 30, 2003	Mar	CMS1		
	SYRUP;ORAL								
	DICYCLOMINE HYDROCHLORIDE								
+	MIKART	10MG/5ML	A040169	001	Mar 24, 2005	Jan	CRLD		
	TABLET;ORAL								
	DICYCLOMINE HYDROCHLORIDE								
	@ SUN PHARM INDS	20MG	A084600	001	Jul 29, 1985	Mar	CAHN		
	<u>DIENOGEST; ESTRADIOL VALERATE</u>								
	TABLET;ORAL								
	ESTRADIOL VALERATE AND DIENOGEST								
AB	WATSON LABS INC	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M	A202349	001	May 06, 2016	Apr	NEWA		
	NATAZIA								
AB	+ BAYER HLTHCARE	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M	N022252	001	May 06, 2010	Apr	CFTG		
	G, N/A								
	<u>DIETHYLPROPION HYDROCHLORIDE</u>								
	TABLET;ORAL								
	DIETHYLPROPION HYDROCHLORIDE								
	@ COREPHARMA	25MG	A040828	001	Nov 05, 2008	Mar	DISC		
	TENUATE								
AA	+ ACTAVIS LABS UT INC	25MG	N011722	002		Apr	CAHN		
AA	+ ALLERGAN SALES LLC	25MG	N011722	002		Mar	CAHN		
	TABLET, EXTENDED RELEASE;ORAL								
	TENUATE DOSPAN								
AB	+ ACTAVIS LABS UT INC	75MG	N012546	001		Apr	CAHN		
AB	+ ALLERGAN SALES LLC	75MG	N012546	001		Mar	CAHN		
	<u>DIFLUNISAL</u>								
	TABLET;ORAL								
	DIFLUNISAL								
	@ IDT AUSTRALIA LTD	500MG	A074604	001	Jun 10, 1996	May	CAHN		
	<u>DIGOXIN</u>								
	INJECTABLE;INJECTION								
	LANOXIN								
AP	+ COVIS PHARMA SARL	0.25MG/ML	N009330	002		Jun	CAHN		
	LANOXIN PEDIATRIC								
+	COVIS PHARMA SARL	0.1MG/ML	N009330	004		Jun	CAHN		
	<u>DIHYDROERGOTAMINE MESYLATE</u>								
	INJECTABLE;INJECTION								
	DIHYDROERGOTAMINE MESYLATE								
AP	EUROHLTH INTL SARL	1MG/ML	A040453	001	Jun 09, 2003	Apr	CAHN		

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILACOR XR

>D>	@	ACTAVIS LABS UT INC	120MG	N020092	001	May 29, 1992	Jul	CAHN
>D>	@		180MG	N020092	002	May 29, 1992	Jul	CAHN
>D>	@		240MG	N020092	003	May 29, 1992	Jul	CAHN
>A>	@	ALLERGAN SALES LLC	120MG	N020092	001	May 29, 1992	Jul	CAHN
>A>	@		180MG	N020092	002	May 29, 1992	Jul	CAHN
>A>	@		240MG	N020092	003	May 29, 1992	Jul	CAHN

DILTIAZEM HYDROCHLORIDE

	@	ACTAVIS LABS FL INC	120MG	A074852	001	Oct 10, 1997	Jan	DISC
	@		180MG	A074852	002	Oct 10, 1997	Jan	DISC
	@		240MG	A074852	003	Oct 10, 1997	Jan	DISC
AB3		VALEANT PHARMS NORTH	120MG	A075116	001	Dec 23, 1999	Jan	CAHN
AB3			180MG	A075116	002	Dec 23, 1999	Jan	CAHN
AB3			240MG	A075116	003	Dec 23, 1999	Jan	CAHN
AB3			300MG	A075116	004	Dec 23, 1999	Jan	CAHN

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

AP	+	AMPHASTAR PHARMS INC	5MG/ML	A074617	001	Feb 28, 1996	Jun	CAHN
AP	+	EUROHLTH INTL SARL	5MG/ML	A074617	001	Feb 28, 1996	Apr	CAHN

DINOPROSTONEINSERT, EXTENDED RELEASE;VAGINAL
CERVIDIL

+	FERRING PHARMS INC	10MG	N020411	001	Mar 30, 1995	Jan	CAHN
---	--------------------	------	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

>A>	@	HIKMA INTL PHARMS	50MG	A083567	001		Jul	CAHN
>D>	@	HIKMA PHARMS	50MG	A083567	001		Jul	CAHN
	@		50MG	A083567	001		Feb	CAHN
	@	SUN PHARM INDS	25MG	A089488	001	Jan 02, 1987	Mar	CAHN
	@		50MG	A089489	001	Jan 02, 1987	Jun	CAHN

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

AP	+	AMPHASTAR PHARMS INC	5MG/ML	A074939	001	Apr 13, 1998	Jun	CAHN
AP	+	EUROHLTH INTL SARL	5MG/ML	A074939	001	Apr 13, 1998	Apr	CAHN

TABLET;ORAL

DIPYRIDAMOLE

	@	IDT AUSTRALIA LTD	25MG	A086944	002	Apr 16, 1991	May	CAHN
	@		50MG	A087562	001	Feb 25, 1992	May	CAHN
	@		75MG	A087561	001	Feb 25, 1992	May	CAHN
>D>	AB	PUREPAC PHARM	25MG	A089425	001	Jul 12, 1990	Jul	DISC
>A>	@		25MG	A089425	001	Jul 12, 1990	Jul	DISC

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

@	AUROLIFE PHARMA LLC	EQ 100MG BASE	A070470	001	Dec 10, 1985	Feb	CAHN
@		EQ 150MG BASE	A070471	001	Dec 10, 1985	Feb	CAHN
@	SUN PHARM INDS	EQ 100MG BASE	A070351	001	Dec 17, 1985	Mar	CAHN
@		EQ 150MG BASE	A070352	001	Dec 17, 1985	Mar	CAHN

DISULFIRAM

TABLET;ORAL

DISULFIRAM

AB		ALVOGEN MALTA	250MG	A091681	001	Aug 08, 2013	Jan	CAHN
----	--	---------------	-------	---------	-----	--------------	-----	------

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

@	IMPAX LABS	EQ 250MG VALPROIC ACID	A078791	001	May 06, 2009	Feb	DISC
@		EQ 500MG VALPROIC ACID	A078791	002	Aug 04, 2009	Feb	DISC

DOBUTAMINE HYDROCHLORIDEINJECTABLE; INJECTION
DOBUTAMINE HYDROCHLORIDE

@ TELIGENT PHARMA INC	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995	Jan CAHN
-----------------------	-------------------	---------	-----	--------------	----------

DOCETAXELINJECTABLE; INJECTION
DOCETAXEL

HOSPIRA INC	20MG/ML (20MG/ML)	N022234	004	Jun 23, 2016	Jun NEWA
	80MG/4ML (20MG/ML)	N022234	005	Jun 23, 2016	Jun NEWA
	120MG/6ML (20MG/ML)	N022234	006	Jun 23, 2016	Jun NEWA

SOLUTION; IV (INFUSION)
DOCETAXEL

EAGLE PHARMS	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Jan CAHN
	80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Jan CAHN
	160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Jan CAHN

DOFETILIDECAPSULE; ORAL
DOFETILIDE

AB	TIGER PHARMS LLC	0.125MG	A207058	001	Jun 06, 2016	May NEWA
AB		0.25MG	A207058	002	Jun 06, 2016	May NEWA
AB		0.5MG	A207058	003	Jun 06, 2016	May NEWA
	TIKOSYN					
AB	PFIZER	0.125MG	N020931	001	Oct 01, 1999	May CFTG
AB		0.25MG	N020931	002	Oct 01, 1999	May CFTG
AB	+	0.5MG	N020931	003	Oct 01, 1999	May CFTG

DOLASETRON MESYLATEINJECTABLE; INJECTION
ANZEMET

+	US PHARM HOLDINGS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997	Jan CAHN
+		12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997	Jan CAHN
+		100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997	Jan CAHN
	@	500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001	Jun DISC
+		500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001	Jan CAHN

TABLET; ORAL
ANZEMET

	US PHARM HOLDINGS	50MG	N020623	001	Sep 11, 1997	Jan CAHN
+		100MG	N020623	002	Sep 11, 1997	Jan CAHN

DOLUTEGRAVIR SODIUMTABLET; ORAL
TIVICAY

	VIIV HLTHCARE	EQ 10MG BASE	N204790	002	Jun 09, 2016	Jun NEWA
		EQ 25MG BASE	N204790	003	Jun 09, 2016	Jun NEWA

DONEPEZIL HYDROCHLORIDETABLET; ORAL
DONEPEZIL HYDROCHLORIDE

AB	DEXCEL PHARMA	23MG	A203713	001	Feb 19, 2016	Feb NEWA
AB	INDICUS PHARMA	23MG	A203419	001	Apr 12, 2016	Mar NEWA
AB	OSMOTICA PHARM CORP	23MG	A203114	001	Jan 26, 2016	Jan NEWA
AB	OSMOTICA PHARM US	23MG	A203114	001	Jan 26, 2016	Jun CAHN
AB	UNICHEM LABS LTD	5MG	A203656	001	Jun 23, 2016	Jun NEWA
AB		10MG	A203656	002	Jun 23, 2016	Jun NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
DONEPEZIL HYDROCHLORIDE

@	SUN PHARM INDS	5MG	A077975	002	Dec 11, 2009	Mar CAHN
@		10MG	A077975	001	Dec 11, 2009	Mar CAHN

DOXAPRAM HYDROCHLORIDEINJECTABLE; INJECTION
DOXAPRAM HYDROCHLORIDE

AP	AMPHASTAR PHARMS INC	20MG/ML	A076266	001	Jan 10, 2003	Jun CAHN
AP	EUROHLTH INTL SARL	20MG/ML	A076266	001	Jan 10, 2003	Apr CAHN

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

@	IDT AUSTRALIA LTD	EQ 1MG BASE	A 075432	001	Oct 18, 2000	Mar	CAHN
@		EQ 2MG BASE	A 075432	002	Oct 18, 2000	Mar	CAHN
@		EQ 4MG BASE	A 075432	003	Oct 18, 2000	Mar	CAHN
@		EQ 8MG BASE	A 075432	004	Oct 18, 2000	Mar	CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

@	SUN PHARM INDS	EQ 25MG BASE	A 071502	001	Feb 18, 1988	Mar	CAHN
@		EQ 50MG BASE	A 071653	001	Feb 18, 1988	Mar	CAHN
@		EQ 75MG BASE	A 071654	001	Feb 18, 1988	Mar	CAHN
@		EQ 100MG BASE	A 071521	001	Feb 18, 1988	Mar	CAHN

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 3MG BASE	A 202337	001	Jan 20, 2016	Jan	NEWA
AB		EQ 6MG BASE	A 202337	002	Jan 20, 2016	Jan	NEWA

DOXERCALCIFEROL

INJECTABLE; INJECTION

DOXERCALCIFEROL

AP	AKORN INC	2MCG/ML (2MCG/ML)	A 203929	002	Mar 28, 2016	Mar	NEWA
	HECTOROL						
AP	GENZYME CORP	2MCG/ML (2MCG/ML)	N 021027	002	Apr 06, 2000	Mar	CFTG

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	ACTAVIS INC	2MG/ML	A 203622	001	Jun 27, 2014	May	CRLD
AP		200MG/100ML	A 203622	002	Jun 27, 2014	May	CRLD
AP	+ PHARMACIA AND UPJOHN	2MG/ML	N 050629	001	Dec 23, 1987	May	CRLD
AP	+	200MG/100ML	N 050629	002	May 03, 1988	May	CRLD

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	G AND W LABS INC	EQ 50MG BASE	A 204446	001	May 28, 2015	Mar	CAHN
AB		EQ 75MG BASE	A 204446	002	May 28, 2015	Mar	CAHN
AB		EQ 100MG BASE	A 204446	003	May 28, 2015	Mar	CAHN
AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A 205115	001	Feb 18, 2016	Feb	NEWA
AB		EQ 75MG BASE	A 205115	002	Feb 18, 2016	Feb	NEWA
AB		EQ 100MG BASE	A 205115	003	Feb 18, 2016	Feb	NEWA

TABLET; ORAL

DOXYCYCLINE

@	SUN PHARM INDS	EQ 50MG BASE	A 065471	001	Apr 17, 2009	Jun	CAHN
@		EQ 75MG BASE	A 065471	002	Apr 17, 2009	Jun	CAHN
@		EQ 100MG BASE	A 065471	003	Apr 17, 2009	Jun	CAHN

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

ACTICLATE CAP

+	AQUA PHARMS	EQ 75MG BASE	N 208253	001	Apr 26, 2016	Apr	NEWA
---	-------------	--------------	----------	-----	--------------	-----	------

DOXYCYCLINE HYCLATE

AB	AMNEAL PHARMS	EQ 100MG BASE	A 207289	001	Jun 27, 2016	Jun	NEWA
AB	SUN PHARM INDS	EQ 100MG BASE	A 062676	001	Jul 10, 1986	Mar	CAHN

TABLET; ORAL

DOXYCYCLINE HYCLATE

@	COREPHARMA	EQ 20MG BASE	A 065182	001	May 13, 2005	Mar	DISC
AB	SUN PHARM INDS	EQ 20MG BASE	A 065134	001	May 13, 2005	Mar	CAHN
AB		EQ 100MG BASE	A 062677	001	Jul 10, 1986	Mar	CAHN
@	VINTAGE PHARMS	EQ 100MG BASE	A 062538	001	Apr 07, 1986	Mar	DISC

TABLET, DELAYED RELEASE; ORAL

DORYX

>A>								
>A>	AB	MAYNE PHARMA	EQ 50MG BASE	N 050795	006	Dec 19, 2014	Jul	CTNA
>D>			EQ 60MG BASE	N 050795	007	May 20, 2016	Jul	CTNA
			EQ 60MG BASE	N 050795	007	May 20, 2016	May	NEWA
	AB		EQ 80MG BASE	N 050795	004	Apr 11, 2013	Apr	CFTG
>D>			EQ 120MG BASE	N 050795	008	May 20, 2016	Jul	CTNA
			EQ 120MG BASE	N 050795	008	May 20, 2016	May	NEWA

TABLET, DELAYED RELEASE;ORAL
DORYX

AB	+	EQ 200MG BASE	N050795	005	Apr 11, 2013	May	CFTG
>A>		DORYX MPC					
>A>		MAYNE PHARMA	EQ 60MG BASE	N050795	007	May 20, 2016	Jul CTNA
>A>			EQ 120MG BASE	N050795	008	May 20, 2016	Jul CTNA
>D>		DOXTERIC					
>D>	AB	MAYNE PHARMA	EQ 50MG BASE	N050795	006	Dec 19, 2014	Jul CTNA
	AB		EQ 50MG BASE	N050795	006	Dec 19, 2014	May CFTG
		DOXYCYCLINE HYCLATE					
		@ IMPAX LABS INC	EQ 75MG BASE	A090505	001	Dec 28, 2010	Mar DISC
		@	EQ 100MG BASE	A090505	002	Dec 28, 2010	Mar DISC
	AB	MYLAN	EQ 50MG BASE	A090431	003	May 23, 2016	May NEWA
	AB		EQ 80MG BASE	A090431	004	Apr 29, 2016	Apr NEWA
	AB		EQ 200MG BASE	A090431	005	May 19, 2016	May NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL
MELAMISA

AB		NOVAST LABS LTD	3MG;0.02MG	A202016	001	Jan 26, 2016	Jan NEWA
		TABLET;ORAL-28					
		DROSPIRENONE AND ETHINYL ESTRADIOL					
AB		GLENMARK PHARMS LTD	3MG;0.03MG	A204848	001	Mar 25, 2016	Mar NEWA

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL
DULOXETINE HYDROCHLORIDE

>A>	AB	HETERO LABS LTD III	EQ 20MG BASE	A204343	001	Aug 03, 2016	Jul NEWA
>A>	AB		EQ 30MG BASE	A204343	002	Aug 03, 2016	Jul NEWA
>A>	AB		EQ 60MG BASE	A204343	003	Aug 03, 2016	Jul NEWA

DUTASTERIDE

CAPSULE;ORAL
DUTASTERIDE

AB		AUROLIFE PHARMA LLC	0.5MG	A202660	001	Nov 20, 2015	Apr CAHN
AB		BIONPHARMA INC	0.5MG	A200899	001	Nov 20, 2015	Jan CAHN
AB		INTERGEL PHARMS INC	0.5MG	A206373	001	Mar 17, 2016	Feb NEWA
AB		MYLAN PHARMS INC	0.5MG	A203241	001	Jun 14, 2016	May NEWA
AB		STRIDES PHARMA	0.5MG	A204262	001	Nov 20, 2015	Mar CAHN

DYPHYLLINE

TABLET;ORAL
LUFYLLIN

		@ MEDA PHARMS	200MG	A084566	001		Jun DISC
		@	400MG	A084566	002		Jun DISC

ECONAZOLE NITRATE

AEROSOL, FOAM;TOPICAL
ECOZA

>A>	+	EXELTIS SUISSE	1%	N205175	001	Oct 24, 2013	Jul CAHN
>D>	+	VELDANA MEDICAL SA	1%	N205175	001	Oct 24, 2013	Jul CAHN
		CREAM;TOPICAL					
		ECONAZOLE NITRATE					
AB		TELIGENT PHARMA INC	1%	A076574	001	Dec 17, 2004	May CAHN
		SPECTAZOLE					
>A>		@ ALVOGEN MALTA	1%	N018751	001	Dec 23, 1982	Jul CAHN
>D>		@ MERZ PHARMS LLC	1%	N018751	001	Dec 23, 1982	Jul CAHN

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION
TENSILON

		@ TELIGENT PHARMA INC	10MG/ML	N007959	001		Jan CAHN
		TENSILON PRESERVATIVE FREE					
		@ TELIGENT PHARMA INC	10MG/ML	N007959	002		Jan CAHN

EFAVIRENZ

TABLET;ORAL
EFAVIRENZ

AB		MYLAN LABS LTD	600MG	A091471	001	Feb 17, 2016	Feb NEWA
AB		MYLAN PHARMS INC	600MG	A091471	001	Feb 17, 2016	Jun CAHN

	TABLET;ORAL								
	SUSTIVA								
AB	+	BRISTOL MYERS SQUIBB	600MG	N021360	002	Feb 01, 2002	Feb	CFTG	
	<u>ELBASVIR; GRAZOPREVIR</u>								
	TABLET;ORAL								
	ZEPATIER								
	+	MERCK SHARP DOHME	50MG;100MG	N208261	001	Jan 28, 2016	Jan	NEWA	
	<u>ELUXADOLINE</u>								
	TABLET;ORAL								
	VIBERZI								
		ALLERGAN HOLDINGS	75MG	N206940	001	May 27, 2015	May	CAHN	
	+		100MG	N206940	002	May 27, 2015	May	CAHN	
	<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE</u>								
	TABLET;ORAL								
	ODEFSEY								
	+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016	Apr	CAIN	
	<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE</u>								
	TABLET;ORAL								
	ODEFSEY								
	+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016	Mar	NEWA	
	<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE</u>								
	TABLET;ORAL								
	DESCOVY								
	+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE	N208215	001	Apr 04, 2016	Apr	NEWA	
	<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE</u>								
	TABLET;ORAL								
	TRUVADA								
		GILEAD	100MG;150MG	N021752	002	Mar 10, 2016	Mar	NEWA	
			133MG;200MG	N021752	003	Mar 10, 2016	Mar	NEWA	
			167MG;250MG	N021752	004	Mar 10, 2016	Mar	NEWA	
	<u>ENALAPRILAT</u>								
	INJECTABLE;INJECTION								
	ENALAPRILAT								
AP	+	AMPHASTAR PHARMS INC	1.25MG/ML	A075634	001	Aug 22, 2000	Jun	CAHN	
AP	+	EUROHLTH INTL SARL	1.25MG/ML	A075634	001	Aug 22, 2000	Apr	CAHN	
	<u>EPHEDRINE SULFATE</u>								
	SOLUTION;INTRAVENOUS								
	AKOVAZ								
	+	FLAMEL IRELAND LTD	50MG/ML	N208289	001	Apr 29, 2016	Apr	NEWA	
	<u>EPINASTINE HYDROCHLORIDE</u>								
	SOLUTION/DROPS;OPHTHALMIC								
	EPINASTINE HYDROCHLORIDE								
AT		SOMERSET THERAPS LLC	0.05%	A090951	001	Oct 31, 2011	Mar	CAHN	
	<u>EPINEPHRINE</u>								
	INJECTABLE;INJECTION								
	SUS-PHRINE SULFITE FREE								
	@	FOREST LABS	1.5MG/AMP	N007942	003	Feb 05, 1999	Mar	CMS1	
	@		5MG/ML	N007942	001		Mar	CMS1	
	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS								
	AUVI-Q								
BX	+	KALEO INC	EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012	Mar	CAHN	
BX			EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012	Mar	CAHN	
	TWINJECT 0.15								
	@	AMEDRA PHARMS	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004	May	DISC	
	TWINJECT 0.3								
	@	AMEDRA PHARMS	EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003	May	DISC	
>A>	SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS								
>A>	EPINEPHRINE								
>A>		BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Jul	CAIN	

>D>	<u>EPINEPHRINE HYDROCHLORIDE</u>							
>D>	SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS							
>D>	EPINEPHRINE							
>D>	BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Jul	CAHN	
		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Feb	CDFR	
	<u>ERGOCALCIFEROL</u>							
	CAPSULE;ORAL							
	DRISDOL							
AA	+ US PHARM HOLDINGS	50,000 IU	N003444	001		Jan	CAHN	
	VITAMIN D							
AA	BIONPHARMA INC	50,000 IU	A080704	001		Jan	CAHN	
	<u>ERGOLOID MESYLATES</u>							
	TABLET;ORAL							
	ERGOLOID MESYLATES							
AB	SUN PHARM INDS	1MG	A081113	001	Oct 31, 1991	Mar	CAHN	
	TABLET;SUBLINGUAL							
	ERGOLOID MESYLATES							
	@ SUN PHARM INDS	0.5MG	A087407	001		Jun	CAHN	
	@	1MG	A087552	001		Jun	CAHN	
	<u>ERYTHROMYCIN</u>							
	SOLUTION;TOPICAL							
	C-SOLVE-2							
	@ FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985	Feb	DISC	
	ERYTHRO-STATIN							
	@ HI TECH PHARMA	2%	A064101	001	Oct 22, 1996	Feb	DISC	
	ERYTHROMYCIN							
AT	+ FOUGERA PHARMS	2%	A064187	001	Sep 30, 1997	Jan	CRLD	
AT	PERRIGO NEW YORK	2%	A063038	001	Jan 11, 1991	Jan	CRLD	
	<u>ESCITALOPRAM OXALATE</u>							
	SOLUTION;ORAL							
	ESCITALOPRAM OXALATE							
AA	MACLEODS PHARMS LTD	EQ 5MG BASE/5ML	A202754	001	Mar 31, 2016	Mar	NEWA	
	<u>ESMOLOL HYDROCHLORIDE</u>							
	SOLUTION;INTRAVENOUS							
	ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER							
	+ HQ SPCLT PHARMA	2GM/100ML (20MG/ML)	N205703	002	Apr 07, 2016	Apr	NEWA	
	ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER							
	+ HQ SPCLT PHARMA	2.5GM/250ML (10MG/ML)	N205703	001	Apr 07, 2016	Jun	CRLD	
		2.5GM/250ML (10MG/ML)	N205703	001	Apr 07, 2016	Apr	NEWA	
	<u>ESOMEPRAZOLE MAGNESIUM</u>							
	CAPSULE, DELAYED REL PELLETS;ORAL							
	ESOMEPRAZOLE MAGNESIUM							
AB	AUROBINDO PHARMA LTD	EQ 20MG BASE	A205606	001	Apr 21, 2016	Apr	NEWA	
AB		EQ 40MG BASE	A205606	002	Apr 21, 2016	Apr	NEWA	
BX	HETERO LABS LTD III	EQ 20MG BASE	A202784	001	Sep 21, 2015	Apr	CTEC	
BX		EQ 40MG BASE	A202784	002	Sep 21, 2015	Apr	CTEC	
	<u>ESOMEPRAZOLE SODIUM</u>							
	INJECTABLE;INTRAVENOUS							
	ESOMEPRAZOLE SODIUM							
>A>	AP AUROBINDO PHARMA LTD	EQ 20MG BASE/VIAL	A204657	001	Aug 10, 2016	Jul	NEWA	
>A>	AP	EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Jul	NEWA	
	<u>ESTRADIOL</u>							
	CREAM;VAGINAL							
	ESTRACE							
	+ ALLERGAN SALES LLC	0.01%	A086069	001	Jan 31, 1984	Apr	CAHN	
	FILM, EXTENDED RELEASE;TRANSDERMAL							
	ALORA							
BX	ALLERGAN SALES LLC	0.025MG/24HR	N020655	004	Apr 05, 2002	Mar	CAHN	
BX		0.05MG/24HR	N020655	001	Dec 20, 1996	Mar	CAHN	
BX		0.075MG/24HR	N020655	002	Dec 20, 1996	Mar	CAHN	
BX		0.1MG/24HR	N020655	003	Dec 20, 1996	Mar	CAHN	

ESTRADIOL ACETATEINSERT, EXTENDED RELEASE;VAGINAL
FEMRING

	APIL	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	Jan	CAHN
+		EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	Jan	CAHN

TABLET;ORAL
FEMTRACE

	APIL	0.45MG	N021633	001	Aug 20, 2004	Jan	CAHN
		0.9MG	N021633	002	Aug 20, 2004	Jan	CAHN
+		1.8MG	N021633	003	Aug 20, 2004	Jan	CAHN

ESTRADIOL HEMIHYDRATE

EMULSION;TOPICAL

ESTRASORB

+	EXELTIS USA INC	0.25%	N021371	001	Oct 09, 2003	Jun	CAHN
---	-----------------	-------	---------	-----	--------------	-----	------

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

AMABELZ

AB	LUPIN LTD	0.5MG;0.1MG	A203339	001	Jun 20, 2016	Jun	NEWA
AB		1MG;0.5MG	A203339	002	Jun 20, 2016	Jun	NEWA

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET;ORAL

CENESTIN

@	TEVA BRANDED PHARM	0.3MG	N020992	001	Jun 21, 2002	Jun	DISC
@		0.45MG	N020992	005	Feb 05, 2004	Jun	DISC
@		0.625MG	N020992	002	Mar 24, 1999	Jun	DISC
@		0.9MG	N020992	003	Mar 24, 1999	Jun	DISC
@		1.25MG	N020992	004	Mar 13, 2000	Jun	DISC

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET;ORAL

ENJUUIA

@	TEVA WOMENS	0.625MG	N021443	003	May 10, 2004	Jun	DISC
---	-------------	---------	---------	-----	--------------	-----	------

ETHACRYNIC ACID

TABLET;ORAL

EDECIN

AB	+	ATON	25MG	N016092	001		Jun	CFTG
AB		ETHACRYNIC ACID						
AB		EDEXBRIDGE PHARMS	25MG	A205609	001	Jun 30, 2016	Jun	NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

AB		JAI PHARMA LTD	0.05MG;1MG	A204704	001	Feb 09, 2016	Jan	NEWA
AB	+	ZOVIA 1/50E-28						
AB	+	WATSON LABS	0.05MG;1MG	A072723	001	Dec 30, 1991	Jan	CTEC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

FAYOSIM

AB		LUPIN LTD	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	A205943	001	Mar 29, 2016	Mar	NEWA
		LEVONORGESTREL AND ETHINYL ESTRADIOL						
>A>	AB	AMNEAL PHARMS	0.03MG;0.15MG	A203871	001	Nov 13, 2015	Jul	CAHN
>D>	AB	HAUPT PHARMA	0.03MG;0.15MG	A203871	001	Nov 13, 2015	Jul	CAHN
>D>	AB		0.03MG,0.01MG;0.15MG,NA	A203872	001	Dec 22, 2015	Jul	CMS1
>A>	AB		0.03MG,0.01MG;0.15MG,N/A	A203872	001	Dec 22, 2015	Jul	CMS1
		QUARTETTE						
AB	+	TEVA BRANDED PHARM	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	N204061	001	Mar 28, 2013	Mar	CFTG

TABLET;ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1		AMNEAL PHARMS	0.02MG;0.1MG	A201108	001	Feb 05, 2014	May	CAHN
>A>	AB		0.03MG;0.15MG	A201095	001	Dec 08, 2014	Jul	CAHN
>D>	AB	HAUPT PHARMA	0.03MG;0.15MG	A201095	001	Dec 08, 2014	Jul	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

	TABLET; ORAL-21						
	BREVICON 21-DAY						
	@ ALLERGAN SALES LLC	0.035MG; 0.5MG	N017566	001		Apr	CAHN
	NORINYL 1+35 21-DAY						
AB	ALLERGAN SALES LLC	0.035MG; 1MG	N017565	001		Mar	CAHN
	TABLET; ORAL-28						
	BREVICON 28-DAY						
AB	ALLERGAN SALES LLC	0.035MG; 0.5MG	N017743	001		Mar	CAHN
	NORINYL 1+35 28-DAY						
AB	ALLERGAN SALES LLC	0.035MG; 1MG	N017565	002		Mar	CAHN
	TABLET, CHEWABLE; ORAL						
	FEMCON FE						
AB	+ APIL	0.035MG; 0.4MG	N021490	001	Nov 14, 2003	Jan	CAHN
	NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB	+ APIL	0.025MG; 0.8MG	N022573	001	Dec 22, 2010	Jan	CAHN
AB	LUPIN LTD	0.035MG; 0.4MG	A091332	001	Mar 23, 2016	Mar	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

	TABLET; ORAL						
	FEMHRT						
AB	APIL	0.0025MG; 0.5MG	N021065	001	Jan 14, 2005	Jan	CAHN
	@	0.005MG; 1MG	N021065	002	Oct 15, 1999	Jan	CAHN
	LERIBANE						
AB	NOVAST LABS LTD	0.0025MG; 0.5MG	A203435	002	Jun 03, 2016	May	NEWA
AB		0.005MG; 1MG	A203435	001	Jun 03, 2016	May	NEWA
	LO LOESTRIN FE						
AB	+ APIL	0.01MG, 0.01MG; 1MG, N/A	N022501	001	Oct 21, 2010	May	CFTG
	+	0.01MG, 0.01MG; 1MG, N/A	N022501	001	Oct 21, 2010	Jan	CAHN
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB	JAI PHARMA LTD	0.01MG, 0.01MG; 1MG, N/A	A205049	001	May 31, 2016	May	NEWA
	TABLET; ORAL-21						
	ESTROSTEP 21						
	@ APIL	0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG	N020130	001	Oct 09, 1996	Jan	CAHN
	LOESTRIN 21 1.5/30						
AB	APIL	0.03MG; 1.5MG	N017875	001		Apr	CAHN
	LOESTRIN 21 1/20						
AB	APIL	0.02MG; 1MG	N017876	001		Apr	CAHN
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL						
AB	GLENMARK PHARMS LTD	0.02MG; 1MG	A206969	001	Jan 20, 2016	Jan	NEWA
	TABLET; ORAL-28						
	ESTROSTEP FE						
AB	+ APIL	0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG	N020130	002	Oct 09, 1996	Jan	CAHN
	LOESTRIN FE 1.5/30						
AB	+ APIL	0.03MG; 1.5MG	N017355	001		Apr	CAHN
	LOESTRIN FE 1/20						
AB	APIL	0.02MG; 1MG	N017354	001		Apr	CAHN
	TABLET, CHEWABLE; ORAL						
	MIBELAS 24 FE						
AB	LUPIN ATLANTIS	0.02MG; 1MG	A206287	001	May 24, 2016	May	NEWA
	MINASTRIN 24 FE						
AB	+ APIL	0.02MG; 1MG	N203667	001	May 08, 2013	May	CFTG
	+	0.02MG; 1MG	N203667	001	May 08, 2013	Jan	CAHN
	TABLET, CHEWABLE, TABLET; ORAL						
	LO MINASTRIN FE						
	+	0.01MG, 0.01MG, N/A; 1MG, N/A, N/A	N204654	001	Jul 24, 2013	Jan	CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

	TABLET; ORAL-28						
	MILI						
AB	AUROBINDO PHARMA LTD	0.035MG; 0.25MG	A205449	001	Jul 07, 2016	Jun	NEWA
	NORGESTIMATE AND ETHINYL ESTRADIOL						
AB	AMNEAL PHARMS	0.035MG; 0.25MG	A203865	001	Oct 27, 2015	May	CAHN
AB	GLENMARK PHARMS	0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.2	A204057	001	Feb 23, 2016	Jun	CAHN
		15MG, 0.25MG					
AB	GLENMARK PHARMS LTD	0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.2	A204057	001	Feb 23, 2016	Feb	NEWA
		15MG, 0.25MG					
AB	HAUPT PHARMA	0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.2	A203873	001	May 12, 2016	May	NEWA
		15MG, 0.25MG					
AB	JAI PHARMA LTD	0.035MG, 0.035MG, 0.035MG; 0.18MG,	A201897	001	Jan 27, 2016	Jan	NEWA
		0.215MG, 0.25MG					

<u>TABLET;ORAL-28</u>							
NORGESTIMATE AND ETHINYL ESTRADIOL							
AB		0.035MG;0.25MG		A201896	001	Jan 27, 2016	Jan NEWA
AB	LUPIN LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG		A205588	001	Apr 26, 2016	Apr NEWA
TRI-MILI							
AB	AUROBINDO PHARMA LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG		A205441	001	Jul 06, 2016	Jun NEWA
<u>ETHINYL ESTRADIOL; NORGESTREL</u>							
TABLET;ORAL-21							
LO/OVRAL							
	@ PELAGIUS	0.03MG;0.3MG		N017612	001		Jun CAHN
TABLET;ORAL-28							
LO/OVRAL-28							
	@ WYETH PHARMS	0.03MG;0.3MG		N017802	001		Jun DISC
NORGESTREL AND ETHINYL ESTRADIOL							
AB	JAI PHARMA LTD	0.03MG;0.3MG		A201828	001	Jun 21, 2016	Jun NEWA
<u>ETHOSUXIMIDE</u>							
CAPSULE;ORAL							
ETHOSUXIMIDE							
AB	BIONPHARMA INC	250MG		A040430	001	Oct 28, 2002	Jan CAHN
<u>ETIDRONATE DISODIUM</u>							
TABLET;ORAL							
DIDRONEL							
AB	APIL	200MG		N017831	001		Apr CAHN
AB	+	400MG		N017831	002		Apr CAHN
<u>ETODOLAC</u>							
CAPSULE;ORAL							
ETODOLAC							
	@ IDT AUSTRALIA LTD	200MG		A074840	001	Aug 29, 1997	May CAHN
	@	300MG		A074840	002	Aug 29, 1997	May CAHN
	@ LEHIGH VALLEY	300MG		A074929	001	Jan 30, 1998	Feb CAHN
<u>ETOMIDATE</u>							
INJECTABLE;INJECTION							
ETOMIDATE							
AP	EUROHLTH INTL SARL	2MG/ML		A074593	001	Nov 04, 1996	Apr CAHN
AP	HIKMA FARMACEUTICA	2MG/ML		A202354	001	Feb 25, 2016	Feb NEWA
<u>EXEMESTANE</u>							
TABLET;ORAL							
EXEMESTANE							
AB	ALVOGEN MALTA	25MG		A200898	001	Jul 28, 2014	Jan CAHN
<u>EXENATIDE SYNTHETIC</u>							
FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS							
BYDUREON PEN							
+	ASTRAZENECA AB	2MG		N022200	002	Feb 28, 2014	Feb NEWA
<u>FAMOTIDINE</u>							
INJECTABLE;INJECTION							
FAMOTIDINE							
AP	AMPHASTAR PHARMS INC	10MG/ML		A075651	001	Apr 16, 2001	Jun CAHN
AP		10MG/ML		A075684	001	Apr 16, 2001	Jun CAHN
AP	EUROHLTH INTL SARL	10MG/ML		A075651	001	Apr 16, 2001	Apr CAHN
AP		10MG/ML		A075684	001	Apr 16, 2001	Apr CAHN
FAMOTIDINE PRESERVATIVE FREE							
AP	AMPHASTAR PHARMS INC	10MG/ML		A075622	001	Apr 16, 2001	Jun CAHN
AP		10MG/ML		A075825	001	Apr 17, 2001	Jun CAHN
AP	EUROHLTH INTL SARL	10MG/ML		A075622	001	Apr 16, 2001	Apr CAHN
AP		10MG/ML		A075825	001	Apr 17, 2001	Apr CAHN
TABLET;ORAL							
FAMOTIDINE							
	@ SUN PHARM INDS	20MG		A075639	002	Dec 12, 2001	Mar CAHN
	@	40MG		A075639	001	Dec 12, 2001	Mar CAHN

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL
FELODIPINE

AB	SUN PHARM INDS	2.5MG	A075896	001	Nov 02, 2004	Mar	CAHN
AB		5MG	A075896	002	Nov 02, 2004	Mar	CAHN
AB		10MG	A075896	003	Nov 02, 2004	Mar	CAHN

FENOFIBRATE

TABLET;ORAL
FENOFIBRATE

AB	AUROBINDO PHARMA LTD	48MG	A205118	001	May 05, 2016	Apr	NEWA
AB		145MG	A205118	002	May 05, 2016	Apr	NEWA
AB	HETERO LABS LTD III	48MG	A204598	001	Jul 12, 2016	Jun	NEWA
AB		145MG	A204598	002	Jul 12, 2016	Jun	NEWA
AB	MYLAN	40MG	A204475	001	Jun 23, 2016	Jun	NEWA
AB		120MG	A204475	002	Jun 23, 2016	Jun	NEWA

FENOGLIDE

AB	SANTARUS INC	40MG	N022118	001	Aug 10, 2007	Jun	CFTG
AB	+	120MG	N022118	002	Aug 10, 2007	Jun	CFTG

FENOFIBRIC ACID

TABLET;ORAL
FIBRICOR

	ARALENZ PHARMS	35MG	N022418	001	Aug 14, 2009	Apr	CAHN
+		105MG	N022418	002	Aug 14, 2009	Apr	CAHN
	ARALEZ PHARMS INC	35MG	N022418	001	Aug 14, 2009	Jun	CAHN
+		105MG	N022418	002	Aug 14, 2009	Jun	CAHN

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

@	AUROLIFE PHARMA LLC	EQ 200MG BASE	A072394	001	Oct 17, 1988	Mar	CAHN
@		EQ 300MG BASE	A072395	001	Oct 17, 1988	Feb	CAHN

TABLET;ORAL

FENOPROFEN CALCIUM

@	AUROLIFE PHARMA LLC	EQ 600MG BASE	A072396	001	Oct 17, 1988	Feb	CAHN
@	SUN PHARM INDS	EQ 600MG BASE	A072902	001	Dec 21, 1990	Mar	CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-12

AB	AVEVA	12.5MCG/HR	A077449	005	Sep 11, 2015	Jan	NEWA
----	-------	------------	---------	-----	--------------	-----	------

FERRIC PYROPHOSPHATE CITRATE

FOR SOLUTION;INTRAVENOUS
TRIFERIC

+	ROCKWELL MEDICAL INC	272MG IRON/PACKET	N208551	001	Apr 25, 2016	Apr	NEWA
---	----------------------	-------------------	---------	-----	--------------	-----	------

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE

@	ALKEM LABS LTD	4MG	A204827	001	Dec 10, 2015	Jan	DISC
@		8MG	A204827	002	Dec 10, 2015	Jan	DISC

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@	BARR	60MG;120MG	A076236	001	Apr 14, 2005	Mar	DISC
@	IMPAX PHARMS	60MG;120MG	A076298	001	Nov 12, 2010	Mar	DISC

>A> FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL

>A> EMULSION;INTRAVENOUS

>A> SMOFLIPID 20%

>A>	+	FRESENIUS KABI USA	3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (100ML)	N207648	001	Jul 13, 2016	Jul	NEWA
>A>	+		3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (250ML)	N207648	002	Jul 13, 2016	Jul	NEWA
>A>	+		3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (500ML)	N207648	003	Jul 13, 2016	Jul	NEWA

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE

@ IMPAX PHARMS	100MG	A076234	001	Aug 28, 2003	Mar	DISC
----------------	-------	---------	-----	--------------	-----	------

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

@ IDT AUSTRALIA LTD	50MG	A076030	001	Oct 28, 2002	May	CAHN
@	100MG	A076030	002	Oct 28, 2002	May	CAHN
@	150MG	A076030	003	Oct 28, 2002	May	CAHN

FLUCICLOVINE F-18

SOLUTION; INTRAVENOUS

AXUMIN

+ BLUE EARTH	9-221mCi/ML	N208054	001	May 27, 2016	May	NEWA
--------------	-------------	---------	-----	--------------	-----	------

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

@ SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Feb	DISC
@	200MG/5ML	A076332	002	Jul 29, 2004	Feb	DISC

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

	EUROHLTH INTL SARL	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008	Apr	CAHN
AP		200MG/100ML (2MG/ML)	A076087	001	Jul 29, 2004	Apr	CAHN
AP		400MG/200ML (2MG/ML)	A076087	003	Jul 29, 2004	Apr	CAHN
	@ TEVA PHARMS USA	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004	Jan	DISC
	@	400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004	Jan	DISC
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	ACS DOBFAR INFO SA	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Mar	CMS1
AP		400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Mar	CMS1
AP	EUROHLTH INTL SARL	200MG/100ML (2MG/ML)	A078107	001	Jul 30, 2008	Jun	CAHN
AP		400MG/200ML (2MG/ML)	A078107	002	Jul 30, 2008	Jun	CAHN

TABLET; ORAL

FLUCONAZOLE

@ IDT AUSTRALIA LTD	50MG	A076086	001	Jul 29, 2004	May	CAHN
@	100MG	A076086	002	Jul 29, 2004	May	CAHN
@	150MG	A076086	003	Jul 29, 2004	May	CAHN
@	200MG	A076086	004	Jul 29, 2004	May	CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	KREITCHMAN PET CTR	10-100mCi/ML	A203942	001	Apr 11, 2016	Mar	NEWA
AP	+ QUEEN HAMAMATSU PET	10-100mCi/ML	A203771	001	Aug 31, 2015	Mar	CTEC
AP	ZEVACOR PHARMA INC	20-300mCi/ML	A203591	001	Aug 31, 2015	Feb	CAHN

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP	EUROHLTH INTL SARL	0.5MG/5ML (0.1MG/ML)	A076256	002	Oct 12, 2004	Apr	CAHN
AP		1MG/10ML (0.1MG/ML)	A076256	001	Oct 12, 2004	Apr	CAHN

FLUOCINOLONE ACETONIDE

OIL; TOPICAL

FLUOCINOLONE ACETONIDE

AT	LYNE	0.01%	A090982	001	Apr 25, 2016	Apr	NEWA
AT		0.01%	A203377	001	Apr 25, 2016	Apr	NEWA
AT	TARO	0.01%	A202368	001	May 19, 2016	May	NEWA
AT		0.01%	A209336	001	May 19, 2016	May	NEWA

OIL/DROPS; OTIC

FLUOCINOLONE ACETONIDE

AT	LYNE	0.01%	A203378	001	Apr 25, 2016	Apr	NEWA
----	------	-------	---------	-----	--------------	-----	------

FLUOROURACIL

INJECTABLE; INJECTION		FLUOROURACIL					
AP	SAGENT PHARMS	2.5GM/50ML (50MG/ML)	A203609	001	Feb 17, 2016	Feb	NEWA
AP		5GM/100ML (50MG/ML)	A203609	002	Feb 17, 2016	Feb	NEWA
	@ SPECTRUM PHARMS	500MG/10ML (50MG/ML)	N012209	001		Jan	CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL		FLUOXETINE					
	@ SUN PHARM INDS	EQ 10MG BASE	A075787	001	Jan 29, 2002	Mar	CAHN
	@	EQ 20MG BASE	A075787	002	Jan 29, 2002	Mar	CAHN
TABLET; ORAL		FLUOXETINE HYDROCHLORIDE					
	+ EDMONT PHARMS LLC	EQ 60MG BASE	N202133	001	Oct 06, 2011	Mar	CRLD
	SARAFEM						
AB1	APIL	EQ 10MG BASE	N021860	001	May 19, 2006	Jan	CAHN
AB1		EQ 15MG BASE	N021860	002	May 19, 2006	Jan	CAHN
AB1	+	EQ 20MG BASE	N021860	003	May 19, 2006	Jan	CAHN

FLURANDRENOLIDE

CREAM; TOPICAL		CORDRAN SP					
AT	+ AQUA PHARMS	0.05%	N012806	002		Mar	CFTG
	FLURANDRENOLIDE						
AT	TELIGENT PHARMA INC	0.05%	A205342	001	Apr 13, 2016	Mar	NEWA
TAPE; TOPICAL		CORDRAN					
	+ ALLERGAN SALES LLC	0.004MG/SQ CM	N016455	001		Apr	CAHN

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL		CORDRAN N					
	@ LILLY	0.05%;EQ 3.5MG BASE/GM	N050346	001		Mar	CMS1
OINTMENT; TOPICAL		CORDRAN N					
	@ LILLY	0.05%;EQ 3.5MG BASE/GM	N050345	001		Mar	CMS1

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL		FLURAZEPAM HYDROCHLORIDE					
	@ AUROLIFE PHARMA LLC	15MG	A071716	001	Jul 31, 1991	Feb	CAHN
	@	30MG	A071717	001	Jul 31, 1991	Feb	CAHN
	@ HIKMA INTL PHARMS	15MG	A071107	001	Dec 08, 1986	May	CAHN
	@ SUN PHARM INDS	15MG	A070454	001	Aug 04, 1986	Mar	CAHN
	@	30MG	A070455	001	Aug 04, 1986	Mar	CAHN

FLURBIPROFEN

TABLET; ORAL		FLURBIPROFEN					
	@ AUROLIFE PHARMA LLC	50MG	A074448	001	Jul 28, 1995	Feb	CAHN
	@	100MG	A074448	002	Jul 28, 1995	Feb	CAHN

FLUTICASONE FUROATE

POWDER; INHALATION		ARNUITY ELLIPTA					
	+ GLAXOSMITHKLINE	0.1MG/INH	N205625	001	Aug 20, 2014	Mar	CRLD

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION		BREQ ELLIPTA					
	+ GLAXO GRP LTD	0.2MG/INH;EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015	Mar	CRLD

FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL		FLONASE					
	@ GLAXOSMITHKLINE	0.05MG/SPRAY	N020121	001	Oct 19, 1994	Jun	DISC

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE;ORAL

FLUVASTATIN SODIUM

AB	MYLAN PHARMS INC	EQ 80MG BASE	A202458	001	Sep 11, 2015	May	CPOT
AB	TEVA PHARMS USA	EQ 80MG BASE	A079011	001	Jan 27, 2016	May	CPOT
AB		80MG	A079011	001	Jan 27, 2016	Jan	NEWA
	LESCOL XL						
AB	+ NOVARTIS	EQ 80MG BASE	N021192	001	Oct 06, 2000	May	CPOT

FLUVOXAMINE MALEATE

TABLET;ORAL

FLUVOXAMINE MALEATE

	@ NOSTRUM LABS INC	25MG	A075900	001	Feb 23, 2006	Feb	CAHN
	@	50MG	A075900	002	Feb 23, 2006	Feb	CAHN
	@	100MG	A075900	003	Feb 23, 2006	Feb	CAHN
	@ SUN PHARM INDS	25MG	A076125	001	Apr 29, 2002	Mar	CAHN
	@	50MG	A076125	002	Apr 29, 2002	Mar	CAHN
	@	100MG	A076125	003	Apr 29, 2002	Mar	CAHN

FOLIC ACID

INJECTABLE; INJECTION

FOLVITE

	@ WYETH PHARMS INC	5MG/ML	N005897	008		May	CAHN
--	--------------------	--------	---------	-----	--	-----	------

TABLET;ORAL

FOLIC ACID

	@ SUN PHARM INDS	1MG	A040582	001	Jul 18, 2005	Mar	CAHN
--	------------------	-----	---------	-----	--------------	-----	------

FOLVITE

	@ WYETH PHARMS INC	1MG	N005897	004		May	CAHN
--	--------------------	-----	---------	-----	--	-----	------

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

	@ ORGANON USA INC	75 IU/0.5ML	N021273	001	Aug 26, 2005	Jun	DISC
--	-------------------	-------------	---------	-----	--------------	-----	------

	@	150 IU/0.5ML	N021273	002	Aug 26, 2005	Jun	DISC
--	---	--------------	---------	-----	--------------	-----	------

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED; INHALATION

BEVESPI AEROSPHERE

+	PEARL THERAPS INC	0.0048MG/INH;0.0090MG/INH	N208294	001	Apr 25, 2016	Apr	NEWA
---	-------------------	---------------------------	---------	-----	--------------	-----	------

FOSAMPRENAVIR CALCIUM

TABLET;ORAL

FOSAMPRENAVIR CALCIUM

AB	MYLAN PHARMS INC	EQ 700MG BASE	A204060	001	Apr 15, 2016	Apr	NEWA
----	------------------	---------------	---------	-----	--------------	-----	------

LEXIVA

AB	+ VIIV HLTHCARE	EQ 700MG BASE	N021548	001	Oct 20, 2003	Apr	CFTG
----	-----------------	---------------	---------	-----	--------------	-----	------

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

AP	+ MERCK AND CO INC	EQ 150MG BASE/VIAL	N022023	002	Nov 12, 2010	May	CFTG
----	--------------------	--------------------	---------	-----	--------------	-----	------

FOSAPREPITANT DIMEGLUMINE

AP	FRESENIUS KABI USA	EQ 150MG BASE/VIAL	A206197	001	Jun 09, 2016	May	NEWA
----	--------------------	--------------------	---------	-----	--------------	-----	------

FOSINOPRIL SODIUM

TABLET;ORAL

FOSINOPRIL SODIUM

	@ ACTAVIS LABS FL INC	10MG	A076620	001	Oct 15, 2004	Jan	DISC
--	-----------------------	------	---------	-----	--------------	-----	------

	@	20MG	A076620	002	Oct 15, 2004	Jan	DISC
--	---	------	---------	-----	--------------	-----	------

	@	40MG	A076620	003	Oct 15, 2004	Jan	DISC
--	---	------	---------	-----	--------------	-----	------

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

	@ ACTAVIS LABS FL INC	10MG;12.5MG	A076608	001	Dec 03, 2004	Jan	DISC
--	-----------------------	-------------	---------	-----	--------------	-----	------

	@	20MG;12.5MG	A076608	002	Dec 03, 2004	Jan	DISC
--	---	-------------	---------	-----	--------------	-----	------

	@ SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004	Feb	DISC
--	----------------------	-------------	---------	-----	--------------	-----	------

	@	20MG;12.5MG	A076739	002	Dec 17, 2004	Feb	DISC
--	---	-------------	---------	-----	--------------	-----	------

GATIFLOXACINSOLUTION/DROPS;OPHTHALMIC
GATIFLOXACIN

AT	ALCON RES LTD	0.5%	A204227	001	Jul 11, 2016	Jun	NEWA
----	---------------	------	---------	-----	--------------	-----	------

GEMCITABINE HYDROCHLORIDEINJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

AP	ACTAVIS INC	200MG/5.26ML (38MG/ML)	A204549	001	Apr 11, 2016	Mar	NEWA
AP		1GM/26.3ML (38MG/ML)	A204549	002	Apr 11, 2016	Mar	NEWA
AP		2GM/52.6ML (38MG/ML)	A204549	003	Apr 11, 2016	Mar	NEWA
AP	+ HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011	Mar	CFTG
AP	+	1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011	Mar	CFTG
AP	+	2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011	Mar	CFTG

GEMFIBROZILTABLET; ORAL
GEMFIBROZIL

AB	CADILA PHARMS LTD	600MG	A203266	001	Jun 17, 2016	Jun	NEWA
----	-------------------	-------	---------	-----	--------------	-----	------

GLIMEPIRIDETABLET; ORAL
GLIMEPIRIDE

@	ACTAVIS LABS FL INC	1MG	A076995	001	Apr 27, 2010	Jan	DISC
@		2MG	A076995	002	Apr 27, 2010	Jan	DISC
@		4MG	A076995	003	Apr 27, 2010	Jan	DISC

GLIMEPIRIDE; ROSIGLITAZONE MALEATETABLET; ORAL
ROSIGLITAZONE MALEATE AND GLIMEPIRIDE

+	TEVA PHARMS USA	1MG; 4MG	A078709	001	Apr 01, 2016	Mar	NEWA
		2MG; 4MG	A078709	002	Apr 01, 2016	Mar	NEWA
		2MG; 8MG	A078709	004	Apr 01, 2016	Mar	NEWA
		4MG; 4MG	A078709	003	Apr 01, 2016	Mar	NEWA
		4MG; 8MG	A078709	005	Apr 01, 2016	Mar	NEWA

GLYBURIDETABLET; ORAL
GLYBURIDE

AB1	PHARMADAX INC	1.25MG	A203581	001	Apr 14, 2016	Apr	NEWA
AB1		2.5MG	A203581	002	Apr 14, 2016	Apr	NEWA
AB1		5MG	A203581	003	Apr 14, 2016	Apr	NEWA
AB1	ZYDUS PHARMS USA INC	1.25mg	A206749	001	May 10, 2016	Apr	NEWA
AB1		2.5mg	A206749	002	May 10, 2016	Apr	NEWA
AB1		5MG	A206749	003	May 10, 2016	Apr	NEWA

GLYBURIDE; METFORMIN HYDROCHLORIDETABLET; ORAL
GLYBURIDE AND METFORMIN HYDROCHLORIDE

@	COREPHARMA	1.25MG; 250MG	A076731	001	Nov 19, 2004	Jan	DISC
@		2.5MG; 500MG	A076731	002	Nov 19, 2004	Jan	DISC
@		5MG; 500MG	A076731	003	Nov 19, 2004	Jan	DISC
AB	ZYDUS PHARMS USA INC	1.25MG; 250MG	A206748	001	Feb 29, 2016	Feb	NEWA
AB		2.5MG; 500MG	A206748	002	Feb 29, 2016	Feb	NEWA
AB		5MG; 500MG	A206748	003	Feb 29, 2016	Feb	NEWA

GLYCOPYRROLATEINJECTABLE; INJECTION
GLYCOPYRROLATE

AP	+ HIKMA FARMACEUTICA	0.2MG/ML	A090963	001	Sep 21, 2011	Feb	CRLD
	ROBINUL						
	@ EUROHLTH INTL SARL	0.2MG/ML	N017558	001		Feb	DISC
AA	NATCO PHARMA LTD	1MG	A040836	001	Mar 05, 2009	May	CAHN
AA		2MG	A040836	002	Mar 05, 2009	May	CAHN
AA		1MG	A091413	001	Jun 20, 2016	Jun	NEWA
AA		2MG	A091413	002	Jun 20, 2016	Jun	NEWA
AA	RISING PHARMS INC	1MG	A040821	001	Dec 29, 2008	Jan	CAHN
AA		2MG	A040821	002	Dec 29, 2008	Jan	CAHN

TABLET; ORAL

AA	+	CASPER PHARMA LLC	1MG	N012827	001		Jan	CAHN
		ROBINUL FORTE						
AA	+	CASPER PHARMA LLC	2MG	N012827	002		Jan	CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE								
AP		AUROBINDO PHARMA LTD	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204238	001	Jul 06, 2016	Jun	NEWA
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A204238	002	Jul 06, 2016	Jun	NEWA
AP		BIONPHARMA INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan	CAHN
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan	CAHN
	@	CLARIS	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007	May	CAHN
AP		EUROHLTH INTL SARL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A077913	001	Jun 26, 2008	Jun	CAHN
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077186	001	Jun 30, 2008	Jun	CAHN
AP			EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077187	001	Jun 30, 2008	Jun	CAHN
AP		HIKMA FARMACEUTICA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078629	001	Dec 23, 2009	Jan	CMS1
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078629	002	Dec 23, 2009	Jan	CMS1
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE								
AP		BIONPHARMA INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan	CAHN

TABLET; ORAL

GRANISETRON HYDROCHLORIDE								
	@	COREPHARMA	EQ 1MG BASE	A078260	001	Dec 31, 2007	Mar	DISC

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYCOFENIX								
	+	MISSION PHARMACAL CO	200MG/5ML; 2.5MG/5ML; 30MG/5ML	N022279	001	May 14, 2015	Apr	CAHN

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE								
	@	IMPAX LABS INC	EQ 1MG BASE	A202238	001	Oct 20, 2015	Mar	DISC
	@		EQ 2MG BASE	A202238	002	Oct 20, 2015	Mar	DISC
	@		EQ 3MG BASE	A202238	003	Oct 20, 2015	Mar	DISC
	@		EQ 4MG BASE	A202238	004	Oct 20, 2015	Mar	DISC

HALOBETASOL PROPIONATE

LOTION; TOPICAL

ULTRAVATE								
	+	SUN PHARM INDS	0.05%	N208183	001	Nov 06, 2015	Jun	CAHN

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL								
	@	CYCLE PHARMS LTD	2MG	A071130	001	Feb 17, 1987	Jan	CAHN
>A>	@	FRONTIDA BIOPHARM	0.5MG	A071156	001	Jan 02, 1987	Jul	CAHN
>A>	@		1MG	A071157	001	Jan 02, 1987	Jul	CAHN
>A>	@		2MG	A071172	001	Jan 02, 1987	Jul	CAHN
>A>	@		5MG	A071212	001	Jan 07, 1988	Jul	CAHN
>A>	@		10MG	A071173	001	Jan 07, 1988	Jul	CAHN
>D>	@	SUN PHARM INDS	0.5MG	A071156	001	Jan 02, 1987	Jul	CAHN
	@		0.5MG	A071156	001	Jan 02, 1987	Jun	CAHN
>D>	@		1MG	A071157	001	Jan 02, 1987	Jul	CAHN
	@		1MG	A071157	001	Jan 02, 1987	Jun	CAHN
>D>	@		2MG	A071172	001	Jan 02, 1987	Jul	CAHN
	@		2MG	A071172	001	Jan 02, 1987	Mar	CAHN
>D>	@		5MG	A071212	001	Jan 07, 1988	Jul	CAHN
	@		5MG	A071212	001	Jan 07, 1988	Mar	CAHN
>D>	@		10MG	A071173	001	Jan 07, 1988	Jul	CAHN
	@		10MG	A071173	001	Jan 07, 1988	Mar	CAHN
	@		20MG	A071177	001	Jan 07, 1988	Mar	CAHN
	@	VINTAGE	0.5MG	A071235	002	Nov 03, 1986	Jan	CMS1
	@		1MG	A071235	003	Nov 03, 1986	Jan	CMS1
	@		5MG	A071235	004	Nov 03, 1986	Jan	CMS1
	@		10MG	A071235	005	Jul 20, 1987	Jan	CMS1

HEPARIN SODIUM

INJECTABLE; INJECTION
 HEPARIN SODIUM
 AP FRESENIUS KABI USA 5,000 UNITS/ML A206552 001 Jun 10, 2016 May NEWA

HEXACHLOROPHENE

EMULSION; TOPICAL
 PHISOHEX
 @ SANOFI AVENTIS US 3% N006882 001 May DISC

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL
 HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE
 @ ACTAVIS ELIZABETH 1.5MG; 5MG A040295 001 Dec 01, 2000 Jan CMS1

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
 HYDRALAZINE HYDROCHLORIDE
 AP MYLAN INSTITUTIONAL 20MG/ML A204680 001 Apr 28, 2016 Apr NEWA

TABLET; ORAL
 HYDRALAZINE HYDROCHLORIDE
 @ ACTAVIS GRP PTC 10MG A091679 001 Mar 04, 2013 Apr DISC
 @ 25MG A091679 002 Mar 04, 2013 Apr DISC
 @ 50MG A091679 003 Mar 04, 2013 Apr DISC
 @ 100MG A091679 004 Mar 04, 2013 Apr DISC
 >A> @ FRONTIDA BIOPHARM 10MG A089359 001 Jul 25, 1986 Jul CAHN
 >A> @ 25MG A089258 001 May 05, 1986 Jul CAHN
 >A> @ 50MG A089259 001 May 05, 1986 Jul CAHN
 >A> @ 100MG A088729 001 Apr 11, 1985 Jul CAHN
 >D> @ SUN PHARM INDS 10MG A089359 001 Jul 25, 1986 Jul CAHN
 @ 10MG A089359 001 Jul 25, 1986 Mar CAHN
 >D> @ 25MG A089258 001 May 05, 1986 Jul CAHN
 @ 25MG A089258 001 May 05, 1986 Mar CAHN
 >D> @ 50MG A089259 001 May 05, 1986 Jul CAHN
 @ 50MG A089259 001 May 05, 1986 Mar CAHN
 >D> @ 100MG A088729 001 Apr 11, 1985 Jul CAHN
 @ 100MG A088729 001 Apr 11, 1985 Jun CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
 HYDRALAZINE AND HYDROCHLOROTHIAZIDE
 @ WATSON LABS 25MG; 15MG A085827 001 Feb CMS1

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
 RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
 @ SUN PHARM INDS 25MG; 15MG; 0.1MG A088570 001 Apr 10, 1984 Mar CAHN

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
 MICROZIDE
 AB + ALLERGAN SALES LLC 12.5MG N020504 001 Dec 27, 1996 Apr CAHN

TABLET; ORAL
 HYDROCHLOROTHIAZIDE
 @ AUROLIFE PHARMA LLC 25MG A083899 001 Feb CAHN
 @ 50MG A085219 001 Feb CAHN
 @ HIKMA INTL PHARMS 25MG A084878 002 Jul 12, 2006 May CAHN
 AB @ 50MG A084878 001 May CAHN
 @ SUN PHARM INDS 25MG A083972 001 Mar CAHN
 @ 50MG A083972 002 Mar CAHN
 @ 100MG A083972 003 Mar CAHN

ORETIC
 @ ABBVIE 50MG N011971 002 Jan DISC

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL
 IRBESARTAN AND HYDROCHLOROTHIAZIDE
 AB AUROBINDO PHARMA LTD 25MG; 300MG A203630 003 Mar 31, 2016 Mar NEWA
 AB INTL SPECLT CHEMS 12.5MG; 150MG A203036 001 Jan 15, 2016 Jan NEWA
 AB 12.5MG; 300MG A203036 002 Jan 15, 2016 Jan NEWA
 AB 25MG; 300MG A203036 003 Jan 15, 2016 Mar CTEC

TABLET;ORAL		IRBESARTAN AND HYDROCHLOROTHIAZIDE						
		25MG;300MG		A203036	003	Jan 15, 2016	Jan	NEWA
>A>	AB	MYLAN PHARMS INC	25MG;300MG	A077969	003	Jul 20, 2016	Jul	NEWA
<u>HYDROCHLOROTHIAZIDE; LISINOPRIL</u>		TABLET;ORAL						
		ZESTORETIC						
AB		ALVOGEN MALTA	12.5MG;10MG	N019888	003	Nov 18, 1993	Jan	CAHN
AB	+		12.5MG;20MG	N019888	001	Sep 20, 1990	Jan	CAHN
AB	+		25MG;20MG	N019888	002	Jul 20, 1989	Jan	CAHN
<u>HYDROCHLOROTHIAZIDE; SPIRONOLACTONE</u>		TABLET;ORAL						
		SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE						
AB		SUN PHARM INDS	25MG;25MG	A089534	001	Jul 02, 1987	Mar	CAHN
<u>HYDROCHLOROTHIAZIDE; VALSARTAN</u>		TABLET;ORAL						
		VALSARTAN AND HYDROCHLOROTHIAZIDE						
AB		PRINSTON INC	12.5MG;80MG	A206083	001	Feb 08, 2016	Jan	NEWA
AB			12.5MG;160MG	A206083	002	Feb 08, 2016	Jan	NEWA
AB			12.5MG;320MG	A206083	003	Feb 08, 2016	Jan	NEWA
AB			25MG;160MG	A206083	004	Feb 08, 2016	Jan	NEWA
AB			25MG;320MG	A206083	005	Feb 08, 2016	Jan	NEWA
<u>HYDROCODONE BITARTRATE; IBUPROFEN</u>		TABLET;ORAL						
		HYDROCODONE BITARTRATE AND IBUPROFEN						
		@ ACTAVIS LABS FL INC	5MG;200MG	A077454	001	Jun 23, 2010	Jan	DISC
AB		AUROLIFE PHARMA LLC	7.5MG;200MG	A204575	001	Jun 02, 2016	May	NEWA
<u>HYDROCORTISONE</u>		TABLET;ORAL						
		HYDROCORTISONE						
AB		PHARMACEUTICS INTL	5MG	A207029	001	Apr 26, 2016	Apr	NEWA
AB			10MG	A207029	002	Apr 26, 2016	Apr	NEWA
AB			20MG	A207029	003	Apr 26, 2016	Apr	NEWA
<u>HYDROCORTISONE VALERATE</u>		CREAM;TOPICAL						
		WESTCORT						
>A>		@ RANBAXY LABS LTD	0.2%	N017950	001		Jul	CAHN
>D>		@ SUN PHARM INDS LTD	0.2%	N017950	001		Jul	CAHN
		@	0.2%	N017950	001		Jun	CAHN
<u>HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>		SUSPENSION/DROPS;OTIC						
		PEDIOTIC						
		@ MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062822	001	Sep 29, 1987	Jan	DISC
<u>HYDROMORPHONE HYDROCHLORIDE</u>		TABLET;ORAL						
		HYDROMORPHONE HYDROCHLORIDE						
AB		AUROLIFE PHARMA LLC	2MG	A205814	001	May 13, 2016	May	NEWA
AB			4MG	A205814	002	May 13, 2016	May	NEWA
AB			8MG	A205814	003	May 13, 2016	May	NEWA
		TABLET, EXTENDED RELEASE;ORAL						
		EXALGO						
AB	+	MALLINCKRODT INC	32MG	N021217	004	Aug 24, 2012	Jun	CFTG
		HYDROMORPHONE HYDROCHLORIDE						
AB		ACTAVIS LABS FL INC	32MG	A202144	004	Jun 30, 2016	Jun	NEWA
AB		OSMOTICA	8MG	A205629	001	Jul 07, 2016	Jun	NEWA
AB			12MG	A205629	002	Jul 07, 2016	Jun	NEWA
AB			16MG	A205629	003	Jul 07, 2016	Jun	NEWA
AB			32MG	A205629	004	Jul 07, 2016	Jun	NEWA

HYDROXOCOBALAMININJECTABLE; INJECTION
CYANOKIT

	@ SERB SA	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006	Jan	CAHN
	+	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Jan	CAHN

HYDROXYCHLOROQUINE SULFATETABLET; ORAL
HYDROXYCHLOROQUINE SULFATE

AB	WATSON LABS	200MG	A040133	001	Nov 30, 1995	Feb	CMFD
----	-------------	-------	---------	-----	--------------	-----	------

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

HYDROXYPROGESTERONE CAPROATE

>D>	@ ACTAVIS LABS UT INC	125MG/ML	N017439	001		Jul	CAHN
>D>	@	250MG/ML	N017439	002		Jul	CAHN
>A>	@ ALLERGAN SALES LLC	125MG/ML	N017439	001		Jul	CAHN
>A>	@	250MG/ML	N017439	002		Jul	CAHN
	+ ASPEN GLOBAL INC	250MG/ML	A200271	001	Aug 24, 2015	Jan	CAHN
	SOLUTION; INTRAMUSCULAR						
	MAKENA						
	+ AMAG PHARMA USA	250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016	Jun	CAHN
	+	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	Jun	CAHN
	+ LUMARA HEALTH INC	250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016	Feb	NEWA
>A>	MAKENA PRESERVATIVE FREE						
>A>	+ AMAG PHARMA USA	250MG/ML (250MG/ML)	N021945	003	Jul 15, 2016	Jul	NEWA

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

	@ AUROLIFE PHARMA LLC	10MG	A087869	001	Dec 20, 1982	Feb	CAHN
	@	25MG	A087870	001	Dec 20, 1982	Feb	CAHN
	@	50MG	A087871	001	Dec 20, 1982	Feb	CAHN
AB	ECI PHARMS LLC	10MG	A040804	001	Jun 30, 2008	May	CAHN
AB		25MG	A040804	002	Jun 30, 2008	May	CAHN
AB		50MG	A040804	003	Jun 30, 2008	May	CAHN
AB	ELITE LABS INC	10MG	A040604	002	Dec 28, 2004	Jun	NEWA
AB		25MG	A040604	003	Dec 28, 2004	Jun	NEWA
	@ SUN PHARM INDS	10MG	A089381	001	May 19, 1986	Mar	CAHN
	@	25MG	A089382	001	May 19, 1986	Mar	CAHN
	@	50MG	A089383	001	May 19, 1986	Mar	CAHN
	@	100MG	A087862	001	Apr 18, 1983	Mar	CAHN

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

IBANDRONATE SODIUM

AP	ACCORD HLTHCARE	EQ 3MG BASE/3ML	A206058	001	Feb 05, 2016	Jan	NEWA
----	-----------------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL

IBANDRONATE SODIUM

AB	AUROBINDO PHARMA LTD	EQ 150MG BASE	A204502	001	Mar 11, 2016	Feb	NEWA
AB	SUN PHARM INDS	EQ 150MG BASE	A078996	001	Aug 15, 2012	Mar	CAHN

IBUPROFEN

TABLET; ORAL

IBUPROFEN

	@ AUROLIFE PHARMA LLC	300MG	A070734	001	Jun 12, 1986	Feb	CAHN
	@	400MG	A070735	001	Jun 12, 1986	Feb	CAHN
	@	600MG	A070736	001	Jun 12, 1986	Feb	CAHN
	@	800MG	A071938	001	Jan 14, 1988	Mar	CAHN
>A>	@ J AND J CONSUMER INC	400MG	A070081	001	Jun 16, 1986	Jul	CAHN
>D>	@ MCNEIL	400MG	A070081	001	Jun 16, 1986	Jul	CAHN
AB	STRIDES PHARMA	400MG	A078329	001	Feb 05, 2009	May	CAHN
AB		600MG	A078329	002	Feb 05, 2009	May	CAHN
AB		800MG	A078329	003	Feb 05, 2009	May	CAHN
	@ SUN PHARM INDS	400MG	A070079	001	Jul 24, 1985	Mar	CAHN
	@	600MG	A070080	001	Jul 24, 1985	Mar	CAHN
	@	800MG	A071448	001	Feb 18, 1987	Mar	CAHN

IBUPROFEN LYSINEINJECTABLE;INTRAVENOUS
IBUPROFEN LYSINE

AP		EXELA PHARMA SCIENCE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	A202402	001	Mar 30, 2016	Mar	NEWA
AP	+	RECORDATI RARE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006	Mar	CFTG

IMATINIB MESYLATETABLET;ORAL
IMATINIB MESYLATE

>A>	AB	APOTEX INC	EQ 100MG BASE	A079179	001	Aug 05, 2016	Jul	NEWA
>A>	AB		EQ 400MG BASE	A079179	002	Aug 05, 2016	Jul	NEWA
>A>	AB	TEVA PHARMS USA	EQ 100MG BASE	A204285	001	Aug 04, 2016	Jul	NEWA
>A>	AB		EQ 400MG BASE	A204285	002	Aug 04, 2016	Jul	NEWA

IMIPRAMINE HYDROCHLORIDETABLET;ORAL
IMIPRAMINE HYDROCHLORIDE

AB		SUN PHARM INDS	10MG	A081048	001	Jun 05, 1990	Mar	CAHN
AB			25MG	A081049	001	Jun 05, 1990	Mar	CAHN
AB			50MG	A081050	001	Jun 05, 1990	Mar	CAHN

IMIPRAMINE PAMOATECAPSULE;ORAL
IMIPRAMINE PAMOATE

AB	+	ROXANE	EQ 75MG HCL	A091099	001	Apr 16, 2010	Feb	CRLD
		TOFRANIL-PM						
		@ MALLINCKRODT INC	EQ 75MG HCL	N017090	001		Feb	DISC
		@	EQ 100MG HCL	N017090	004		Feb	DISC
		@	EQ 125MG HCL	N017090	003		Feb	DISC
		@	EQ 150MG HCL	N017090	002		Feb	DISC

INDIUM IN-111 CHLORIDEINJECTABLE;INJECTION
INDIUM IN 111 CHLORIDE

+		MALLINKRODT NUCLEAR	5mCi/0.5ML	N019841	001	Sep 27, 1994	Jan	CAHN
---	--	---------------------	------------	---------	-----	--------------	-----	------

INDIUM IN-111 OXYQUINOLINEINJECTABLE;INJECTION
INDIUM IN 111 OXYQUINOLINE

+		GE HEALTHCARE	1mCi/ML	N019044	001	Dec 24, 1985	Mar	CMS1
---	--	---------------	---------	---------	-----	--------------	-----	------

INDIUM IN-111 PENTETREOTIDE KITINJECTABLE;INJECTION
OCTREOSCAN

+		MALLINKRODT NUCLEAR	3mCi/ML	N020314	001	Jun 02, 1994	Jan	CAHN
---	--	---------------------	---------	---------	-----	--------------	-----	------

INDOCYANINE GREENINJECTABLE;INJECTION
INDOCYANINE GREEN

AP		DIAGNOSTIC GREEN	25MG/VIAL	A040811	001	Nov 21, 2007	Jan	CAHN
----	--	------------------	-----------	---------	-----	--------------	-----	------

INDOMETHACIN SODIUMINJECTABLE;INJECTION
INDOMETHACIN SODIUM

AP		HOSPIRA INC	EQ 1MG BASE/VIAL	A204118	001	Apr 19, 2016	Apr	NEWA
----	--	-------------	------------------	---------	-----	--------------	-----	------

INSULIN DETEMIR RECOMBINANTINJECTABLE;SUBCUTANEOUS
LEVEMIR FLEXPEN

@		NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	002	Jun 16, 2005	Feb	DISC
---	--	------------------	------------------------------	---------	-----	--------------	-----	------

INSULIN HUMANSOLUTION;SUBCUTANEOUS
HUMULIN R

+		LILLY	10000 UNITS/20ML (500 UNITS/ML)	N018780	004	Mar 31, 1994	Jan	CAIN
+		HUMULIN R KWIKPEN						
+		LILLY	1500 UNITS/3ML (500 UNITS/ML)	N018780	002	Dec 29, 2015	Jan	NEWA

INSULIN RECOMBINANT HUMAN

POWDER; INHALATION

AFREZZA

	MANNKIND	4 UNITS/INH	N022472	001	Jun 27, 2014	Mar	CAHN
+		8 UNITS/INH	N022472	002	Jun 27, 2014	Mar	CAHN
		12 UNITS/INH	N022472	003	Apr 17, 2015	Mar	CAHN

IOXILAN

INJECTABLE; INJECTION

OXILAN-300

	@ GUERBET	62%	N020316	001	Dec 21, 1995	Jun	DISC
--	-----------	-----	---------	-----	--------------	-----	------

OXILAN-350

	@ GUERBET	73%	N020316	002	Dec 21, 1995	Jun	DISC
--	-----------	-----	---------	-----	--------------	-----	------

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

>D>	AN	+	MYLAN SPECLT	0.02%	A074755	001	Jan 10, 1997	Jul	DISC
>A>			@	0.02%	A074755	001	Jan 10, 1997	Jul	DISC
>D>	AN		RITEDOSE CORP	0.02%	A075693	001	Jan 26, 2001	Jul	CRLD
>A>	AN	+		0.02%	A075693	001	Jan 26, 2001	Jul	CRLD

IRBESARTAN

TABLET; ORAL

IRBESARTAN

AB			HISUN PHARM HANGZHOU	75MG	A206194	001	Jun 14, 2016	May	NEWA
AB				150MG	A206194	002	Jun 14, 2016	May	NEWA
AB				300MG	A206194	003	Jun 14, 2016	May	NEWA

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

CAMPTOSAR

AP	+		PFIZER INC	300MG/15ML (20MG/ML)	N020571	003	Aug 05, 2010	Apr	CTEC
			IRINOTECAN HYDROCHLORIDE						
AP			EUROHLTH INTL SARL	40MG/2ML (20MG/ML)	A078753	001	Dec 24, 2008	Jun	CAHN
AP				100MG/5ML (20MG/ML)	A078753	002	Dec 24, 2008	Jun	CAHN
AP			QILU PHARM CO LTD	40MG/2ML (20MG/ML)	A203380	001	May 03, 2016	Apr	NEWA
AP				100MG/5ML (20MG/ML)	A203380	002	May 03, 2016	Apr	NEWA
AP				300MG/15ML (20MG/ML)	A203380	003	May 03, 2016	Apr	NEWA
AP			SANDOZ INC	40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009	Jan	CAHN
AP				100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009	Jan	CAHN

IRON DEXTRAN

INJECTABLE; INJECTION

INFED

BP	+		ALLERGAN SALES LLC	EQ 50MG IRON/ML	N017441	001		Apr	CAHN
----	---	--	--------------------	-----------------	---------	-----	--	-----	------

ISONIAZID

TABLET; ORAL

ISONIAZID

AA			MIKART	100MG	A040090	001	Jun 26, 1997	Jun	CMFD
AA				300MG	A040090	002	Jun 26, 1997	Jun	CMFD
			@ SUN PHARM INDS	100MG	A080136	001		Mar	CAHN
			@	300MG	A083633	001		Mar	CAHN

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

DILATRATE-SR

>D>	+		AUXILIUM PHARMS INC	40MG	N019790	001	Sep 02, 1988	Jul	CAHN
	+			40MG	N019790	001	Sep 02, 1988	Mar	CAHN
>A>	+		AUXILIUM PHARMS LLC	40MG	N019790	001	Sep 02, 1988	Jul	CAHN

TABLET; ORAL

ISOSORBIDE DINITRATE

	@	SUN PHARM INDS	5MG	A086166	002	Sep 19, 1986	Mar	CAHN
	@		10MG	A086169	001	Sep 19, 1986	Jun	CAHN
	@		20MG	A086167	001	Sep 19, 1986	Jun	CAHN
	@		30MG	A087564	001	Sep 18, 1986	Jun	CAHN

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

	@	SUN PHARM INDS	2.5MG	A084204	001	Sep 18, 1986	Jun	CAHN
	@		5MG	A086168	001	Sep 18, 1986	Jun	CAHN

TABLET;SUBLINGUAL								
ISOSORBIDE DINITRATE								
	@	10MG			A 087545	001	Sep 18, 1986	Jun CAHN
TABLET, EXTENDED RELEASE;ORAL								
ISOSORBIDE DINITRATE								
	@ COREPHARMA	40MG			A 040723	001	Mar 17, 2008	Mar DISC
	+ SUN PHARM INDS INC	40MG			A 040009	001	Dec 30, 1998	Mar CTEC
<u>ISOSULFAN BLUE</u>								
INJECTABLE;INJECTION								
ISOSULFAN BLUE								
AP	AUROBINDO PHARMA LTD	1%			A 206831	001	Feb 02, 2016	Jan NEWA
AP	+ MYLAN INSTITUTIONAL	1%			A 090874	001	Jul 20, 2010	Jan CTEC
<u>ISOTRETINOIN</u>								
CAPSULE;ORAL								
ABSORICA								
>D>	BX	RANBAXY	10MG		N 021951	001	May 25, 2012	Jul CAHN
>D>	BX		20MG		N 021951	002	May 25, 2012	Jul CAHN
>D>			25MG		N 021951	005	Aug 15, 2014	Jul CAHN
>D>	BX		30MG		N 021951	003	May 25, 2012	Jul CAHN
>D>			35MG		N 021951	006	Aug 15, 2014	Jul CAHN
>D>	BX	+	40MG		N 021951	004	May 25, 2012	Jul CAHN
>A>	BX	RANBAXY LABS LTD	10MG		N 021951	001	May 25, 2012	Jul CAHN
>A>	BX		20MG		N 021951	002	May 25, 2012	Jul CAHN
>A>			25MG		N 021951	005	Aug 15, 2014	Jul CAHN
>A>	BX		30MG		N 021951	003	May 25, 2012	Jul CAHN
>A>			35MG		N 021951	006	Aug 15, 2014	Jul CAHN
>A>	BX	+	40MG		N 021951	004	May 25, 2012	Jul CAHN
<u>ITRACONAZOLE</u>								
CAPSULE;ORAL								
ITRACONAZOLE								
AB	ACCORD HLTHCARE	100MG			A 205991	001	May 26, 2016	May NEWA
SOLUTION;ORAL								
ITRACONAZOLE								
	@ AMNEAL PHARMS	10MG/ML			A 205573	001	Oct 30, 2015	Apr DISC
	SPORANOX							
	+ JANSSEN PHARMS	10MG/ML			N 020657	001	Feb 21, 1997	Apr CTEC
<u>IVERMECTIN</u>								
LOTION;TOPICAL								
SKLICE								
	+ ARBOR PHARMS LLC	0.5%			N 202736	001	Feb 07, 2012	May CAHN
<u>KETOCONAZOLE</u>								
TABLET;ORAL								
KETOCONAZOLE								
	@ SUN PHARM INDS	200MG			A 075314	001	Jun 15, 1999	Jan CAHN
<u>KETOPROFEN</u>								
CAPSULE;ORAL								
KETOPROFEN								
	@ AUROLIFE PHARMA LLC	50MG			A 074024	001	Dec 29, 1995	Feb CAHN
	@	75MG			A 074024	002	Dec 29, 1995	Feb CAHN
<u>KETOROLAC TROMETHAMINE</u>								
INJECTABLE;INJECTION								
KETOROLAC TROMETHAMINE								
	@ EUROHLTH INTL SARL	15MG/ML			A 075222	001	Apr 26, 1999	Apr CAHN
	@	30MG/ML			A 075222	002	Apr 26, 1999	Apr CAHN
	@	30MG/ML			A 075228	001	Apr 26, 1999	May CAHN
<u>LABETALOL HYDROCHLORIDE</u>								
INJECTABLE;INJECTION								
LABETALOL HYDROCHLORIDE								
AP	SAGENT STRIDES	5MG/ML			A 079134	001	Feb 03, 2010	Jan CTNA
TRANDATE								
	@ SEBELA IRELAND LTD	5MG/ML			N 019425	001	Dec 31, 1985	Jan CAHN

TABLET;ORAL						
LABETALOL HYDROCHLORIDE						
AB	NOSTRUM LABS INC	100MG	A075215	001	Jul 29, 1999	Jan CAHN
AB		200MG	A075215	002	Jul 29, 1999	Jan CAHN
AB		300MG	A075215	003	Jul 29, 1999	Jan CAHN
<u>LACOSAMIDE</u>						
SOLUTION;ORAL						
LACOSAMIDE						
AA	AMNEAL PHARMS	10MG/ML	A204839	001	Apr 28, 2016	Apr NEWA
	VIMPAT					
AA	+ UCB INC	10MG/ML	N022255	001	Apr 20, 2010	Apr CFTG
TABLET;ORAL						
LACOSAMIDE						
AB	ACTAVIS LABS FL INC	50MG	A204855	001	Apr 28, 2016	Apr NEWA
AB		100MG	A204855	002	Apr 28, 2016	Apr NEWA
AB		150MG	A204855	003	Apr 28, 2016	Apr NEWA
AB		200MG	A204855	004	Apr 28, 2016	Apr NEWA
AB	ALEMBIC PHARMS LTD	50MG	A204974	001	Apr 28, 2016	Apr NEWA
AB		100MG	A204974	002	Apr 28, 2016	Apr NEWA
AB		150MG	A204974	003	Apr 28, 2016	Apr NEWA
AB		200MG	A204974	004	Apr 28, 2016	Apr NEWA
AB	AUROBINDO PHARMA LTD	50MG	A204994	001	Apr 28, 2016	Apr NEWA
AB		100MG	A204994	002	Apr 28, 2016	Apr NEWA
AB		150MG	A204994	003	Apr 28, 2016	Apr NEWA
AB		200MG	A204994	004	Apr 28, 2016	Apr NEWA
AB	MSN LABS PVT LTD	50MG	A204921	001	Apr 28, 2016	Apr NEWA
AB		100MG	A204921	002	Apr 28, 2016	Apr NEWA
AB		150MG	A204921	003	Apr 28, 2016	Apr NEWA
AB		200MG	A204921	004	Apr 28, 2016	Apr NEWA
AB	MYLAN PHARMS INC	50MG	A205026	001	Apr 28, 2016	Apr NEWA
AB		100MG	A205026	002	Apr 28, 2016	Apr NEWA
AB		150MG	A205026	003	Apr 28, 2016	Apr NEWA
AB		200MG	A205026	004	Apr 28, 2016	Apr NEWA
AB	SUN PHARMA GLOBAL	50MG	A205031	001	Apr 28, 2016	Apr NEWA
AB		100MG	A205031	002	Apr 28, 2016	Apr NEWA
AB		150MG	A205031	003	Apr 28, 2016	Apr NEWA
AB		200MG	A205031	004	Apr 28, 2016	Apr NEWA
VIMPAT						
AB	UCB INC	50MG	N022253	001	Oct 28, 2008	Apr CFTG
AB		100MG	N022253	002	Oct 28, 2008	Apr CFTG
AB		150MG	N022253	003	Oct 28, 2008	Apr CFTG
AB	+	200MG	N022253	004	Oct 28, 2008	Apr CFTG
<u>LAMIVUDINE</u>						
TABLET;ORAL						
LAMIVUDINE						
AB	MYLAN PHARMS INC	150MG	A204528	001	Mar 04, 2016	Feb NEWA
AB		300MG	A204528	002	Mar 04, 2016	Feb NEWA
<u>LAMOTRIGINE</u>						
TABLET;ORAL						
LAMOTRIGINE						
AB	JUBILANT CADISTA	25MG	A079132	001	Jan 27, 2009	Jun CAHN
AB		100MG	A079132	002	Jan 27, 2009	Jun CAHN
AB		150MG	A079132	003	Jan 27, 2009	Jun CAHN
AB		200MG	A079132	004	Jan 27, 2009	Jun CAHN
TABLET, EXTENDED RELEASE;ORAL						
LAMICTAL XR						
AB	+ GLAXOSMITHKLINE LLC	200MG	N022115	004	May 29, 2009	Jan CRLD
TABLET, ORALLY DISINTEGRATING;ORAL						
LAMOTRIGINE						
AB	SCIEGEN PHARMS INC	25MG	A206382	001	Jun 17, 2016	Jun NEWA
AB		50MG	A206382	002	Jun 17, 2016	Jun NEWA
AB		100MG	A206382	003	Jun 17, 2016	Jun NEWA
AB		200MG	A206382	004	Jun 17, 2016	Jun NEWA

LANSOPRAZOLECAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

>A>	AB	ANCHEN PHARMS	15MG	A203203	001	Jul 25, 2016	Jul	NEWA
>A>	AB		30MG	A203203	002	Jul 25, 2016	Jul	NEWA

LATANOPROSTSOLUTION/DROPS;OPHTHALMIC
LATANOPROST

AT	FDC LTD		0.005%	A202442	001	Apr 22, 2016	Apr	NEWA
----	---------	--	--------	---------	-----	--------------	-----	------

LETROZOLETABLET;ORAL
LETROZOLE

AB	HIKMA PHARMS		2.5MG	A203796	001	Jun 03, 2016	May	NEWA
AB	KREMERS URBAN PHARMS		2.5MG	A091098	001	Jun 03, 2011	Jan	CAHN

LEUCOVORIN CALCIUMTABLET;ORAL
LEUCOVORIN CALCIUM

@	IDT AUSTRALIA LTD		EQ 15MG BASE	A075327	001	Mar 24, 1999	May	CAHN
	ROXANE		EQ 15MG BASE	A072735	001	Feb 22, 1993	Jun	CTEC

LEVABUTEROL HYDROCHLORIDESOLUTION;INHALATION
LEVABUTEROL HYDROCHLORIDE

AN	RITEDOSE CORP		EQ 0.0103% BASE	A203653	001	Mar 22, 2016	Mar	NEWA
AN			EQ 0.021% BASE	A203653	002	Mar 22, 2016	Mar	NEWA
AN			EQ 0.042% BASE	A203653	003	Mar 22, 2016	Mar	NEWA

LEVETIRACETAMINJECTABLE;IV (INFUSION)
LEVETIRACETAM

AP	AUROBINDO PHARMA LTD		500MG/5ML (100MG/ML)	A204312	001	Feb 01, 2016	Jan	NEWA
AP	JUBILANT LIFE		500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016	May	NEWA

TABLET, EXTENDED RELEASE;ORAL
LEVETIRACETAM

AB	INTELLIPHARMACEUTICS		500MG	A204511	001	Feb 23, 2016	Feb	NEWA
AB			750MG	A204511	002	Feb 23, 2016	Feb	NEWA
AB	LOTUS PHARM CO LTD		500MG	A202095	002	Jun 06, 2016	May	NEWA
AB			750MG	A202095	001	Jun 06, 2016	May	NEWA
AB	SUN PHARM INDS		500MG	A091285	001	Sep 12, 2011	Mar	CAHN
AB			750MG	A091285	002	Sep 12, 2011	Mar	CAHN

TABLET, FOR SUSPENSION;ORAL
SPRITAM

	APRECIA PHARMS CO		250MG	N207958	001	Jul 31, 2015	Feb	CDFR
			500MG	N207958	002	Jul 31, 2015	Feb	CDFR
			750MG	N207958	003	Jul 31, 2015	Feb	CDFR
+			1GM	N207958	004	Jul 31, 2015	Mar	CRLD
			1GM	N207958	004	Jul 31, 2015	Feb	CDFR

LEVOBUNOLOL HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
LEVOBUNOLOL HYDROCHLORIDE

>A>	AT	ALCON LABS INC	0.25%	A074851	001	Oct 28, 1996	Jul	CAHN
>D>	AT	FALCON PHARMS	0.25%	A074851	001	Oct 28, 1996	Jul	CAHN

LEVOFLOXACININJECTABLE;INJECTION
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

@	JANSSEN PHARMS		EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jun	DISC
@			EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jun	DISC
@			EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jun	DISC

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	AUROBINDO PHARMA LTD		EQ 250MG/50ML (EQ 5MG/ML)	A206919	001	Feb 10, 2016	Jan	NEWA
AP			EQ 500MG/100ML (EQ 5MG/ML)	A206919	002	Feb 10, 2016	Jan	NEWA
AP			EQ 750MG/150ML (EQ 5MG/ML)	A206919	003	Feb 10, 2016	Jan	NEWA

SOLUTION/DROPS;OPHTHALMIC
LEVOFLOXACIN

AT	+	RISING PHARMS INC	0.5%	A077700	001	Dec 20, 2010	Jan	CAHN
----	---	-------------------	------	---------	-----	--------------	-----	------

LEVOLEUCOVORIN CALCIUM

POWDER; IV (INFUSION)
FUSILEV

AP	+	SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Jun CFTG
AP		LEVOLEUCOVORIN CALCIUM					
AP		EUROHLTH INTL SARL	EQ 50MG BASE/VIAL	A206263	001	Jun 16, 2016	Jun NEWA

LEVONORGESTREL

TABLET; ORAL
LEVONORGESTREL

+		PERRIGO R AND D	0.75MG	A090740	001	Dec 30, 2010	Apr CRLD
	@	WATSON LABS	0.75MG	A078665	001	Aug 28, 2009	Apr DISC
		PLAN B					
	@	TEVA BRANDED PHARM	0.75MG	N021045	002	Aug 24, 2006	Apr DISC

LEVOTHYROXINE SODIUM

POWDER; INTRAVENOUS
LEVOTHYROXINE SODIUM

AP		FERA PHARMS LLC	100MCG/VIAL	A206163	001	Jun 29, 2016	Jun NEWA
AP			500MCG/VIAL	A206163	002	Jun 29, 2016	Jun NEWA
AP	+	FRESENIUS KABI USA	100MCG/VIAL	N202231	001	Jun 24, 2011	Jun CFTG
AP	+		500MCG/VIAL	N202231	003	Jun 24, 2011	Jun CFTG

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL
LEVOLET

>A>	@	LEHIGH VALLEY	0.025MG	N021137	001	Jun 06, 2003	Jul CAHN
>A>	@		0.05MG	N021137	002	Jun 06, 2003	Jul CAHN
>A>	@		0.075MG	N021137	003	Jun 06, 2003	Jul CAHN
>A>	@		0.088MG	N021137	004	Jun 06, 2003	Jul CAHN
>A>	@		0.1MG	N021137	005	Jun 06, 2003	Jul CAHN
>A>	@		0.112MG	N021137	006	Jun 06, 2003	Jul CAHN
>A>	@		0.125MG	N021137	007	Jun 06, 2003	Jul CAHN
>A>	@		0.137MG	N021137	008	Jun 06, 2003	Jul CAHN
>A>	@		0.15MG	N021137	009	Jun 06, 2003	Jul CAHN
>A>	@		0.175MG	N021137	010	Jun 06, 2003	Jul CAHN
>A>	@		0.2MG	N021137	011	Jun 06, 2003	Jul CAHN
>A>	@		0.3MG	N021137	012	Jun 06, 2003	Jul CAHN
>D>	@	VINTAGE	0.025MG	N021137	001	Jun 06, 2003	Jul CAHN
>D>	@		0.05MG	N021137	002	Jun 06, 2003	Jul CAHN
>D>	@		0.075MG	N021137	003	Jun 06, 2003	Jul CAHN
>D>	@		0.088MG	N021137	004	Jun 06, 2003	Jul CAHN
>D>	@		0.1MG	N021137	005	Jun 06, 2003	Jul CAHN
>D>	@		0.112MG	N021137	006	Jun 06, 2003	Jul CAHN
>D>	@		0.125MG	N021137	007	Jun 06, 2003	Jul CAHN
>D>	@		0.137MG	N021137	008	Jun 06, 2003	Jul CAHN
>D>	@		0.15MG	N021137	009	Jun 06, 2003	Jul CAHN
>D>	@		0.175MG	N021137	010	Jun 06, 2003	Jul CAHN
>D>	@		0.2MG	N021137	011	Jun 06, 2003	Jul CAHN
>D>	@		0.3MG	N021137	012	Jun 06, 2003	Jul CAHN

LEVOTHROID

@	LLOYD	0.025MG	N021116	001	Oct 24, 2002	May DISC
@		0.05MG	N021116	002	Oct 24, 2002	May DISC
@		0.075MG	N021116	003	Oct 24, 2002	May DISC
@		0.088MG	N021116	010	Oct 24, 2002	May DISC
@		0.1MG	N021116	004	Oct 24, 2002	May DISC
@		0.112MG	N021116	011	Oct 24, 2002	May DISC
@		0.125MG	N021116	005	Oct 24, 2002	May DISC
@		0.137MG	N021116	012	Dec 07, 2004	May DISC
@		0.15MG	N021116	006	Oct 24, 2002	May DISC
@		0.175MG	N021116	007	Oct 24, 2002	May DISC
@		0.2MG	N021116	008	Oct 24, 2002	May DISC
@		0.3MG	N021116	009	Oct 24, 2002	May DISC

LEVOTHYROXINE SODIUM

AB1,	MYLAN	0.3MG	A076187	011	Jun 05, 2002	May CRLD
AB2,						
AB3,						
AB4	+					

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

AT	SEPTODONT INC	5%	A040911	001	May 23, 2011	Jun	CAHN
AT	TELIGENT PHARMA INC	5%	A205318	001	Feb 01, 2016	Jan	NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

@	HOSPIRA	400MG/100ML	N018388	002		Feb	DISC
---	---------	-------------	---------	-----	--	-----	------

LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

@	HOSPIRA	800MG/100ML	N018388	003	Nov 05, 1982	Feb	DISC
---	---------	-------------	---------	-----	--------------	-----	------

JELLY; TOPICAL

ANESTACON

@	BIONPHARMA INC	2%	A080429	001		Jan	CAHN
---	----------------	----	---------	-----	--	-----	------

SOLUTION; TOPICAL

LIDOCAINE HYDROCHLORIDE

AT	TELIGENT PHARMA INC	4%	A204494	001	Mar 12, 2014	May	CAHN
----	---------------------	----	---------	-----	--------------	-----	------

>A> LIFITEGRAST

>A> SOLUTION/DROPS; OPHTHALMIC

>A> XIIDRA

>A>	+	SHIRE DEV LLC	5%	N208073	001	Jul 11, 2016	Jul	NEWA
-----	---	---------------	----	---------	-----	--------------	-----	------

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

JENTADUETO XR

	BOEHRINGER INGELHEIM	2.5MG; 1GM	N208026	001	May 27, 2016	May	NEWA
--	----------------------	------------	---------	-----	--------------	-----	------

+ 5MG; 1GM

N208026	002	May 27, 2016	May	NEWA
---------	-----	--------------	-----	------

LINEZOLID

SOLUTION; IV (INFUSION)

LINEZOLID

>A>	AP	AUROBINDO PHARMA LTD	600MG/300ML (2MG/ML)	A206917	001	Aug 04, 2016	Jul	NEWA
-----	----	----------------------	----------------------	---------	-----	--------------	-----	------

AP	FRESENIUS KABI USA	600MG/300ML (2MG/ML)	A204764	001	Mar 15, 2016	Feb	NEWA
----	--------------------	----------------------	---------	-----	--------------	-----	------

TABLET; ORAL

LINEZOLID

AB	GATE PHARMS	600MG	A091210	001	Feb 05, 2016	Jan	NEWA
----	-------------	-------	---------	-----	--------------	-----	------

AB	GLENMARK PHARMS	600MG	A078987	001	Dec 21, 2015	Mar	CAHN
----	-----------------	-------	---------	-----	--------------	-----	------

LIOTHYRONINE SODIUM

TABLET; ORAL

LIOTHYRONINE SODIUM

AB	MAYNE PHARMA INC	EQ 0.005MG BASE	A090097	001	Mar 20, 2009	Mar	CAHN
----	------------------	-----------------	---------	-----	--------------	-----	------

AB		EQ 0.025MG BASE	A090097	002	Mar 20, 2009	Mar	CAHN
----	--	-----------------	---------	-----	--------------	-----	------

AB		EQ 0.05MG BASE	A090097	003	Mar 20, 2009	Mar	CAHN
----	--	----------------	---------	-----	--------------	-----	------

AB	SUN PHARM INDS LTD	EQ 0.005MG BASE	A091382	001	Apr 20, 2016	Apr	NEWA
----	--------------------	-----------------	---------	-----	--------------	-----	------

AB		EQ 0.025MG BASE	A091382	002	Apr 20, 2016	Apr	NEWA
----	--	-----------------	---------	-----	--------------	-----	------

AB		EQ 0.05MG BASE	A091382	003	Apr 20, 2016	Apr	NEWA
----	--	----------------	---------	-----	--------------	-----	------

LISINOPRIL

>A> SOLUTION; ORAL

>A> QBRELLIS

>A>	+	SILVERGATE PHARMS	1MG/ML	N208401	001	Jul 29, 2016	Jul	NEWA
-----	---	-------------------	--------	---------	-----	--------------	-----	------

TABLET; ORAL

ZESTRIL

AB	ALVOGEN MALTA	2.5MG	N019777	005	Apr 29, 1993	Jan	CAHN
----	---------------	-------	---------	-----	--------------	-----	------

AB		5MG	N019777	001	May 19, 1988	Jan	CAHN
----	--	-----	---------	-----	--------------	-----	------

AB		10MG	N019777	002	May 19, 1988	Jan	CAHN
----	--	------	---------	-----	--------------	-----	------

AB		20MG	N019777	003	May 19, 1988	Jan	CAHN
----	--	------	---------	-----	--------------	-----	------

AB		30MG	N019777	006	Jan 20, 1999	Jan	CAHN
----	--	------	---------	-----	--------------	-----	------

AB	+	40MG	N019777	004	May 19, 1988	Jan	CAHN
----	---	------	---------	-----	--------------	-----	------

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

AB	DELCOR ASSET CORP	150MG	A076243	002	Feb 24, 2003	Feb	CAHN
----	-------------------	-------	---------	-----	--------------	-----	------

AB		300MG	A076243	001	Jun 27, 2002	Feb	CAHN
----	--	-------	---------	-----	--------------	-----	------

AB		600MG	A078763	001	Apr 15, 2008	Feb	CAHN
----	--	-------	---------	-----	--------------	-----	------

AB	HIKMA PHARMS	600MG	A078763	001	Apr 15, 2008	Jan	CMFD
----	--------------	-------	---------	-----	--------------	-----	------

>A>	<u>LIXISENATIDE</u>							
>A>	SOLUTION;SUBCUTANEOUS							
>A>	ADLYXIN							
>A>	+	SANOFI-AVENTIS US	0.05MG/ML	N208471	001	Jul 27, 2016	Jul	NEWA
>A>	+		0.1MG/ML	N208471	002	Jul 27, 2016	Jul	NEWA
	<u>LOMITAPIDE MESYLATE</u>							
	CAPSULE;ORAL							
	JUXTAPID							
		AEGERION	EQ 20MG BASE	N203858	003	Dec 21, 2012	Jan	CRLD
	+		EQ 60MG BASE	N203858	006	Apr 23, 2015	Jan	CRLD
	<u>LOPERAMIDE HYDROCHLORIDE</u>							
	CAPSULE;ORAL							
	IMODIUM							
		@ J AND J CONSUMER INC	2MG	N017694	001		Feb	DISC
		LOPERAMIDE HYDROCHLORIDE						
AB	+	MYLAN	2MG	A072741	001	Sep 18, 1991	Feb	CRLD
	<u>LORAZEPAM</u>							
	TABLET;ORAL							
	LORAZEPAM							
>A>		@ FRONTIDA BIOPHARM	2MG	A072555	001	Mar 29, 1991	Jul	CAHN
>D>		@ MUTUAL PHARM	2MG	A072555	001	Mar 29, 1991	Jul	CAHN
	<u>LORCASERIN HYDROCHLORIDE</u>							
>A>	TABLET, EXTENDED RELEASE;ORAL							
>A>	BELVIQ XR							
>A>	+	EISAI INC	20MG	N208524	001	Jul 15, 2016	Jul	NEWA
	<u>LOSARTAN POTASSIUM</u>							
	TABLET;ORAL							
	LOSARTAN POTASSIUM							
BX		HETERO LABS LTD V	25MG	A203835	001	Aug 12, 2015	Apr	CTEC
BX			50MG	A203835	002	Aug 12, 2015	Apr	CTEC
BX			100MG	A203835	003	Aug 12, 2015	Apr	CTEC
BX		LUPIN LTD	25MG	A078232	001	Oct 06, 2010	Apr	CTEC
BX			50MG	A078232	002	Oct 06, 2010	Apr	CTEC
BX			100MG	A078232	003	Oct 06, 2010	Apr	CTEC
	<u>LOVASTATIN</u>							
	TABLET;ORAL							
	LOVASTATIN							
AB		SUN PHARM INDS	10MG	A077520	001	Apr 14, 2006	Mar	CAHN
AB			20MG	A077520	002	Apr 14, 2006	Mar	CAHN
AB			40MG	A077520	003	Apr 14, 2006	Mar	CAHN
	<u>LOXAPINE</u>							
	POWDER;INHALATION							
	ADASUVE							
	+	ALEXZA PHARMS	10MG	N022549	001	Dec 21, 2012	Feb	CAHN
	<u>MAGNESIUM SULFATE</u>							
	INJECTABLE;INJECTION							
	MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP		FRESENIUS KABI USA	1GM/100ML	A206486	001	Mar 07, 2016	Feb	NEWA
AP	+	HOSPIRA	1GM/100ML	N020488	001	Jul 11, 1995	Feb	CFTG
AP		HQ SPCLT PHARMA	1GM/100ML	A207349	001	Mar 02, 2016	Feb	NEWA
	MAGNESIUM SULFATE IN PLASTIC CONTAINER							
AP		FRESENIUS KABI USA	4GM/100ML (40MG/ML)	A206485	001	Mar 15, 2016	Feb	NEWA
AP			4GM/50ML (80MG/ML)	A206485	002	Mar 15, 2016	Feb	NEWA
AP			2GM/50ML (40MG/ML)	A206485	003	Mar 15, 2016	Mar	NEWA
AP			20GM/500ML (40MG/ML)	A206485	004	Mar 15, 2016	Mar	NEWA
AP			40GM/1000ML (40MG/ML)	A206485	005	Mar 15, 2016	Mar	NEWA
AP		HOSPIRA	2GM/50ML (40MG/ML)	N020309	003	Jan 26, 2007	Mar	CFTG
AP	+		4GM/100ML (40MG/ML)	N020309	001	Jun 24, 1994	Feb	CFTG
AP	+		4GM/50ML (80MG/ML)	N020309	002	Jun 24, 1994	Feb	CFTG
AP			20GM/500ML (40MG/ML)	N020309	004	Jan 18, 1995	Mar	CFTG
AP			40GM/1000ML (40MG/ML)	N020309	005	Jan 18, 1995	Mar	CFTG

SOLUTION;INTRAMUSCULAR, INTRAVENOUS
MAGNESIUM SULFATE

+	FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316	003	Jan 29, 2016	Jan NEWA
+		25GM/50ML (500MG/ML)	N019316	004	Jan 29, 2016	Jan NEWA

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

@	RISING PHARMS INC	12.5MG	A040179	001	Jan 30, 1997	Jan CAHN
@		25MG	A040179	002	Jan 30, 1997	Jan CAHN

TABLET, CHEWABLE;ORAL

ANTIVERT

@	CASPER PHARMA LLC	25MG	N010721	005		Jun DISC
---	-------------------	------	---------	-----	--	----------

MEFLOQUINE HYDROCHLORIDE

TABLET;ORAL

MEFLOQUINE HYDROCHLORIDE

@	HIKMA INTL PHARMS	250MG	A077699	001	Apr 21, 2010	May CAHN
---	-------------------	-------	---------	-----	--------------	----------

MEGESTROL ACETATE

SUSPENSION;ORAL

MEGACE ES

AB	+	ENDO PHARMS INC	125MG/ML	N021778	001	Jul 05, 2005	Feb CAHN
----	---	-----------------	----------	---------	-----	--------------	----------

MELOXICAM

TABLET;ORAL

MELOXICAM

>A>	@	FRONTIDA BIOPHARM	7.5MG	A077935	001	Jul 19, 2006	Jul CAHN
>A>	@		15MG	A077935	002	Jul 19, 2006	Jul CAHN
>D>	@	SUN PHARM INDS	7.5MG	A077935	001	Jul 19, 2006	Jul CAHN
	@		7.5MG	A077935	001	Jul 19, 2006	Jan CAHN
>D>	@		15MG	A077935	002	Jul 19, 2006	Jul CAHN
	@		15MG	A077935	002	Jul 19, 2006	Jan CAHN

MELPHALAN

TABLET;ORAL

ALKERAN

+	APOTEX INC	2MG	N014691	002		Jan CAHN
---	------------	-----	---------	-----	--	----------

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

AP	+	APOTEX INC	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992	Jan CAHN
----	---	------------	-------------------	---------	-----	--------------	----------

POWDER; IV (INFUSION)

EVOMELA

		SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Mar NEWA
--	--	-----------------	-------------------	---------	-----	--------------	----------

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

@	US PHARM HOLDINGS	25MG/ML	N005010	007		Jan CAHN
@		50MG/ML	N005010	002		Jan CAHN
@		75MG/ML	N005010	009		Jan CAHN
@		100MG/ML	N005010	003		Jan CAHN

SYRUP;ORAL

DEMEROL

@	US PHARM HOLDINGS	50MG/5ML	N005010	005		Jan CAHN
---	-------------------	----------	---------	-----	--	----------

TABLET;ORAL

DEMEROL

AA	+	US PHARM HOLDINGS	50MG	N005010	001		Jan CAHN
AA	+		100MG	N005010	004		Jan CAHN

MEPERIDINE HYDROCHLORIDE

@	SUN PHARM INDS	50MG	A080448	001		Mar CAHN
@		100MG	A080448	002		Mar CAHN

MEPROBAMATE

TABLET;ORAL

MEPROBAMATE

@	AUROLIFE PHARMA LLC	400MG	A080655	001		Feb CAHN
@	SUN PHARM INDS	200MG	A080699	001		Mar CAHN
@		400MG	A080699	002		Mar CAHN

MERCAPTOPURINE

TABLET; ORAL		MERCAPTOPURINE					
AB	DR REDDYS LABS INTL	50MG	A040461	001	Feb 11, 2004	Apr	CAHN
	PURINETHOL						
	@ STASON PHARMS	50MG	N009053	002		Jan	CAHN

MEROPENEM

INJECTABLE; INJECTION		MEROPENEM					
AP	AMNEAL PHARMS	500MG/VIAL	A205883	001	Apr 12, 2016	Mar	NEWA
AP		1GM/VIAL	A205883	002	Apr 12, 2016	Mar	NEWA
AP	GLAND PHARMA LTD	500MG/VIAL	A206141	001	Jun 08, 2016	May	NEWA
AP		1GM/VIAL	A206141	002	Jun 08, 2016	May	NEWA
AP	PAR STERILE PRODUCTS	500MG/VIAL	A204139	001	Jun 09, 2016	May	NEWA
AP		1GM/VIAL	A204139	002	Jun 09, 2016	May	NEWA
AP	SAVIOR LIFETEC CORP	500MG/VIAL	A206086	001	Apr 19, 2016	Apr	NEWA
AP		1GM/VIAL	A206086	002	Apr 19, 2016	Apr	NEWA

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL		DELZICOL					
+	APIL	400MG	N204412	001	Feb 01, 2013	Jan	CAHN
TABLET, DELAYED RELEASE; ORAL		ASACOL					
	@ APIL	400MG	N019651	001	Jan 31, 1992	Jan	CAHN
	ASACOL HD						
+	APIL	800MG	N021830	001	May 29, 2008	Jan	CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL		METFORMIN HYDROCHLORIDE					
AB	CSPC OUYI PHARM CO	500MG	A205096	001	Jul 11, 2016	Jun	NEWA
AB		850MG	A205096	002	Jul 11, 2016	Jun	NEWA
AB		1GM	A205096	003	Jul 11, 2016	Jun	NEWA
AB	SUN PHARM INDS	500MG	A076038	001	Feb 21, 2002	Mar	CAHN
AB		850MG	A076038	002	Feb 21, 2002	Mar	CAHN
AB		1GM	A076038	003	Feb 21, 2002	Mar	CAHN
TABLET, EXTENDED RELEASE; ORAL		GLUMETZA					
AB3	SANTARUS INC	500MG	N021748	001	Jun 03, 2005	Jan	CTEC
AB3	+	1GM	N021748	002	Jun 03, 2005	Jan	CTEC
METFORMIN HYDROCHLORIDE		ACTAVIS LABS FL INC					
>A>	AB3	500MG	A203755	001	Aug 01, 2016	Jul	NEWA
>A>	AB3	1GM	A203755	002	Aug 01, 2016	Jul	NEWA
	@ IMPAX LABS	500MG	A076249	001	Jul 30, 2004	Mar	DISC
	@	750MG	A076985	001	Sep 13, 2005	Mar	DISC
AB1	MARKSANS PHARMA	500MG	A090295	001	Apr 29, 2016	Apr	NEWA
AB		750MG	A090295	002	Apr 29, 2016	Apr	NEWA
	@ SUN PHARM INDS	500MG	A077124	001	Dec 21, 2005	Mar	CAHN
>A>	AB3	SUN PHARMA GLOBAL	A202917	001	Aug 01, 2016	Jul	NEWA
>A>	AB3	1GM	A202917	002	Aug 01, 2016	Jul	NEWA

METHENAMINE HIPPURATE

TABLET; ORAL		HIPREX						
AB	+	US PHARM HOLDINGS	1GM	N017681	001	Jan	CAHN	
		METHENAMINE HIPPURATE						
AB		AUROBINDO PHARMA LTD	1GM	A205661	001	Jul 05, 2016	Jun	NEWA

METHIMAZOLE

TABLET; ORAL		METHIMAZOLE						
>D>	AB	CEDAR PHARMS	5MG	A040547	001	Feb 18, 2005	Jul	CAHN
>D>	AB		10MG	A040547	002	Feb 18, 2005	Jul	CAHN
>D>		@	20MG	A040547	004	Feb 18, 2005	Jul	CAHN
>A>	AB	ECI PHARMS LLC	5MG	A040547	001	Feb 18, 2005	Jul	CAHN
>A>	AB		10MG	A040547	002	Feb 18, 2005	Jul	CAHN
>A>		@	20MG	A040547	004	Feb 18, 2005	Jul	CAHN
AB		RISING PHARMS INC	5MG	A202068	001	Mar 07, 2012	Jan	CAHN
AB			10MG	A202068	002	Mar 07, 2012	Jan	CAHN

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

AP AUROBINDO PHARMA LTD 1GM/10ML (100MG/ML) A206128 001 May 27, 2016 May NEWA

TABLET; ORAL

METHOCARBAMOL

@ SANDOZ

500MG

A084616 001

Feb DISC

@

750MG

A084615 001

Feb DISC

@ SUN PHARM INDS

500MG

A084488 001

Mar CAHN

@

750MG

A084486 001

Mar CAHN

ROBAXIN

>D> AA + AUXILIUM PHARMS INC 500MG N011011 004 Jul CAHN

AA + 500MG N011011 004 Mar CAHN

>A> AA + AUXILIUM PHARMS LLC 500MG N011011 004 Jul CAHN

ROBAXIN-750

>D> AA + AUXILIUM PHARMS INC 750MG N011011 006 Jul CAHN

AA + 750MG N011011 006 Mar CAHN

>A> AA + AUXILIUM PHARMS LLC 750MG N011011 006 Jul CAHN

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

@ PAR STERILE PRODUCTS 200MG/VIAL

N011559 004 Dec 21, 2012 Jun DISC

METHOTREXATE

SOLUTION; SUBCUTANEOUS

OTREXUP

ANTARES PHARMA INC

12.5MG/0.4ML (12.5MG/0.4ML)

N204824 006 Mar 24, 2016

May NEWA

17.5MG/0.4ML (17.5MG/0.4ML)

N204824 007 Mar 24, 2016

May NEWA

22.5MG/0.4ML (22.5MG/0.4ML)

N204824 008 Mar 24, 2016

May NEWA

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP SANDOZ INC EQ 50MG BASE/2ML (EQ 25MG BASE/ML) A090039 001 Mar 31, 2009 Jan CAHN

AP EQ 250MG BASE/10ML (EQ 25MG

BASE/ML)

A090039 002

Mar 31, 2009

Jan CAHN

AP EQ 1GM BASE/40ML (EQ 25MG BASE/ML) A090029 001 Mar 31, 2009 Jan CAHN

METHOXSALEN

INJECTABLE; INJECTION

UVADEX

+ MALLINCKRODT HOSP 0.02MG/ML N020969 001 Feb 25, 1999 Apr CAHN

METHYLDOPA

TABLET; ORAL

METHYLDOPA

@ SUN PHARM INDS

125MG

A070073 001 Oct 09, 1986

Mar CAHN

@

250MG

A070060 001 Oct 09, 1986

Mar CAHN

@

500MG

A070074 001 Oct 09, 1986

Mar CAHN

METHYLENE BLUE

SOLUTION; INTRAVENOUS

PROVAYBLUE

+ PROVEPHARM SAS 50MG/10ML (5MG/ML) N204630 001 Apr 08, 2016 Apr NEWA

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHERGINE

@ EDISON THERAPS LLC

0.2MG

N006035 003

Jan DISC

METHYLERGONOVINE MALEATE

+ NOVEL LABS INC 0.2MG A091577 001 May 02, 2011 Jan CRLD

METHYLNALTREXONE BROMIDE

SOLUTION; SUBCUTANEOUS

RELISTOR

>D> SALIX PHARMS 8MG/0.4ML (8MG/0.4ML) N021964 002 Sep 27, 2010 Jul CRLD

>A> + 8MG/0.4ML (8MG/0.4ML) N021964 002 Sep 27, 2010 Jul CRLD

>A>	TABLET;ORAL						
>A>	RELISTOR						
>A>	+ SALIX PHARMS INC	150MG	N208271	001	Jul 19, 2016	Jul	NEWA
<u>METHYLPHENIDATE HYDROCHLORIDE</u>							
CAPSULE, EXTENDED RELEASE;ORAL							
METHYLPHENIDATE HYDROCHLORIDE							
>A>	AB2	COREPHARMA	10MG	A205105	001	Jul 28, 2016	Jul NEWA
>A>	AB2		20MG	A205105	002	Jul 28, 2016	Jul NEWA
>A>	AB2		30MG	A205105	003	Jul 28, 2016	Jul NEWA
>A>	AB2		40MG	A205105	004	Jul 28, 2016	Jul NEWA
>A>	AB2		50MG	A205105	005	Jul 28, 2016	Jul NEWA
>A>	AB2		60MG	A205105	006	Jul 28, 2016	Jul NEWA
	AB1	WATSON LABS INC	60MG	A078458	004	Jun 23, 2016	Jun NEWA
RITALIN LA							
	AB1	+ NOVARTIS	60MG	N021284	005	Oct 27, 2014	Jun CFTG
SOLUTION;ORAL							
METHYLPHENIDATE HYDROCHLORIDE							
	AA	NOSTRUM LABS INC	5MG/5ML	A201466	001	Nov 12, 2013	Feb CAHN
	AA		10MG/5ML	A201466	002	Nov 12, 2013	Feb CAHN
TABLET, EXTENDED RELEASE;ORAL							
METHYLPHENIDATE HYDROCHLORIDE							
	AB	TEDOR PHARMA INC	10MG	A204772	001	Feb 29, 2016	Feb NEWA
	AB		20MG	A204772	002	Feb 29, 2016	Feb NEWA
<u>METHYLPREDNISOLONE SODIUM SUCCINATE</u>							
INJECTABLE;INJECTION							
METHYLPREDNISOLONE SODIUM SUCCINATE							
	AP	HIKMA FARMACEUTICA	EQ 500MG BASE/VIAL	A202691	001	Feb 16, 2016	Feb NEWA
	AP		EQ 1GM BASE/VIAL	A202691	002	Feb 16, 2016	Feb NEWA
	AP	SAGENT PHARMS	EQ 40MG BASE/VIAL	A040888	001	Jul 18, 2011	Jan CAHN
	AP		EQ 125MG BASE/VIAL	A040888	002	Jul 18, 2011	Jan CAHN
	AP		EQ 500MG BASE/VIAL	A040888	003	Jul 18, 2011	Jan CAHN
	AP		EQ 1GM BASE/VIAL	A040888	004	Jul 18, 2011	Jan CAHN
	AP		EQ 2GM BASE/VIAL	A040888	005	Jul 18, 2011	Jan CAHN
<u>METHYLTESTOSTERONE</u>							
TABLET;ORAL							
ANDROID 10							
		@ VALEANT PHARM INTL	10MG	A086450	001		Apr DISC
METHYLTESTOSTERONE							
		@ IMPAX LABS	25MG	A084310	001		Mar DISC
<u>METOCLOPRAMIDE HYDROCHLORIDE</u>							
TABLET;ORAL							
METOCLOPRAMIDE HYDROCHLORIDE							
	AB	SUN PHARM INDS	EQ 5MG BASE	A071536	002	Jan 16, 1997	Mar CAHN
		@	EQ 10MG BASE	A071536	001	Apr 28, 1993	Mar CAHN
<u>METOPROLOL TARTRATE</u>							
INJECTABLE;INJECTION							
METOPROLOL TARTRATE							
	AP	EUROHLTH INTL SARL	1MG/ML	A076495	001	Jul 07, 2003	Apr CAHN
TABLET;ORAL							
METOPROLOL TARTRATE							
		@ SANDOZ	50MG	A073288	001	Mar 25, 1994	May DISC
		@	100MG	A073289	001	Mar 25, 1994	May DISC
	AB	SUN PHARM INDS	25MG	A073654	002	Jul 15, 2009	Mar CAHN
	AB		100MG	A073654	001	Dec 21, 1993	Mar CAHN
<u>METRONIDAZOLE</u>							
GEL;VAGINAL							
NUVESSA							
		+ ALLERGAN SALES LLC	1.3%	N205223	001	Mar 24, 2014	Apr CAHN
TABLET;ORAL							
METRONIDAZOLE							
	AB	FLAMINGO PHARMS	250MG	A207309	001	May 16, 2016	May NEWA
	AB		500MG	A207309	002	May 16, 2016	May NEWA
	AB	NOSTRUM LABS INC	250MG	A070772	001	Jul 16, 1986	Jan CAHN
	AB		500MG	A070773	001	Jul 16, 1986	Jan CAHN
	AB	STRIDES PHARMA	250MG	A208162	001	May 25, 2016	May NEWA
	AB		500MG	A208162	002	May 25, 2016	May NEWA

TABLET;ORAL							
METRONIDAZOLE							
AB	VIVIMED LABS	250MG	A070040	001	Jan 29, 1985	May	CMFD
AB		500MG	A070039	001	Jan 29, 1985	May	CMFD
<u>MICONAZOLE</u>							
TABLET;BUCCAL							
ORAVIG							
	+ MIDATECH PHARMA US	50MG	N022404	001	Apr 16, 2010	Jan	CAHN
<u>MIDAZOLAM HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
MIDAZOLAM HYDROCHLORIDE							
AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075247	002	Jun 23, 2000	May	CAHN
AP		EQ 1MG BASE/ML	A075421	002	Jun 20, 2000	Apr	CAHN
AP		EQ 5MG BASE/ML	A075247	001	Jun 23, 2000	May	CAHN
AP		EQ 5MG BASE/ML	A075421	001	Jun 20, 2000	Apr	CAHN
<u>MIGLITOL</u>							
TABLET;ORAL							
GLYSET							
AB	+ PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996	Feb	CRLD
AB		100MG	N020682	003	Dec 18, 1996	Feb	CRLD
<u>MILNACIPRAN HYDROCHLORIDE</u>							
TABLET;ORAL							
MILNACIPRAN HYDROCHLORIDE							
AB	AMNEAL PHARMS	12.5MG	A205081	001	Apr 22, 2016	Apr	NEWA
AB		25MG	A205081	002	Apr 22, 2016	Apr	NEWA
AB		50MG	A205081	003	Apr 22, 2016	Apr	NEWA
AB		100MG	A205081	004	Apr 22, 2016	Apr	NEWA
	@ LIBERTY PHARMA INC	12.5MG	A205071	001	Jan 27, 2016	Jan	DISC
		12.5MG	A205071	001	Jan 27, 2016	Jan	NEWA
	@	25MG	A205071	002	Jan 27, 2016	Jan	DISC
		25MG	A205071	002	Jan 27, 2016	Jan	NEWA
	@	50MG	A205071	003	Jan 27, 2016	Jan	DISC
		50MG	A205071	003	Jan 27, 2016	Jan	NEWA
	@	100MG	A205071	004	Jan 27, 2016	Jan	DISC
		100MG	A205071	004	Jan 27, 2016	Jan	NEWA
SAVELLA							
AB	CYPRESS BIOSCIENCE	12.5MG	N022256	001	Jan 14, 2009	Apr	CFTG
AB		25MG	N022256	002	Jan 14, 2009	Apr	CFTG
AB	+	50MG	N022256	003	Jan 14, 2009	Apr	CFTG
AB		100MG	N022256	004	Jan 14, 2009	Apr	CFTG
<u>MILRINONE LACTATE</u>							
INJECTABLE;INJECTION							
MILRINONE LACTATE							
AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075660	001	May 28, 2002	Apr	CAHN
MILRINONE LACTATE IN DEXTROSE 5%							
AP	CLARIS	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005	Mar	CAHN
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER							
	@ CLARIS	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Mar	CAHN
AP	EUROHLTH INTL SARL	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008	Jun	CAHN
AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008	Jun	CAHN
<u>MINOCYCLINE HYDROCHLORIDE</u>							
TABLET;ORAL							
MINOCYCLINE HYDROCHLORIDE							
AB	SUN PHARM INDS	EQ 50MG BASE	A090217	001	Jan 29, 2016	Jan	NEWA
AB		EQ 75MG BASE	A090217	002	Jan 29, 2016	Jan	NEWA
AB		EQ 100MG BASE	A090217	003	Jan 29, 2016	Jan	NEWA
TABLET, EXTENDED RELEASE;ORAL							
MINOCYCLINE HYDROCHLORIDE							
AB	AUROBINDO PHARMA LTD	EQ 80MG BASE	A202261	006	Jun 13, 2016	May	NEWA
AB		EQ 105MG BASE	A202261	007	Jun 13, 2016	May	NEWA
	@ IMPAX LABS INC	EQ 45MG BASE	A090024	001	Feb 03, 2009	Mar	DISC
	@	EQ 90MG BASE	A090024	002	Feb 03, 2009	Mar	DISC
	@	EQ 135MG BASE	A090024	003	Feb 03, 2009	Mar	DISC

<u>MINOXIDIL</u>							
TABLET; ORAL							
MINOXIDIL							
AB	SUN PHARM INDS	10MG	A072709	001	Dec 14, 1995	Mar	CAHN
<u>MIPOMERSEN SODIUM</u>							
SOLUTION; SUBCUTANEOUS							
KYNAMRO							
+	KASTLE THERAPS LLC	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013	Jun	CAHN
<u>MIRTAZAPINE</u>							
TABLET; ORAL							
MIRTAZAPINE							
@	ACTAVIS LABS FL INC	15MG	A076336	001	Jun 20, 2003	Jan	DISC
@		30MG	A076336	002	Jun 20, 2003	Jan	DISC
@		45MG	A076336	003	Jun 20, 2003	Jan	DISC
<u>MITOMYCIN</u>							
INJECTABLE; INJECTION							
MITOMYCIN							
AP	EUROHLTH INTL SARL	5MG/VIAL	A064117	001	Apr 19, 1995	Apr	CAHN
AP		5MG/VIAL	A064180	001	Dec 23, 1999	Jan	CAHN
AP		20MG/VIAL	A064117	002	Apr 19, 1995	Apr	CAHN
AP		20MG/VIAL	A064180	002	Dec 23, 1999	Jan	CAHN
<u>MODAFINIL</u>							
TABLET; ORAL							
MODAFINIL							
AB	WATSON LABS INC	100MG	A076715	001	Nov 01, 2012	Jan	CAHN
AB		200MG	A076715	002	Nov 01, 2012	Jan	CAHN
<u>MOMETASONE FUROATE</u>							
SPRAY, METERED; NASAL							
MOMETASONE FUROATE							
AB	APOTEX INC	EQ 0.05MG BASE/SPRAY	A091161	001	Mar 22, 2016	Mar	NEWA
AB	+ MERCK SHARP DOHME	EQ 0.05MG BASE/SPRAY	N020762	001	Oct 01, 1997	Mar	CFTG
<u>MORPHINE SULFATE</u>							
CAPSULE, EXTENDED RELEASE; ORAL							
KADIAN							
AB	+ ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Feb	CTEC
AB		20MG	N020616	001	Jul 03, 1996	Feb	CTEC
AB		30MG	N020616	004	Mar 09, 2001	Feb	CTEC
AB		40MG	N020616	009	Jul 09, 2012	Feb	CTEC
AB		50MG	N020616	002	Jul 03, 1996	Feb	CTEC
AB		60MG	N020616	005	Mar 09, 2001	Feb	CTEC
AB		70MG	N020616	010	Jul 09, 2012	Feb	CTEC
AB		80MG	N020616	006	Oct 27, 2006	Feb	CTEC
AB	+	100MG	N020616	003	Jul 03, 1996	Feb	CTEC
AB	+	200MG	N020616	007	Feb 27, 2007	Feb	CTEC
AB	+ ALLERGAN SALES LLC	10MG	N020616	008	Apr 20, 2007	Apr	CAHN
AB		20MG	N020616	001	Jul 03, 1996	Apr	CAHN
AB		30MG	N020616	004	Mar 09, 2001	Apr	CAHN
AB		40MG	N020616	009	Jul 09, 2012	Apr	CAHN
AB		50MG	N020616	002	Jul 03, 1996	Apr	CAHN
AB		60MG	N020616	005	Mar 09, 2001	Apr	CAHN
AB		70MG	N020616	010	Jul 09, 2012	Apr	CAHN
AB		80MG	N020616	006	Oct 27, 2006	Apr	CAHN
AB	+	100MG	N020616	003	Jul 03, 1996	Apr	CAHN
AB		130MG	N020616	011	Jul 09, 2012	Apr	CAHN
AB		150MG	N020616	012	Jul 09, 2012	Apr	CAHN
AB	+	200MG	N020616	007	Feb 27, 2007	Apr	CAHN
MORPHINE SULFATE							
AB	IMPAX LABS INC	20MG	A200411	001	Apr 12, 2016	Mar	NEWA
AB		30MG	A200411	002	Apr 12, 2016	Mar	NEWA
AB		50MG	A200411	003	Apr 12, 2016	Mar	NEWA
AB		60MG	A200411	004	Apr 12, 2016	Mar	NEWA
AB		80MG	A200411	005	Apr 12, 2016	Mar	NEWA
AB		100MG	A200411	006	Apr 12, 2016	Mar	NEWA
AB	PAR PHARM INC	20MG	A200812	001	Nov 10, 2011	Feb	CTEC

CAPSULE, EXTENDED RELEASE;ORAL							
MORPHINE SULFATE							
AB		30MG	A200812	002	Nov 10, 2011	Feb	CTEC
AB		50MG	A200812	003	Nov 10, 2011	Feb	CTEC
AB		60MG	A200812	004	Nov 10, 2011	Feb	CTEC
AB		80MG	A200812	005	Nov 10, 2011	Feb	CTEC
AB		100MG	A200812	006	Nov 10, 2011	Feb	CTEC
AB	TEVA PHARMS USA	20MG	A202718	001	Dec 29, 2014	Feb	CTEC
AB		30MG	A202718	002	Dec 29, 2014	Feb	CTEC
AB		40MG	A202718	007	Jun 03, 2015	Feb	CTEC
AB		50MG	A202718	003	Dec 29, 2014	Feb	CTEC
AB		60MG	A202718	004	Dec 29, 2014	Feb	CTEC
AB		70MG	A202718	008	Jun 03, 2015	Feb	CTEC
AB		80MG	A202718	005	Dec 29, 2014	Feb	CTEC
AB		100MG	A202718	006	Dec 29, 2014	Feb	CTEC
AB	UPSHER SMITH	10MG	A202104	001	Jun 03, 2013	Feb	CTEC
AB		20MG	A202104	002	Jun 03, 2013	Feb	CTEC
AB		30MG	A202104	003	Jun 03, 2013	Feb	CTEC
AB		50MG	A202104	004	Jun 03, 2013	Feb	CTEC
AB		60MG	A202104	005	Jun 03, 2013	Feb	CTEC
AB		80MG	A202104	006	Jun 03, 2013	Feb	CTEC
AB		100MG	A202104	007	Jun 03, 2013	Feb	CTEC
SOLUTION;ORAL							
MORPHINE SULFATE							
AA	NOSTRUM LABS INC	10MG/5ML	A201011	001	Feb 05, 2014	Mar	CAHN
AA		20MG/5ML	A201011	002	Feb 05, 2014	Mar	CAHN
AA	RHODES PHARMS	20MG/5ML	A206420	001	Jul 12, 2016	Jun	NEWA
AA	TRIS PHARMA INC	20MG/5ML	A203519	001	May 18, 2016	May	NEWA
TABLET, EXTENDED RELEASE;ORAL							
MORPHINE SULFATE							
AB	COREPHARMA	15MG	A091357	001	Jun 23, 2016	Jun	NEWA
AB		30MG	A091357	002	Jun 23, 2016	Jun	NEWA
AB		60MG	A091357	003	Jun 23, 2016	Jun	NEWA
AB		100MG	A091357	004	Jun 23, 2016	Jun	NEWA
AB		200MG	A091357	005	Jun 23, 2016	Jun	NEWA
<u>MOXIFLOXACIN HYDROCHLORIDE</u>							
TABLET;ORAL							
MOXIFLOXACIN HYDROCHLORIDE							
AB	CROSSMEDIKA SA	EQ 400MG BASE	A205348	001	Jan 14, 2016	Jan	NEWA
<u>MYCOPHENOLATE MOFETIL</u>							
CAPSULE;ORAL							
MYCOPHENOLATE MOFETIL							
AB	JUBILANT CADISTA	250MG	A090762	001	Dec 15, 2014	Jun	CAHN
TABLET;ORAL							
MYCOPHENOLATE MOFETIL							
AB	JUBILANT CADISTA	500MG	A090661	001	Dec 15, 2014	Jun	CAHN
<u>NALIDIXIC ACID</u>							
TABLET;ORAL							
NALIDIXIC ACID							
	@ SUN PHARM INDS	250MG	A070270	001	Jun 29, 1988	Mar	CAHN
	@	500MG	A070271	001	Jun 29, 1988	Jun	CAHN
	@	1GM	A070272	001	Jun 29, 1988	Mar	CAHN
<u>NALOXONE HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
NALOXONE HYDROCHLORIDE							
AP	MYLAN INSTITUTIONAL	0.4MG/ML	A205014	001	Jun 29, 2016	Jun	NEWA
<u>NAPROXEN</u>							
SUSPENSION;ORAL							
NAPROSYN							
AB	+ ATNAHS PHARMA US	25MG/ML	N018965	001	Mar 23, 1987	Jun	CAHN
TABLET;ORAL							
NAPROSYN							
AB	ATNAHS PHARMA US	250MG	N017581	002		Feb	CAHN
AB		375MG	N017581	003		Feb	CAHN
AB	+	500MG	N017581	004	Apr 15, 1982	Feb	CAHN
NAPROXEN							
	@ SANDOZ	250MG	A074140	001	Dec 21, 1993	Feb	DISC

	TABLET;ORAL								
	NAPROXEN								
	@	375MG		A074140	002	Dec 21, 1993		Feb	DISC
	@	500MG		A074140	003	Dec 21, 1993		Feb	DISC
	TABLET, DELAYED RELEASE;ORAL								
	EC-NAPROSYN								
AB	+	ATNAHS PHARMA US	375MG	N020067	002	Oct 14, 1994		Feb	CAHN
AB	+		500MG	N020067	003	Oct 14, 1994		Feb	CAHN
	NAPROXEN								
	@	SANDOZ	375MG	A075061	001	Feb 18, 1998		Feb	DISC
	@		500MG	A075061	002	Feb 18, 1998		Feb	DISC
	<u>NAPROXEN SODIUM</u>								
	TABLET;ORAL								
	ANAPROX								
AB		ATNAHS PHARMA US	EQ 250MG BASE	N018164	001			Feb	CAHN
		ANAPROX DS							
AB	+	ATNAHS PHARMA US	EQ 500MG BASE	N018164	003	Sep 30, 1987		Feb	CAHN
	<u>NATEGLINIDE</u>								
	TABLET;ORAL								
	NATEGLINIDE								
AB		ZYDUS PHARMS USA INC	60MG	A205248	001	Jul 06, 2016		Jun	NEWA
AB			120MG	A205248	002	Jul 06, 2016		Jun	NEWA
	<u>NEBIVOLOL HYDROCHLORIDE; VALSARTAN</u>								
	TABLET;ORAL								
	BYVALSON								
		FOREST LABS LLC	EQ 5MG BASE;80MG	N206302	001	Jun 03, 2016		Jun	NEWA
	<u>NEFAZODONE HYDROCHLORIDE</u>								
	TABLET;ORAL								
	NEFAZODONE HYDROCHLORIDE								
	@	SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003		Feb	DISC
	@		100MG	A076409	002	Sep 16, 2003		Feb	DISC
	@		150MG	A076409	003	Sep 16, 2003		Feb	DISC
	@		200MG	A076409	004	Sep 16, 2003		Feb	DISC
	@		250MG	A076409	005	Sep 16, 2003		Feb	DISC
	<u>NEOMYCIN SULFATE</u>								
	TABLET;ORAL								
	NEOMYCIN SULFATE								
AA		LANNETT HOLDINGS INC	500MG	A204435	001	Jun 10, 2016		May	NEWA
	<u>NICARDIPINE HYDROCHLORIDE</u>								
	CAPSULE;ORAL								
	CARDENE								
	@	CHIESI USA INC	20MG	N019488	001	Dec 21, 1988		May	DISC
	@		30MG	N019488	002	Dec 21, 1988		May	DISC
	NICARDIPINE HYDROCHLORIDE								
AB	+	MYLAN	30MG	A074642	002	Jul 18, 1996		May	CRLD
	INJECTABLE;INJECTION								
	NICARDIPINE HYDROCHLORIDE								
AP		EUROHLTH INTL SARL	25MG/10ML (2.5MG/ML)	A078714	001	Dec 28, 2009		Jun	CAHN
	<u>NIFEDIPINE</u>								
	CAPSULE;ORAL								
	NIFEDIPINE								
>D>	@	VALIDUS PHARMS	10MG	A073250	001	Oct 08, 1991		Jul	CMFD
>A>	AB		10MG	A073250	001	Oct 08, 1991		Jul	CMFD
	@		10MG	A073250	001	Oct 08, 1991		Mar	CAHN
>D>	@		20MG	A074045	001	Apr 30, 1992		Jul	CMFD
>A>	AB		20MG	A074045	001	Apr 30, 1992		Jul	CMFD
	@		20MG	A074045	001	Apr 30, 1992		Mar	CAHN
	TABLET, EXTENDED RELEASE;ORAL								
	ADALAT CC								
AB1		ALVOGEN	30MG	N020198	001	Apr 21, 1993		Feb	CAHN
AB1	+		60MG	N020198	002	Apr 21, 1993		Feb	CAHN
AB1	+		90MG	N020198	003	Apr 21, 1993		Feb	CAHN
	NIFEDIPINE								
AB2		OSMOTICA PHARM US	30MG	A077127	001	Nov 21, 2005		Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL
NIFEDIPINE

AB2		60MG	A077127	002	Nov 21, 2005	Jun	CAHN
AB1	VALEANT PHARMS NORTH	30MG	A075269	001	Dec 04, 2000	Jan	CAHN
AB1		60MG	A075269	002	Dec 04, 2000	Jan	CAHN
AB1		90MG	A076070	001	Aug 16, 2002	Jan	CAHN

NILUTAMIDE

TABLET;ORAL
NILANDRON

>D>	+	CONCORDIA PHARMS INC	150MG	N020169	002	Apr 30, 1999	Jul	CFTG
>A>	AB	+	150MG	N020169	002	Apr 30, 1999	Jul	CFTG
>A>		NILUTAMIDE						
>A>	AB	ANI PHARMS INC	150MG	A207631	001	Jul 15, 2016	Jul	NEWA

NIMODIPINE

CAPSULE;ORAL
NIMODIPINE

AB	+	BIONPHARMA INC	30MG	A076740	001	Jan 17, 2008	Jan	CAHN
----	---	----------------	------	---------	-----	--------------	-----	------

NITISINONE

CAPSULE;ORAL
ORFADIN

+	SWEDISH ORPHAN	20MG	N021232	004	Jun 13, 2016	Jun	NEWA
---	----------------	------	---------	-----	--------------	-----	------

SUSPENSION;ORAL
ORFADIN

+	SWEDISH ORPHAN	4MG/ML	N206356	001	Apr 22, 2016	Apr	NEWA
---	----------------	--------	---------	-----	--------------	-----	------

NITRIC OXIDE

GAS;INHALATION
INOMAX

+	MALLINCKRODT HOSP	800PPM	N020845	003	Dec 23, 1999	Jan	CAHN
---	-------------------	--------	---------	-----	--------------	-----	------

NITROFURANTOIN

SUSPENSION;ORAL
FURADANTIN

AB	+	CASPER PHARMA LLC	25MG/5ML	N009175	001		Jun	CAHN
----	---	-------------------	----------	---------	-----	--	-----	------

NITROFURANTOIN

AB		ACTAVIS MID ATLANTIC	25MG/5ML	A205180	001	May 03, 2016	Apr	NEWA
AB		NOSTRUM LABS INC	25MG/5ML	A201355	001	Aug 14, 2013	Feb	CAHN

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL
NITROFURANTOIN

AB		SUN PHARM INDS	25MG	A201722	001	Feb 16, 2016	Feb	NEWA
AB			50MG	A201722	002	Feb 16, 2016	Feb	NEWA
AB			100MG	A201722	003	Feb 16, 2016	Feb	NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL
MACROBID

AB	+	ALVOGEN MALTA	75MG;25MG	N020064	001	Dec 24, 1991	Jan	CAHN
----	---	---------------	-----------	---------	-----	--------------	-----	------

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL
MINITRAN

AB1		VALEANT PHARMS NORTH	0.2MG/HR	A089772	001	Aug 30, 1996	May	CAHN
-----	--	----------------------	----------	---------	-----	--------------	-----	------

POWDER;SUBLINGUAL
GONITRO

+	POHL BOSKAMP	0.4MG/PACKET	N208424	001	Jun 08, 2016	Jun	NEWA
---	--------------	--------------	---------	-----	--------------	-----	------

NIZATIDINE

SOLUTION;ORAL
NIZATIDINE

+	AMNEAL PHARMS	15MG/ML	A090576	001	Nov 18, 2009	Feb	CRLD
---	---------------	---------	---------	-----	--------------	-----	------

NOREPINEPHRINE BITARTRATEINJECTABLE; INJECTION
NOREPINEPHRINE BITARTRATE

AP	CLARIS	EQ 1MG BASE/ML	A 040859	001	Mar 27, 2012	Jan	CAHN
AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A 040462	001	Oct 31, 2003	Apr	CAHN

NORETHINDRONETABLET; ORAL-28
NOR-QD

AB1	+ APIL	0.35MG	N 017060	001		Jan	CAHN
-----	--------	--------	----------	-----	--	-----	------

NORTRIPTYLINE HYDROCHLORIDECAPSULE; ORAL
NORTRIPTYLINE HYDROCHLORIDE

@	AUROLIFE PHARMA LLC	EQ 10MG BASE	A 074835	001	Jun 30, 1997	Feb	CAHN
@		EQ 25MG BASE	A 074835	002	Jun 30, 1997	Feb	CAHN
@		EQ 50MG BASE	A 074835	003	Jun 30, 1997	Feb	CAHN
@		EQ 75MG BASE	A 074835	004	Jun 30, 1997	Feb	CAHN
@	IDT AUSTRALIA LTD	EQ 10MG BASE	A 074054	001	Dec 31, 1992	May	CAHN
@		EQ 25MG BASE	A 074054	002	Dec 31, 1992	May	CAHN
@		EQ 50MG BASE	A 074054	003	Dec 31, 1992	May	CAHN
@		EQ 75MG BASE	A 074054	004	Dec 31, 1992	May	CAHN

NYSTATINTABLET; ORAL
NYSTATIN

AA	SUN PHARM INDS	500,000 UNITS	A 062838	001	Dec 22, 1988	Mar	CAHN
----	----------------	---------------	----------	-----	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDECREAM; TOPICAL
NYSTATIN TRIAMCINOLONE ACETONIDE

@	PHARMADERM	100,000 UNITS/GM; 0.1%	A 062596	001	Oct 08, 1985	Mar	CMS1
---	------------	------------------------	----------	-----	--------------	-----	------

OINTMENT; TOPICAL
MYKACET

AT	G AND W LABS INC	100,000 UNITS/GM; 0.1%	A 062733	001	Mar 06, 1987	May	CMS1
AT	GLENMARK PHARMS LTD	100,000 UNITS/GM; 0.1%	A 208300	001	Jun 23, 2016	Jun	NEWA

OBETICHOLIC ACIDTABLET; ORAL
OCALIVA

	INTERCEPT PHARMS INC	5MG	N 207999	001	May 27, 2016	May	NEWA
+		10MG	N 207999	002	May 27, 2016	May	NEWA

OCTREOTIDE ACETATEINJECTABLE; INJECTION
OCTREOTIDE ACETATE

@	WOCKHARDT USA	EQ 0.2MG BASE/ML	A 090986	001	May 11, 2011	Jan	DISC
@		EQ 1MG BASE/ML	A 090986	002	May 11, 2011	Jan	DISC
	OCTREOTIDE ACETATE (PRESERVATIVE FREE)						
@	WOCKHARDT USA	EQ 0.05MG BASE/ML	A 090985	001	May 11, 2011	Jan	DISC
@		EQ 0.1MG BASE/ML	A 090985	002	May 11, 2011	Jan	DISC
@		EQ 0.5MG BASE/ML	A 090985	003	May 11, 2011	Jan	DISC
	OCTREOTIDE ACETATE PRESERVATIVE FREE						
@	WOCKHARDT USA	EQ 0.05MG BASE/ML	A 090985	001	May 11, 2011	Feb	CMS1
@		EQ 0.1MG BASE/ML	A 090985	002	May 11, 2011	Feb	CMS1
@		EQ 0.5MG BASE/ML	A 090985	003	May 11, 2011	Feb	CMS1

OFLOXACINSOLUTION/DROPS; OPHTHALMIC
OFLOXACIN

AT	ALVOGEN	0.3%	A 076830	001	Aug 31, 2004	Mar	CAHN
----	---------	------	----------	-----	--------------	-----	------

SOLUTION/DROPS; OTIC
FLOXIN OTIC

@	DAIICHI	0.3%	N 020799	001	Dec 16, 1997	Feb	DISC
---	---------	------	----------	-----	--------------	-----	------

OFLOXACIN

AT	ALVOGEN	0.3%	A 090395	001	Aug 11, 2009	Mar	CAHN
AT	+ BAUSCH AND LOMB	0.3%	A 076128	001	Mar 17, 2008	Feb	CRLD

OLANZAPINETABLET; ORAL
OLANZAPINE

AB	INVAGEN PHARMS	2.5MG	A203333	001	Mar 15, 2016	Feb	NEWA
AB		5MG	A203333	002	Mar 15, 2016	Feb	NEWA
AB		7.5MG	A203333	003	Mar 15, 2016	Feb	NEWA
AB		10MG	A203333	004	Mar 15, 2016	Feb	NEWA
AB		15MG	A203333	005	Mar 15, 2016	Feb	NEWA
AB		20MG	A203333	006	Mar 15, 2016	Feb	NEWA
AB	QILU PHARM CO LTD	2.5MG	A204319	001	Jan 27, 2016	Jan	NEWA
AB		5MG	A204319	002	Jan 27, 2016	Jan	NEWA
AB		7.5MG	A204319	003	Jan 27, 2016	Jan	NEWA
AB		10MG	A204319	004	Jan 27, 2016	Jan	NEWA
AB		15MG	A204319	005	Jan 27, 2016	Jan	NEWA
AB		20MG	A204319	006	Jan 27, 2016	Jan	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
OLANZAPINE

AB	INVAGEN PHARMS	5MG	A203456	001	Mar 16, 2016	Feb	NEWA
AB		10MG	A203456	002	Mar 16, 2016	Feb	NEWA
AB		15MG	A203456	003	Mar 16, 2016	Feb	NEWA
AB		20MG	A203456	004	Mar 16, 2016	Feb	NEWA

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

AT	SOMERSET THERAPY LLC	EQ 0.1% BASE	A206306	001	Dec 07, 2015	Mar	CAHN
----	----------------------	--------------	---------	-----	--------------	-----	------

OMEGA-3-ACID ETHYL ESTERSCAPSULE; ORAL
OMEGA-3-ACID ETHYL ESTERS

AB	AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	Jan	CMS1
----	---------------	--	---------	-----	--------------	-----	------

OMEGA-3-ACID ETHYL ESTERS TYPE ACAPSULE; ORAL
OMTRYG

+ TRYGG 1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS

N204977	001	Apr 23, 2014	Mar	CAIN
---------	-----	--------------	-----	------

OMEPRAZOLECAPSULE, DELAYED REL PELLETS; ORAL
OMEPRAZOLE

AB	+ SANDOZ	20MG	A075757	002	Jan 28, 2003	Mar	CRLD
AB	+ PRILOSEC	40MG	A076515	001	Jan 21, 2009	Mar	CRLD
	@ ASTRAZENECA PHARMS	10MG	N019810	003	Oct 05, 1995	Jun	DISC
	@	20MG	N019810	001	Sep 14, 1989	Jun	DISC
	@	40MG	N019810	002	Jan 15, 1998	Jun	DISC

OMEPRAZOLE; SODIUM BICARBONATECAPSULE; ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

>A>	AB	AJANTA PHARMA LTD	20MG;1.1GM	A204228	001	Jul 15, 2016	Jul	NEWA
>A>	AB		40MG;1.1GM	A204228	002	Jul 15, 2016	Jul	NEWA
>A>	AB	DR REDDYS LABS LTD	20MG;1.1GM	A204068	001	Jul 15, 2016	Jul	NEWA
>A>	AB		40MG;1.1GM	A204068	002	Jul 15, 2016	Jul	NEWA

FOR SUSPENSION; ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

>A>	AA	AJANTA PHARMA LTD	20MG/PACKET;1.68GM/PACKET	A205545	001	Jul 27, 2016	Jul	NEWA
>A>	AA		40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Jul	NEWA
>D>		SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jul	CTEC
>A>	AA		20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jul	CTEC
>D>			40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jul	CTEC
>A>	AA		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jul	CTEC

ONDANSETRONFILM; ORAL
ZUPLENZ

	MIDATECH PHARMA US	4MG	N022524	001	Jul 02, 2010	Jun	CAHN
+		8MG	N022524	002	Jul 02, 2010	Jun	CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A076967	001	Dec 26, 2006	Apr	CAHN
	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE						
AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A206845	001	Mar 10, 2016	Feb	NEWA
AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077011	001	Dec 26, 2006	Apr	CAHN

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

@ HIKMA INTL PHARMS EQ 4MG BASE

A077545 001 Sep 06, 2007 May CAHN

@ EQ 8MG BASE

A077545 002 Sep 06, 2007 May CAHN

@ EQ 24MG BASE

A077545 003 Sep 06, 2007 May CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

OSELTAMIVIR PHOSPHATE

>A>	NATCO PHARMA LTD	EQ 30MG BASE	A202595	001	Aug 03, 2016	Jul	NEWA
>A> AB		EQ 45MG BASE	A202595	002	Aug 03, 2016	Jul	NEWA
>A> AB		EQ 75MG BASE	A202595	003	Aug 03, 2016	Jul	NEWA

TAMIFLU

>D>	ROCHE	EQ 30MG BASE	N021087	003	Jul 02, 2007	Jul	CFTG
>A> AB		EQ 30MG BASE	N021087	003	Jul 02, 2007	Jul	CFTG
>D>		EQ 45MG BASE	N021087	002	Jul 02, 2007	Jul	CFTG
>A> AB		EQ 45MG BASE	N021087	002	Jul 02, 2007	Jul	CFTG
>D>	+	EQ 75MG BASE	N021087	001	Oct 27, 1999	Jul	CFTG
>A> AB	+	EQ 75MG BASE	N021087	001	Oct 27, 1999	Jul	CFTG

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

	@ SANOFI AVENTIS US	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	Jun	DISC
AP	+	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	May	CFTG

OXALIPLATIN

AP	QILU PHARM CO LTD	50MG/10ML (5MG/ML)	A204368	001	Jun 07, 2016	May	NEWA
AP		50MG/VIAL	A204616	001	May 11, 2016	Apr	NEWA
AP		100MG/20ML (5MG/ML)	A204368	002	Jun 07, 2016	May	NEWA
AP		100MG/VIAL	A204616	002	May 11, 2016	Apr	NEWA
	+	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Jun	CRLD
AP		200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	May	NEWA
AP	SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009	Jan	CAHN
AP		100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009	Jan	CAHN

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

@ SUN PHARM INDS 10MG

A071026 002 Aug 10, 1987 Mar CAHN

@ 15MG

A071026 003 Aug 10, 1987 Mar CAHN

@ 30MG

A071026 001 Aug 10, 1987 Mar CAHN

TABLET; ORAL

OXAZEPAM

>A>	@ FRONTIDA BIOPHARM	15MG	A070683	001	Jan 16, 1987	Jul	CAHN
>D>	@ SUN PHARM INDS	15MG	A070683	001	Jan 16, 1987	Jul	CAHN
	@	15MG	A070683	001	Jan 16, 1987	Jun	CAHN

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

AB	ANI PHARMS INC	150MG	A078005	001	Dec 11, 2007	Jun	CMFD
AB		300MG	A078005	002	Dec 11, 2007	Jun	CMFD
AB		600MG	A078005	003	Dec 11, 2007	Jun	CMFD

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXICONAZOLE NITRATE

AB	TARO	EQ 1% BASE	A205076	001	Mar 07, 2016	Feb	NEWA
AB	+ FOUGERA PHARMS	EQ 1% BASE	N019828	001	Dec 30, 1988	Feb	CFTG

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL

OXYTROL

AB	+ ALLERGAN SALES LLC	3.9MG/24HR	N021351	002	Feb 26, 2003	Apr	CAHN
	GEL, METERED; TRANSDERMAL						
	GELNIQUE 3%						
	+ ALLERGAN SALES LLC	3%	N202513	001	Dec 07, 2011	Apr	CAHN

OXYBUTYNIN CHLORIDE

GEL; TRANSDERMAL

GELNIQUE

	+ ALLERGAN SALES LLC	10% (100MG/PACKET)	N022204	001	Jan 27, 2009	Apr	CAHN
	TABLET, EXTENDED RELEASE; ORAL						
	OXYBUTYNIN CHLORIDE						
AB	ACCORD HLTHCARE	5MG	A207138	001	Feb 29, 2016	Feb	NEWA
AB		10MG	A207138	002	Feb 29, 2016	Feb	NEWA
AB		15MG	A207138	003	Feb 29, 2016	Feb	NEWA
AB	OSMOTICA PHARM US	5MG	A078503	001	Feb 04, 2009	Jun	CAHN
AB		10MG	A078503	002	Feb 04, 2009	Jun	CAHN
AB		15MG	A078503	003	Feb 04, 2009	Jun	CAHN
AB	UNIQUE PHARM LABS	5MG	A206121	001	May 27, 2016	May	NEWA
AB		10MG	A206121	002	May 27, 2016	May	NEWA
AB		15MG	A206121	003	May 27, 2016	May	NEWA

OXYCODONE

CAPSULE, EXTENDED RELEASE; ORAL

XTAMPZA ER

	COLLEGIUM PHARM INC	9MG	N208090	001	Apr 26, 2016	May	CAIN
		13.5MG	N208090	002	Apr 26, 2016	May	CAIN
		18MG	N208090	003	Apr 26, 2016	May	CAIN
		27MG	N208090	004	Apr 26, 2016	May	CAIN
	+ COLLEGIUM PHARM INC	36MG	N208090	005	Apr 26, 2016	May	CAIN

OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE HYDROCHLORIDE

AB	ANI PHARMS INC	5MG	A205177	001	Mar 31, 2016	Mar	NEWA
	CAPSULE, EXTENDED RELEASE; ORAL						
	XTAMPZA ER						
	COLLEGIUM PHARM INC	EQ 9MG BASE	N208090	001	Apr 26, 2016	Apr	NEWA
		EQ 13.5MG BASE	N208090	002	Apr 26, 2016	Apr	NEWA
		EQ 18MG BASE	N208090	003	Apr 26, 2016	Apr	NEWA
		EQ 27MG BASE	N208090	004	Apr 26, 2016	Apr	NEWA
	+ COLLEGIUM PHARM INC	EQ 36MG BASE	N208090	005	Apr 26, 2016	May	CRLD
		EQ 36MG BASE	N208090	005	Apr 26, 2016	Apr	NEWA
	TABLET; ORAL						
	OXYCODONE HYDROCHLORIDE						
AB	ALVOGEN MALTA	5MG	A202116	001	Dec 30, 2011	Jan	CAHN
AB		15MG	A202116	002	Dec 30, 2011	Jan	CAHN
AB		30MG	A202116	003	Dec 30, 2011	Jan	CAHN
AB	KEN LIFESCIENCE	5MG	A207119	001	Apr 12, 2016	Mar	NEWA
AB		10MG	A207119	002	Apr 12, 2016	Mar	NEWA
AB		15MG	A207119	003	Apr 12, 2016	Mar	NEWA
AB		20MG	A207119	004	Apr 12, 2016	Mar	NEWA
AB		30MG	A207119	005	Apr 12, 2016	Mar	NEWA

OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE

SPRAY, METERED; NASAL

KOVANAZE

	+ ST RENATUS	0.1MG/SPRAY; 6MG/SPRAY	N208032	001	Jun 29, 2016	Jun	NEWA
--	--------------	------------------------	---------	-----	--------------	-----	------

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OXYMORPHONE HYDROCHLORIDE

AB	AUROLIFE PHARMA LLC	5MG	A204459	001	Apr 26, 2016	Apr	NEWA
AB		10MG	A204459	002	Apr 26, 2016	Apr	NEWA

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

AP	SANDOZ INC	6MG/ML	A078167	001	Dec 26, 2007	Jan	CAHN
----	------------	--------	---------	-----	--------------	-----	------

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA SUSTENNA

JANSSEN PHARMS 117MG/0.75ML (117MG/0.75ML)

N022264	003	Jul 31, 2009	Mar	CRLD
---------	-----	--------------	-----	------

+ 156MG/ML (156MG/ML)

N022264	004	Jul 31, 2009	Mar	CRLD
---------	-----	--------------	-----	------

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

AP	DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533	001	Apr 21, 2016	Apr	NEWA
----	--------------------	---	---------	-----	--------------	-----	------

AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A201533	002	Apr 21, 2016	Apr	NEWA
----	--	--	---------	-----	--------------	-----	------

SOLUTION; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

DR REDDYS LABS LTD EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)

N203050	001	Mar 01, 2016	Mar	NEWA
---------	-----	--------------	-----	------

EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

N203050	002	Mar 01, 2016	Mar	NEWA
---------	-----	--------------	-----	------

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP	SAGENT PHARMS	30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	Jan	CAHN
----	---------------	--------------------	---------	-----	--------------	-----	------

AP		90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	Jan	CAHN
----	--	--------------------	---------	-----	--------------	-----	------

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)

PANTOPRAZOLE SODIUM

AP	AUROBINDO PHARMA LTD	EQ 40MG BASE/VIAL	A205675	001	Mar 30, 2016	Mar	NEWA
----	----------------------	-------------------	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	AMNEAL PHARMS	EQ 20MG BASE	A205119	001	Jan 26, 2016	Jan	NEWA
----	---------------	--------------	---------	-----	--------------	-----	------

AB		EQ 40MG BASE	A205119	002	Jan 26, 2016	Jan	NEWA
----	--	--------------	---------	-----	--------------	-----	------

PARICALCITOL

CAPSULE; ORAL

PARICALCITOL

AB	BIONPHARMA INC	1MCG	A202539	001	Mar 27, 2014	Jan	CAHN
----	----------------	------	---------	-----	--------------	-----	------

AB		2MCG	A202539	002	Mar 27, 2014	Jan	CAHN
----	--	------	---------	-----	--------------	-----	------

AB		4MCG	A202539	003	Mar 27, 2014	Jan	CAHN
----	--	------	---------	-----	--------------	-----	------

AB	LOTUS PHARM CO LTD	1MCG	A206710	001	Feb 24, 2016	Feb	NEWA
----	--------------------	------	---------	-----	--------------	-----	------

AB		2MCG	A206710	002	Feb 24, 2016	Feb	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		4MCG	A206710	003	Feb 24, 2016	Feb	NEWA
----	--	------	---------	-----	--------------	-----	------

SOLUTION; INTRAVENOUS

PARICALCITOL

AP	ACCORD HLTHCARE	0.002MG/ML (0.002MG/ML)	N207174	001	Feb 04, 2016	Feb	NEWA
----	-----------------	-------------------------	---------	-----	--------------	-----	------

AP		0.005MG/ML (0.005MG/ML)	N207174	002	Feb 04, 2016	Feb	NEWA
----	--	-------------------------	---------	-----	--------------	-----	------

AP		0.01MG/2ML (0.005MG/ML)	N207174	003	Feb 04, 2016	Feb	NEWA
----	--	-------------------------	---------	-----	--------------	-----	------

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

AB	KREMERS URBAN PHARMS	EQ 12.5MG BASE	A204744	001	Jun 10, 2016	May	NEWA
----	----------------------	----------------	---------	-----	--------------	-----	------

AB		EQ 25MG BASE	A204744	002	Jun 10, 2016	May	NEWA
----	--	--------------	---------	-----	--------------	-----	------

AB		EQ 37.5MG BASE	A204744	003	Jun 10, 2016	May	NEWA
----	--	----------------	---------	-----	--------------	-----	------

<u>PENCICLOVIR</u>									
CREAM;TOPICAL									
DENA VIR									
	+	DENCO ASSET	1%		N020629	001	Sep 24, 1996	Apr	CAIN
<u>PENTETATE CALCIUM TRISODIUM</u>									
SOLUTION;INHALATION, INTRAVENOUS									
PENTETATE CALCIUM TRISODIUM									
	+	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)		N021749	001	Aug 11, 2004	Apr	CMFD
	@		EQ 1GM BASE/5ML (EQ 200MG BASE/ML)		N021749	001	Aug 11, 2004	Feb	CAHN
<u>PENTETATE ZINC TRISODIUM</u>									
SOLUTION;INHALATION, INTRAVENOUS									
PENTETATE ZINC TRISODIUM									
	+	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)		N021751	001	Aug 11, 2004	Apr	CMFD
	@		EQ 1GM BASE/5ML (EQ 200MG BASE/ML)		N021751	001	Aug 11, 2004	Feb	CAHN
<u>PENTOBARBITAL SODIUM</u>									
INJECTABLE;INJECTION									
NEMBUTAL SODIUM									
AP	+	OAK PHARMS	50MG/ML		A083246	001		May	CTEC
PENTOBARBITAL SODIUM									
AP		MYLAN INSTITUTIONAL	50MG/ML		A206404	001	May 23, 2016	May	NEWA
<u>PENTOXIFYLLINE</u>									
TABLET, EXTENDED RELEASE;ORAL									
PENTOXIFYLLINE									
AB	+	APOTEX	400MG		A075191	001	Jun 09, 1999	Mar	CRLD
	@	IMPAX LABS	400MG		A075093	001	Aug 10, 1999	Mar	DISC
	@	PLIVA	400MG		A074874	001	May 25, 1999	Mar	DISC
TREN TAL									
	@	US PHARM HOLDINGS	400MG		N018631	001	Aug 30, 1984	Jan	CAHN
<u>PERAMPANEL</u>									
SUSPENSION;ORAL									
FYCOMPA									
	+	EISAI INC	0.5MG/ML		N208277	001	Apr 29, 2016	Apr	NEWA
<u>PERPHENAZINE</u>									
TABLET;ORAL									
PERPHENAZINE									
AB		WILSHIRE PHARMS INC	2MG		A205973	001	Dec 17, 2015	Jan	CAHN
AB			4MG		A205973	002	Dec 17, 2015	Jan	CAHN
AB			8MG		A205973	003	Dec 17, 2015	Jan	CAHN
AB			16MG		A205973	004	Dec 17, 2015	Jan	CAHN
<u>PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM</u>									
TABLET;ORAL									
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE									
	@	ABLE	200MG,N/A,N/A;N/A,800MG,160MG		N021105	001	Jun 26, 2001	Jan	CMS1
<u>PHENTERMINE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
PHENTERMINE HYDROCHLORIDE									
AA		SUN PHARM INDS	30MG		A040525	001	Oct 23, 2003	Mar	CAHN
	@		37.5MG		A040527	001	Oct 23, 2003	Mar	CAHN
TABLET;ORAL									
PHENTERMINE HYDROCHLORIDE									
AA		INGENUS PHARMS NJ	37.5MG		A091451	001	Sep 21, 2012	Jan	CAHN
AA		SUN PHARM INDS	37.5MG		A040526	001	Oct 23, 2003	Mar	CAHN
TABLET, ORALLY DISINTEGRATING;ORAL									
SUPRENZA									
	@	CITIUS PHARMS	15MG		N202088	001	Jun 13, 2011	Jun	DISC
	@		30MG		N202088	002	Jun 13, 2011	Jun	DISC
	@		37.5MG		N202088	003	Mar 27, 2012	Jun	DISC

PHENYLBUTAZONE

CAPSULE; ORAL

PHENYLBUTAZONE

@	SUN PHARM INDS	100MG	A088994	001	Dec 04, 1985	Mar	CAHN
---	----------------	-------	---------	-----	--------------	-----	------

TABLET; ORAL

PHENYLBUTAZONE

@	SUN PHARM INDS	100MG	A088863	001	Dec 04, 1985	Mar	CAHN
---	----------------	-------	---------	-----	--------------	-----	------

PHYTONADIONE

INJECTABLE; INJECTION

AQUAMEPHYTON

@	TELIGENT PHARMA INC	1MG/0.5ML	N012223	002		Jan	CAHN
---	---------------------	-----------	---------	-----	--	-----	------

@		10MG/ML	N012223	001		Jan	CAHN
---	--	---------	---------	-----	--	-----	------

PIMAVANSERIN TARTRATE

TABLET; ORAL

NUPLAZID

+	ACADIA PHARMS INC	EQ 17MG BASE	N207318	001	Apr 29, 2016	Apr	NEWA
---	-------------------	--------------	---------	-----	--------------	-----	------

PINDOLOL

TABLET; ORAL

PINDOLOL

@	IDT AUSTRALIA LTD	5MG	A073608	001	Mar 29, 1993	May	CAHN
---	-------------------	-----	---------	-----	--------------	-----	------

@		10MG	A073609	001	Mar 29, 1993	May	CAHN
---	--	------	---------	-----	--------------	-----	------

AB	SUN PHARM INDS	5MG	A074063	001	Jan 27, 1994	Mar	CAHN
----	----------------	-----	---------	-----	--------------	-----	------

AB		10MG	A074063	002	Jan 27, 1994	Mar	CAHN
----	--	------	---------	-----	--------------	-----	------

PIROXICAM

CAPSULE; ORAL

PIROXICAM

@	SUN PHARM INDS	20MG	A073536	001	Mar 12, 1993	Mar	CAHN
---	----------------	------	---------	-----	--------------	-----	------

PODOFILOX

GEL; TOPICAL

CONDYLOX

+	ALLERGAN SALES LLC	0.5%	N020529	001	Mar 13, 1997	Mar	CAHN
---	--------------------	------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

CONDYLOX

AT	+	ALLERGAN SALES LLC	0.5%	N019795	001	Dec 13, 1990	Mar	CAHN
----	---	--------------------	------	---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

@	MEDA PHARMS	227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT	N018983	010	Jan 31, 1989	May	DISC
---	-------------	---	---------	-----	--------------	-----	------

COLYTE WITH FLAVOR PACKS

>D>		MEDA PHARMS	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983	012	Oct 08, 1998	Jul	CTEC
-----	--	-------------	--	---------	-----	--------------	-----	------

>A>	AA		240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983	012	Oct 08, 1998	Jul	CTEC
-----	----	--	--	---------	-----	--------------	-----	------

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLYMYXIN B SULFATE

AP	AUROBINDO PHARMA LTD	EQ 500,000 UNITS BASE/VIAL	A206589	001	Apr 04, 2016	Mar	NEWA
----	----------------------	----------------------------	---------	-----	--------------	-----	------

AP	GLAND PHARMA LTD	EQ 500,000 UNITS BASE/VIAL	A207322	001	Apr 14, 2016	Apr	NEWA
----	------------------	----------------------------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB	GLENMARK PHARMS LTD	10MEQ	A202868	001	Jan 19, 2016	Jan	NEWA
----	---------------------	-------	---------	-----	--------------	-----	------

AB	KREMERS URBAN PHARMS	8MEQ	A204210	001	Mar 28, 2016	Mar	NEWA
----	----------------------	------	---------	-----	--------------	-----	------

AB		10MEQ	A204210	002	Mar 28, 2016	Mar	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB	TRIS PHARMA INC	8MEQ	A201944	001	Mar 04, 2016	Feb	NEWA
----	-----------------	------	---------	-----	--------------	-----	------

AB		10MEQ	A201944	002	Mar 04, 2016	Feb	NEWA
----	--	-------	---------	-----	--------------	-----	------

FOR SOLUTION; ORAL

POTASSIUM CHLORIDE

>D>		PHARMA RES SOFTWARE	20MEQ	N208019	001	Aug 19, 2015	Jul	CRLD
-----	--	---------------------	-------	---------	-----	--------------	-----	------

>A>	+		20MEQ	N208019	001	Aug 19, 2015	Jul	CRLD
-----	---	--	-------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

>A>	AB1	GLENMARK PHARMS LTD	10MEQ	A203562	001	Jul 26, 2016	Jul NEWA
>A>	AB1		20MEQ	A203562	002	Jul 26, 2016	Jul NEWA
>A>	AB2	NOVEL LABS INC	8MEQ	A206759	001	Aug 09, 2016	Jul NEWA
	AB1		10MEQ	A206347	001	Jan 21, 2016	Jan NEWA
>A>	AB2		10MEQ	A206759	002	Aug 09, 2016	Jul NEWA
	AB1		20MEQ	A206347	002	Jan 21, 2016	Jan NEWA

PRAMIPEXOLE DIHYDROCHLORIDE

>D>	TABLET, DELAYED RELEASE;ORAL						
>D>	PRAMIPEXOLE DIHYDROCHLORIDE						
>D>	AB	SANDOZ INC	0.375MG	A202353	001	Dec 04, 2014	Jul CDFR
>D>	AB		0.75MG	A202353	002	Dec 04, 2014	Jul CDFR
>D>	AB		1.5MG	A202353	003	Dec 04, 2014	Jul CDFR
>D>	AB		3MG	A202353	004	Dec 04, 2014	Jul CDFR
>D>	AB		4.5MG	A202353	005	Dec 04, 2014	Jul CDFR

TABLET, EXTENDED RELEASE;ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

	AB	ACTAVIS ELIZABETH	0.375MG	A201963	001	Apr 21, 2016	Apr NEWA
	AB		0.75MG	A201963	002	Apr 21, 2016	Apr NEWA
	AB		1.5MG	A201963	003	Apr 21, 2016	Apr NEWA
	AB		3MG	A201963	004	Apr 21, 2016	Apr NEWA
	AB		4.5MG	A201963	005	Apr 21, 2016	Apr NEWA
	AB	MACLEODS PHARMS LTD	0.375MG	A206156	001	Jun 24, 2016	Jun NEWA
	AB		0.75MG	A206156	002	Jun 24, 2016	Jun NEWA
	AB		1.5MG	A206156	003	Jun 24, 2016	Jun NEWA
	AB		2.25MG	A206156	004	Jun 24, 2016	Jun NEWA
	AB		3MG	A206156	005	Jun 24, 2016	Jun NEWA
	AB		4.5MG	A206156	007	Jun 24, 2016	Jun NEWA
>A>	AB	SANDOZ INC	0.375MG	A202353	001	Dec 04, 2014	Jul CDFR
>A>	AB		0.75MG	A202353	002	Dec 04, 2014	Jul CDFR
>A>	AB		1.5MG	A202353	003	Dec 04, 2014	Jul CDFR
>A>	AB		3MG	A202353	004	Dec 04, 2014	Jul CDFR
>A>	AB		4.5MG	A202353	005	Dec 04, 2014	Jul CDFR

PRAVASTATIN SODIUM

TABLET;ORAL
PRAVASTATIN SODIUM

	AB	CIPLA LTD	80MG	A077904	004	Mar 22, 2016	Mar NEWA
		@ MYLAN	10MG	A077013	001	Oct 23, 2006	Mar DISC
		@	20MG	A077013	002	Oct 23, 2006	Mar DISC
		@	40MG	A077013	003	Oct 23, 2006	Mar DISC
		@	80MG	A077013	004	Dec 28, 2007	Mar DISC

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL
PRAZOSIN HYDROCHLORIDE

	@	IDT AUSTRALIA LTD	EQ 1MG BASE	A072576	001	May 16, 1989	May CAHN
	@		EQ 2MG BASE	A072577	001	May 16, 1989	May CAHN
	@		EQ 5MG BASE	A072578	001	May 16, 1989	May CAHN

PREDNISOLONE

TABLET;ORAL
PREDNISOLONE

	@	AUROLIFE PHARMA LLC	5MG	A084773	001		Feb CAHN
--	---	---------------------	-----	---------	-----	--	----------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL
ORAPRED

	@	CONCORDIA PHARMS INC	EQ 15MG BASE/5ML	A075117	001	Dec 14, 2000	Mar DISC
AA	+	WOCKHARDT	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Mar CRLD

PREDNISONE

TABLET;ORAL
PREDNISONE

	@	AUROLIFE PHARMA LLC	5MG	A084774	001		Mar CAHN
	@		10MG	A089983	001	Jan 12, 1989	Mar CAHN
	@		20MG	A085813	001		Mar CAHN
	@		50MG	A089984	001	Jan 12, 1989	Mar CAHN
AB		DELCOR ASSET CORP	5MG	A080292	001		Mar CAHN

TABLET;ORAL
PREDNISONE

AB		10MG	A088832	001	Dec 04, 1985	Mar	CAHN
AB		20MG	A083677	001		Mar	CAHN
AB	SUN PHARM INDS	20MG	A089247	001	Dec 04, 1985	Mar	CAHN
	@	50MG	A086596	001		Jun	CAHN

PRIMAQUINE PHOSPHATE

TABLET;ORAL
PRIMAQUINE PHOSPHATE

AB	INGENUS PHARMS NJ	EQ 15MG BASE	A206043	001	Jun 23, 2016	Jun	NEWA
----	-------------------	--------------	---------	-----	--------------	-----	------

PRIMIDONE

TABLET;ORAL
PRIMIDONE

>A>	AB	FRONTIDA BIOPHARM	50MG	A040626	001	Sep 29, 2005	Jul	CAHN
>A>	AB		250MG	A040626	002	Sep 29, 2005	Jul	CAHN
>A>		@ HIKMA INTL PHARMS	50MG	A040667	001	Jul 27, 2006	Jul	CAHN
>A>	AB		250MG	A040667	002	Jul 27, 2006	Jul	CAHN
>D>		@ HIKMA PHARMS LLC	50MG	A040667	001	Jul 27, 2006	Jul	CAHN
>D>	AB		250MG	A040667	002	Jul 27, 2006	Jul	CAHN
		@ IMPAX LABS	50MG	A040717	001	Feb 12, 2008	Mar	DISC
		@	250MG	A040717	002	Feb 12, 2008	Mar	DISC
>D>	AB	SUN PHARM INDS	50MG	A040626	001	Sep 29, 2005	Jul	CAHN
	AB		50MG	A040626	001	Sep 29, 2005	Mar	CAHN
>D>	AB		250MG	A040626	002	Sep 29, 2005	Jul	CAHN
	AB		250MG	A040626	002	Sep 29, 2005	Mar	CAHN

PROCAINAMIDE HYDROCHLORIDE

CAPSULE;ORAL
PROCAINAMIDE HYDROCHLORIDE

	@	IDT AUSTRALIA LTD	375MG	A089220	001	Jul 01, 1986	May	CAHN
--	---	-------------------	-------	---------	-----	--------------	-----	------

PROGESTERONE

CAPSULE;ORAL
PROGESTERONE

AB		BIONPHARMA INC	100MG	A200900	001	Aug 16, 2013	Jan	CAHN
AB			200MG	A200900	002	Aug 16, 2013	Jan	CAHN
		PROMETRIUM						
AB		VIRTUS PHARMS	100MG	N019781	001	May 14, 1998	Jun	CAHN
AB	+		200MG	N019781	002	Oct 15, 1999	Jun	CAHN
		@	300MG	N019781	003	Oct 15, 1999	Jun	CAHN

GEL;VAGINAL
CRINONE

+		ALLERGAN SALES LLC	4%	N020701	001	Jul 31, 1997	Apr	CAHN
+			8%	N020701	002	Jul 31, 1997	Apr	CAHN

INJECTABLE;INJECTION
PROGESTERONE

AO	+	ALLERGAN SALES LLC	50MG/ML	N017362	002		Apr	CAHN
----	---	--------------------	---------	---------	-----	--	-----	------

PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL
PROMETHAZINE HYDROCHLORIDE

AA		NOSTRUM LABS INC	6.25MG/5ML	A040891	001	Mar 13, 2009	Feb	CAHN
----	--	------------------	------------	---------	-----	--------------	-----	------

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

	@	IMPAX LABS	12.5MG	A040724	001	Feb 12, 2008	Mar	DISC
	@		25MG	A040724	002	Feb 12, 2008	Mar	DISC
	@		50MG	A040791	001	May 20, 2008	Mar	DISC
	@	SUN PHARM INDS	12.5MG	A084555	001		Mar	CAHN
	@		25MG	A084554	001		Mar	CAHN
	@		50MG	A084557	001		Jan	CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
PROPAFENONE HYDROCHLORIDE

AB		MYLAN PHARMS INC	225MG	A203803	001	Apr 29, 2016	Apr	NEWA
AB			325MG	A203803	002	Apr 29, 2016	Apr	NEWA
AB			425MG	A203803	003	Apr 29, 2016	Apr	NEWA

TABLET;ORAL

PROPAFENONE HYDROCHLORIDE

AB	ORION CORP ORION	150MG	A202445	001	May 11, 2016	Apr	NEWA
AB		225MG	A202445	002	May 11, 2016	Apr	NEWA
AB		300MG	A202445	003	May 11, 2016	Apr	NEWA
AB	SUN PHARM INDS	150MG	A075998	001	Nov 29, 2001	Mar	CAHN
AB		225MG	A075998	002	Nov 29, 2001	Mar	CAHN
AB		300MG	A075998	003	Nov 29, 2001	Mar	CAHN

PROPRANOLOL HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
INDERAL LA

AB	ANI PHARMS INC	60MG	N018553	004	Mar 18, 1987	Apr	CAHN
AB		80MG	N018553	002	Apr 19, 1983	Apr	CAHN
AB		120MG	N018553	003	Apr 19, 1983	Apr	CAHN
AB	+	160MG	N018553	001	Apr 19, 1983	Apr	CAHN
PROPRANOLOL HYDROCHLORIDE							
BX	UPSHER SMITH	60MG	A078311	001	Mar 06, 2009	Jun	CMFD
	@	60MG	A078311	001	Mar 06, 2009	May	DISC
BX		60MG	A078311	001	Mar 06, 2009	Mar	CTEC
BX		80MG	A078311	002	Mar 06, 2009	Jun	CMFD
	@	80MG	A078311	002	Mar 06, 2009	May	DISC
BX		80MG	A078311	002	Mar 06, 2009	Mar	CTEC
BX		120MG	A078311	003	Mar 06, 2009	Jun	CMFD
	@	120MG	A078311	003	Mar 06, 2009	May	DISC
BX		120MG	A078311	003	Mar 06, 2009	Mar	CTEC
BX		160MG	A078311	004	Mar 06, 2009	Jun	CMFD
	@	160MG	A078311	004	Mar 06, 2009	May	DISC
BX		160MG	A078311	004	Mar 06, 2009	Mar	CTEC

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE

AP	AMPHASTAR PHARMS INC	1MG/ML	A075792	001	Aug 29, 2000	Jun	CAHN
AP	EUROHLTH INTL SARL	1MG/ML	A075792	001	Aug 29, 2000	Apr	CAHN
	@ SANDOZ	1MG/ML	A076400	001	Feb 26, 2003	Mar	DISC

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

>A>	@ FRONTIDA BIOPHARM	10MG	A070319	001	Oct 22, 1985	Jul	CAHN
>A>	@	20MG	A070320	001	Oct 22, 1985	Jul	CAHN
>A>	@	40MG	A070103	001	Oct 22, 1985	Jul	CAHN
>A>	@	60MG	A070321	001	Sep 24, 1986	Jul	CAHN
>A>	@	80MG	A070322	001	Aug 04, 1986	Jul	CAHN
>D>	@ SUN PHARM INDS	10MG	A070319	001	Oct 22, 1985	Jul	CAHN
	@	10MG	A070319	001	Oct 22, 1985	Mar	CAHN
>D>	@	20MG	A070320	001	Oct 22, 1985	Jul	CAHN
	@	20MG	A070320	001	Oct 22, 1985	Mar	CAHN
>D>	@	40MG	A070103	001	Oct 22, 1985	Jul	CAHN
	@	40MG	A070103	001	Oct 22, 1985	Mar	CAHN
>D>	@	60MG	A070321	001	Sep 24, 1986	Jul	CAHN
	@	60MG	A070321	001	Sep 24, 1986	Jun	CAHN
>D>	@	80MG	A070322	001	Aug 04, 1986	Jul	CAHN
	@	80MG	A070322	001	Aug 04, 1986	Mar	CAHN

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

>A>	@ HIKMA INTL PHARMS	50MG	A080154	001		Jul	CAHN
>D>	@ HIKMA PHARMS LLC	50MG	A080154	001		Jul	CAHN
	@ SUN PHARM INDS	50MG	A083982	001		Mar	CAHN

PYRIDOSTIGMINE BROMIDE

TABLET, EXTENDED RELEASE;ORAL

PYRIDOSTIGMINE BROMIDE

AB	ALVOGEN MALTA	180MG	A204737	001	Jun 26, 2015	Jan	CAHN
----	---------------	-------	---------	-----	--------------	-----	------

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION

PYRIDOXINE HYDROCHLORIDE

>D>	+	FRESENIUS KABI USA	100MG/ML	A080618	001		Jul	CTEC
>A>	AP	+	100MG/ML	A080618	001		Jul	CTEC
>A>	AP	MYLAN INSTITUTIONAL	100MG/ML	A204879	001	Jul 14, 2016	Jul	NEWA

QUAZEPAM

TABLET; ORAL

DORAL

	@	CUTIS HEALTH LLC	7.5MG	N018708	003	Feb 26, 1987	Mar	CAHN
+			15MG	N018708	001	Dec 27, 1985	Apr	CMFD
	@		15MG	N018708	001	Dec 27, 1985	Mar	CAHN

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

	@	ACTAVIS GRP PTC	EQ 25MG BASE	A201762	001	Feb 27, 2013	Apr	DISC
	@		EQ 50MG BASE	A201762	002	Feb 27, 2013	Apr	DISC
	@		EQ 100MG BASE	A201762	003	Feb 27, 2013	Apr	DISC
	@		EQ 150MG BASE	A201762	004	Feb 27, 2013	Apr	DISC
	@		EQ 200MG BASE	A201762	005	Feb 27, 2013	Apr	DISC
	@		EQ 300MG BASE	A201762	006	Feb 27, 2013	Apr	DISC
	@		EQ 400MG BASE	A201762	007	Feb 27, 2013	Apr	DISC
AB		MACLEODS PHARMS LTD	EQ 25MG BASE	A203359	001	May 17, 2016	May	NEWA
AB			EQ 50MG BASE	A203359	002	May 17, 2016	May	NEWA
AB			EQ 100MG BASE	A203359	003	May 17, 2016	May	NEWA
AB			EQ 200MG BASE	A203359	004	May 17, 2016	May	NEWA
AB			EQ 300MG BASE	A203359	005	May 17, 2016	May	NEWA
AB			EQ 400MG BASE	A203359	006	May 17, 2016	May	NEWA
AB		UNICHEM LABS LTD	EQ 25MG BASE	A202674	001	Mar 08, 2016	Feb	NEWA
AB			EQ 50MG BASE	A202674	002	Mar 08, 2016	Feb	NEWA
AB			EQ 100MG BASE	A202674	003	Mar 08, 2016	Feb	NEWA
AB			EQ 200MG BASE	A202674	004	Mar 08, 2016	Feb	NEWA
AB			EQ 300MG BASE	A202674	005	Mar 08, 2016	Feb	NEWA
AB			EQ 400MG BASE	A202674	006	Mar 08, 2016	Feb	NEWA

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

	@	ACTAVIS LABS FL INC	EQ 5MG BASE	A076049	001	Jan 14, 2005	Jan	DISC
	@		EQ 10MG BASE	A076049	002	Jan 14, 2005	Jan	DISC
	@		EQ 20MG BASE	A076049	003	Jan 14, 2005	Jan	DISC
	@		EQ 40MG BASE	A076049	004	Jan 14, 2005	Jan	DISC

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

	@	AUROLIFE PHARMA LLC	324MG	A089894	001	Dec 15, 1988	Mar	CAHN
BX	+	SUN PHARM INDS	324MG	A089338	001	Feb 11, 1987	Mar	CAHN

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

	@	SUN PHARM INDS	100MG	A081029	001	Apr 14, 1989	Jun	CAHN
AB			200MG	A081030	001	Apr 14, 1989	Mar	CAHN
AB			300MG	A081031	001	Apr 14, 1989	Mar	CAHN

QUININE SULFATE

CAPSULE; ORAL

QUALAQUIN

AB	+	SUN PHARM INDS	324MG	N021799	001	Aug 12, 2005	Jun	CAHN
----	---	----------------	-------	---------	-----	--------------	-----	------

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE; ORAL

ACIPHEX SPRINKLE

		FSC THERAP	5MG	N204736	001	Mar 26, 2013	Jun	CAHN
+			10MG	N204736	002	Mar 26, 2013	Jun	CAHN

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL

RALOXIFENE HYDROCHLORIDE

AB		AMNEAL PHARMS	60MG	A208206	001	Apr 08, 2016	Mar	NEWA
AB		GLENMARK PHARMS LTD	60MG	A204491	001	Mar 22, 2016	Mar	NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

AP	MYLAN LABS LTD	EQ 25MG BASE/ML	A079076	001	Jun 09, 2016	May	NEWA
AP	ZYDUS PHARMS USA INC	EQ 25MG BASE/ML	A091534	001	Feb 22, 2013	May	CPOT
ZANTAC							
AP	+ IGI LABS INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jan	CAHN
ZANTAC IN PLASTIC CONTAINER							
	@ IGI LABS INC	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Jan	CAHN
	@	EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	Jan	CAHN
SYRUP; ORAL							
RANITIDINE HYDROCHLORIDE							
AA	NOSTRUM LABS INC	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011	Mar	CAHN
	@ WOCKHARDT	EQ 15MG BASE/ML	A079211	001	May 26, 2009	Apr	DISC
	@	EQ 15MG BASE/ML	A079212	001	Feb 23, 2009	Apr	DISC

RASAGILINE MESYLATE

TABLET; ORAL

RASAGILINE MESYLATE

AB	ORCHID HLTHCARE	EQ 0.5MG BASE	A201970	001	Mar 15, 2016	Feb	NEWA
AB		EQ 1MG BASE	A201970	002	Mar 15, 2016	Feb	NEWA

RESERPINE

TABLET; ORAL

RESERPINE

	@ HIKMA INTL PHARMS	0.1MG	A080975	001		Feb	CAHN
	@	0.25MG	A080975	002		Feb	CAHN
	@	1MG	A080975	003		Feb	CAHN

RETAPAMULIN

OINTMENT; TOPICAL

ALTABAX

+	AQUA PHARMS LLC	1%	N022055	001	Apr 12, 2007	Jan	CAHN
---	-----------------	----	---------	-----	--------------	-----	------

RIBOFLAVIN 5'-PHOSPHATE SODIUM

SOLUTION/DROPS; OPHTHALMIC

PHOTREXA

+	AVEDRO INC	0.146%	N203324	001	Apr 15, 2016	Apr	NEWA
PHOTREXA VISCOUS IN DEXTRAN 20%							
+	AVEDRO INC	0.146%	N203324	002	Apr 15, 2016	Jun	CMS1
PHOTREXA VISCOUS IN DEXTROSE 20%							
+	AVEDRO INC	0.146%	N203324	002	Apr 15, 2016	Apr	NEWA

RIFAMPIN

INJECTABLE; INJECTION

RIFAMPIN

AP	EUROHLTH INTL SARL	600MG/VIAL	A064217	001	Oct 29, 1999	Apr	CAHN
AP	HIKMA PHARMS	600MG/VIAL	A205039	001	Mar 03, 2016	Feb	NEWA
AP	WATSON PHARMS INC	600MG/VIAL	A206736	001	Jan 19, 2016	Jan	NEWA

RILUZOLE

TABLET; ORAL

RILUZOLE

AB	ALKEM LABS LTD	50MG	A204048	001	Mar 30, 2016	Mar	NEWA
----	----------------	------	---------	-----	--------------	-----	------

RIMEXOLONE

SUSPENSION/DROPS; OPHTHALMIC

VEXOL

	@ ALCON	1%	N020474	001	Dec 30, 1994	Jun	DISC
--	---------	----	---------	-----	--------------	-----	------

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

AB	APIL	5MG	N020835	002	Apr 14, 2000	Jan	CAHN
AB		30MG	N020835	001	Mar 27, 1998	Jan	CAHN
AB	+	35MG	N020835	003	May 25, 2002	Jan	CAHN
	@	75MG	N020835	004	Apr 16, 2007	Jan	CAHN
AB	+	150MG	N020835	005	Apr 22, 2008	Jan	CAHN

TABLET, DELAYED RELEASE;ORAL							
ATELVIA							
AB	+	APIL	35MG	N022560	001	Oct 08, 2010	Jan CAHN
<u>RISPERIDONE</u>							
SOLUTION;ORAL							
RISPERIDONE							
		@ WOCHKHARDT	1MG/ML	A078744	001	Oct 08, 2009	Apr DISC
<u>RIVASTIGMINE</u>							
FILM, EXTENDED RELEASE;TRANSDERMAL							
RIVASTIGMINE							
AB		ALVOGEN MALTA	4.6MG/24HR	A204403	001	Sep 03, 2015	Jan CAHN
AB			9.5MG/24HR	A204403	002	Sep 03, 2015	Jan CAHN
AB			13.3MG/24HR	A204403	003	Aug 31, 2015	Jan CAHN
<u>RIVASTIGMINE TARTRATE</u>							
CAPSULE;ORAL							
EXELON							
AB	+	NOVARTIS	EQ 6MG BASE	N020823	006	Apr 21, 2000	Jan CRLD
RIVASTIGMINE TARTRATE							
AB		AUROBINDO PHARMA LTD	EQ 1.5MG BASE	A204572	001	Mar 25, 2016	Mar NEWA
AB			EQ 3MG BASE	A204572	002	Mar 25, 2016	Mar NEWA
AB			EQ 4.5MG BASE	A204572	003	Mar 25, 2016	Mar NEWA
AB			EQ 6MG BASE	A204572	004	Mar 25, 2016	Mar NEWA
<u>RIZATRIPTAN BENZOATE</u>							
TABLET;ORAL							
RIZATRIPTAN BENZOATE							
AB		ALKEM LABS LTD	EQ 5MG BASE	A203269	001	Feb 18, 2016	Feb NEWA
AB			EQ 10MG BASE	A203269	002	Feb 18, 2016	Feb NEWA
AB		NOSTRUM LABS INC	EQ 5MG BASE	A202047	001	Dec 31, 2012	Jan CAHN
AB			EQ 10MG BASE	A202047	002	Dec 31, 2012	Jan CAHN
<u>ROPIVACAINE HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
ROPIVACAINE HYDROCHLORIDE							
AP		AKORN INC	5MG/ML	A203955	001	Apr 11, 2016	Mar NEWA
SOLUTION;INJECTION							
NAROPIN							
		@ FRESENIUS KABI USA	50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	May DISC
			50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	May NEWA
AP			20MG/10ML (2MG/ML)	N020533	001	May 01, 1998	May CMS1
AP			20MG/10ML (2MG/ML)	N020533	001	Sep 24, 1996	Mar CDFR
AP			40MG/20ML (2MG/ML)	N020533	002	Sep 24, 1996	Mar NEWA
		@	75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Apr DISC
			75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Apr NEWA
AP			100MG/20ML (5MG/ML)	N020533	003	May 01, 1998	Jun CFTG
			100MG/20ML (5MG/ML)	N020533	003	May 01, 1998	May CMS1
			100MG/20ML (5MG/ML)	N020533	003	Sep 24, 1996	Mar CDFR
AP			100MG/10ML (10MG/ML)	N020533	005	Sep 24, 1996	Mar NEWA
AP			150MG/20ML (7.5MG/ML)	N020533	004	Sep 24, 1996	Mar CDFR
AP			150MG/30ML (5MG/ML)	N020533	008	Sep 24, 1996	Mar NEWA
AP			200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996	Jun CFTG
			200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996	Mar NEWA
AP	+		200MG/20ML (10MG/ML)	N020533	011	Sep 24, 1996	Mar NEWA
			400MG/200ML (2MG/ML)	N020533	007	Sep 24, 1996	Mar NEWA
			500MG/100ML (5MG/ML)	N020533	009	Jan 04, 2011	Apr CMS1
			500MG/100ML (5MG/ML)	N020533	009	Sep 24, 1996	Mar NEWA
			1GM/200ML (5MG/ML)	N020533	010	Jan 04, 2011	Apr CMS1
			1GM/200ML (5MG/ML)	N020533	010	Sep 24, 1996	Mar NEWA
ROPIVACAINE HYDROCHLORIDE							
AP		AUROBINDO PHARMA LTD	40MG/20ML (2MG/ML)	A205612	001	Jul 13, 2016	Jun NEWA
AP			100MG/20ML (5MG/ML)	A205612	003	Jul 13, 2016	Jun NEWA
AP			100MG/10ML (10MG/ML)	A205612	006	Jul 13, 2016	Jun NEWA
AP			150MG/30ML (5MG/ML)	A205612	004	Jul 13, 2016	Jun NEWA
AP			150MG/20ML (7.5MG/ML)	A205612	005	Jul 13, 2016	Jun NEWA
AP			200MG/100ML (2MG/ML)	A205612	002	Jul 13, 2016	Jun NEWA
AP			200MG/20ML (10MG/ML)	A205612	007	Jul 13, 2016	Jun NEWA
AP		HOSPIRA	20MG/10ML (2MG/ML)	A090194	001	Sep 23, 2014	Mar CDFR
AP			40MG/20ML (2MG/ML)	A090194	005	Sep 23, 2014	Mar NEWA
AP			100MG/10ML (10MG/ML)	A090194	004	Sep 23, 2014	Mar CDFR

SOLUTION;INJECTION

ROPIVACAINE HYDROCHLORIDE

AP		150MG/30ML (5MG/ML)	A090194	002	Sep 23, 2014	Mar	CDFR
AP		150MG/20ML (7.5MG/ML)	A090194	003	Sep 23, 2014	Mar	CDFR
AP		200MG/20ML (10MG/ML)	A090194	006	Sep 23, 2014	Mar	NEWA
AP	NAVINTA LLC	150MG/30ML (5MG/ML)	A078601	002	Jul 17, 2014	Mar	CDFR
AP		200MG/20ML (10MG/ML)	A078601	003	Jul 17, 2014	Mar	CDFR
AP	SAGENT STRIDES	40MG/20ML (2MG/ML)	A090318	001	Sep 23, 2014	Mar	CDFR
AP		150MG/30ML (5MG/ML)	A090318	002	Sep 23, 2014	Mar	CDFR
AP		150MG/20ML (7.5MG/ML)	A090318	003	Sep 23, 2014	Mar	CDFR
AP		200MG/20ML (10MG/ML)	A090318	004	Sep 23, 2014	Mar	CDFR

ROSUVASTATIN CALCIUM

TABLET;ORAL

CRESTOR

AB	IPR	5MG	N021366	002	Aug 12, 2003	Apr	CFTG
AB		10MG	N021366	003	Aug 12, 2003	Apr	CFTG
AB		20MG	N021366	004	Aug 12, 2003	Apr	CFTG
AB	+	40MG	N021366	005	Aug 12, 2003	Apr	CFTG

ROSUVASTATIN CALCIUM

>A>	AB	APOTEX INC	5MG	A079145	001	Jul 19, 2016	Jul	NEWA
>A>	AB		10MG	A079145	002	Jul 19, 2016	Jul	NEWA
>A>	AB		20MG	A079145	003	Jul 19, 2016	Jul	NEWA
>A>	AB		40MG	A079145	004	Jul 19, 2016	Jul	NEWA
>A>	AB	AUROBINDO PHARMA LTD	5MG	A079170	001	Jul 19, 2016	Jul	NEWA
>A>	AB		10MG	A079170	002	Jul 19, 2016	Jul	NEWA
>A>	AB		20MG	A079170	003	Jul 19, 2016	Jul	NEWA
>A>	AB		40MG	A079170	004	Jul 19, 2016	Jul	NEWA
>A>	AB	GLENMARK PHARMS LTD	5MG	A079172	001	Jul 19, 2016	Jul	NEWA
>A>	AB		10MG	A079172	002	Jul 19, 2016	Jul	NEWA
>A>	AB		20MG	A079172	003	Jul 19, 2016	Jul	NEWA
>A>	AB		40MG	A079172	004	Jul 19, 2016	Jul	NEWA
>A>	AB	MYLAN PHARMS INC	5MG	A079161	001	Jul 19, 2016	Jul	NEWA
>A>	AB		10MG	A079161	002	Jul 19, 2016	Jul	NEWA
>A>	AB		20MG	A079161	003	Jul 19, 2016	Jul	NEWA
>A>	AB		40MG	A079161	004	Jul 19, 2016	Jul	NEWA
>A>	AB	PAR PHARM INC	5MG	A079168	001	Jul 19, 2016	Jul	NEWA
>A>	AB		10MG	A079168	002	Jul 19, 2016	Jul	NEWA
>A>	AB		20MG	A079168	003	Jul 19, 2016	Jul	NEWA
>A>	AB		40MG	A079168	004	Jul 19, 2016	Jul	NEWA
>A>	AB	SANDOZ INC	5MG	A079171	001	Jul 19, 2016	Jul	NEWA
>A>	AB		10MG	A079171	002	Jul 19, 2016	Jul	NEWA
>A>	AB		20MG	A079171	003	Jul 19, 2016	Jul	NEWA
>A>	AB		40MG	A079171	004	Jul 19, 2016	Jul	NEWA
>A>	AB	SUN PHARMA GLOBAL	5MG	A079169	001	Jul 19, 2016	Jul	NEWA
>A>	AB		10MG	A079169	002	Jul 19, 2016	Jul	NEWA
>A>	AB		20MG	A079169	003	Jul 19, 2016	Jul	NEWA
>A>	AB		40MG	A079169	004	Jul 19, 2016	Jul	NEWA
>A>	AB	TEVA PHARMS USA	5MG	A079166	001	Jul 19, 2016	Jul	NEWA
>A>	AB		10MG	A079166	002	Jul 19, 2016	Jul	NEWA
>A>	AB		20MG	A079166	003	Jul 19, 2016	Jul	NEWA
>A>	AB		40MG	A079166	004	Jul 19, 2016	Jul	NEWA
AB		WATSON LABS INC	5MG	A079167	001	Apr 29, 2016	Apr	NEWA
AB			10MG	A079167	002	Apr 29, 2016	Apr	NEWA
AB			20MG	A079167	003	Apr 29, 2016	Apr	NEWA
AB			40MG	A079167	004	Apr 29, 2016	Apr	NEWA

RUFINAMIDE

TABLET;ORAL

BANZEL

AB	EISAI INC	200MG	N021911	002	Nov 14, 2008	May	CFTG
AB	+	400MG	N021911	003	Nov 14, 2008	May	CFTG

RUFINAMIDE

AB	GLENMARK PHARMS LTD	200MG	A205075	001	May 16, 2016	May	NEWA
AB		400MG	A205075	002	May 16, 2016	May	NEWA
AB	MYLAN PHARMS INC	200MG	A205095	001	May 16, 2016	May	NEWA
AB		400MG	A205095	002	May 16, 2016	May	NEWA
AB	ROXANE	200MG	A204988	001	May 16, 2016	May	NEWA
AB		400MG	A204988	002	May 16, 2016	May	NEWA

SCOPOLAMINEFILM, EXTENDED RELEASE; TRANSDERMAL
TRANSDERM SCOP

AB + GLAXOSMITHKLINE CON 1MG/72HR N017874 001 May CAHN

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

>A>	@	FRONTIDA BIOPHARM	EQ 25MG BASE	A077818	001	Feb 06, 2007	Jul	CAHN
>A>	@		EQ 50MG BASE	A077818	002	Feb 06, 2007	Jul	CAHN
>A>	@		EQ 100MG BASE	A077818	003	Feb 06, 2007	Jul	CAHN
>D>	@	SUN PHARM INDS	EQ 25MG BASE	A077818	001	Feb 06, 2007	Jul	CAHN
	@		EQ 25MG BASE	A077818	001	Feb 06, 2007	Mar	CAHN
>D>	@		EQ 50MG BASE	A077818	002	Feb 06, 2007	Jul	CAHN
	@		EQ 50MG BASE	A077818	002	Feb 06, 2007	Mar	CAHN
>D>	@		EQ 100MG BASE	A077818	003	Feb 06, 2007	Jul	CAHN
	@		EQ 100MG BASE	A077818	003	Feb 06, 2007	Mar	CAHN

SILDENAFIL CITRATE

TABLET; ORAL

SILDENAFIL CITRATE

	@	ACTAVIS GRP PTC	EQ 20MG BASE	A200149	001	Feb 25, 2013	Apr	DISC
AB		RUBICON RES PVT LTD	EQ 20MG BASE	A204883	001	Jun 20, 2016	Jun	NEWA
	@	TEVA	EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb	DISC
			EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb	NEWA
	@		EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb	DISC
			EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb	NEWA
	@		EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb	DISC
			EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb	NEWA

SILODOSIN

CAPSULE; ORAL

RAPAFLO

	+	ALLERGAN SALES LLC	4MG	N022206	001	Oct 08, 2008	Apr	CAHN
			8MG	N022206	002	Oct 08, 2008	Apr	CAHN

SIMVASTATIN

SUSPENSION; ORAL

SIMVASTATIN

		ROSEMONT PHARMS LTD	20MG/5ML	N206679	001	Apr 21, 2016	Apr	NEWA
+			40MG/5ML	N206679	002	Apr 21, 2016	Apr	NEWA

TABLET; ORAL

SIMVASTATIN

	@	SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006	Feb	DISC
	@		10MG	A076285	002	Dec 20, 2006	Feb	DISC
	@		20MG	A076285	003	Dec 20, 2006	Feb	DISC
	@		40MG	A076285	004	Dec 20, 2006	Feb	DISC
	@		80MG	A076285	005	Jun 23, 2006	Feb	DISC

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; IV (INFUSION)

AMMONUL

AP	+	MEDICIS	10%;10% (5GM/50ML; 5GM/50ML)	N020645	001	Feb 17, 2005	Feb	CFTG
			SODIUM PHENYLACETATE AND SODIUM BENZOATE					
AP		AILEX PHARMS PVT LTD	10%;10% (5GM/50ML; 5GM/50ML)	A207096	001	Feb 24, 2016	Feb	NEWA
>A> AP		NAVINTA LLC	10%;10% (5GM/50ML; 5GM/50ML)	A205880	001	Aug 04, 2016	Jul	NEWA

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE

		HOSPIRA INC	0.5MEQ/ML	A202981	001	Mar 04, 2016	Feb	NEWA
--	--	-------------	-----------	---------	-----	--------------	-----	------

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		JUBILANT HOLLISTRSTR	9MG/ML	A203352	001	May 18, 2016	May	NEWA
----	--	----------------------	--------	---------	-----	--------------	-----	------

SODIUM FLUORIDE F-18INJECTABLE; INTRAVENOUS
SODIUM FLUORIDE F-18

AP	KREITCHMAN PET CTR	10-200mCi/ML	A203936	001	May 19, 2016	May	NEWA
AP	ZEVACOR PHARMA INC	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb	CAHN

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I 131

JUBILANT DRAXIMAGE 0.009-0.1mCi
@ 2-200mCi

N021305	006	May 19, 2005	Mar	CMS1
N021305	004	Nov 18, 2004	Mar	CMS1

SODIUM PHENYL BUTYRATE

POWDER; ORAL

BUPHENYL

AB	+ HORIZON PHARMA INC	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Mar	CAHN
	SODIUM PHENYL BUTYRATE						

AB	PAR PHARM	3GM/TEASPOONFUL	A203918	001	Jun 15, 2016	Jun	NEWA
----	-----------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL

BUPHENYL

AB	+ HORIZON PHARMA INC	500MG	N020572	001	May 13, 1996	Mar	CAHN
	SODIUM PHENYL BUTYRATE						

AB	PAR PHARM	500MG	A204395	001	Apr 15, 2016	Apr	NEWA
----	-----------	-------	---------	-----	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA	BELCHER PHARMS LLC	454GM/BOT	A205727	001	Feb 23, 2016	Feb	NEWA
AA	INVATECH PHARMA	454GM/BOT	A206815	001	Feb 18, 2016	Feb	NEWA

SOFOSBUVIR; VELPATASVIR

TABLET; ORAL

EPCLUSA

+	GILEAD SCIENCES INC	400MG; 100MG	N208341	001	Jun 28, 2016	Jun	NEWA
---	---------------------	--------------	---------	-----	--------------	-----	------

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

@	IMPAX PHARMS	80MG	A075663	001	Nov 07, 2000	Mar	DISC
@		120MG	A075663	002	Nov 07, 2000	Mar	DISC
@		160MG	A075663	003	Nov 07, 2000	Mar	DISC
@		240MG	A075663	004	Nov 07, 2000	Mar	DISC
@	SUN PHARM INDS	80MG	A075515	001	Oct 15, 2001	Mar	CAHN
@		80MG	A076576	001	Apr 08, 2004	Mar	CAHN
@		120MG	A075515	004	Oct 15, 2001	Mar	CAHN
@		120MG	A076576	002	Apr 08, 2004	Mar	CAHN
@		160MG	A075515	002	Oct 15, 2001	Mar	CAHN
@		160MG	A076576	003	Apr 08, 2004	Mar	CAHN
@		240MG	A075515	003	Oct 15, 2001	Mar	CAHN

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

AB	SUN PHARM INDS	25MG	A089424	001	Jul 23, 1986	Mar	CAHN
AB		50MG	A089424	002	Aug 11, 1999	Mar	CAHN
AB		100MG	A089424	003	Aug 11, 1999	Mar	CAHN

SUCRALFATE

TABLET; ORAL

SUCRALFATE

AB	MYLAN IRELAND LTD	1GM	A074415	001	Jun 08, 1998	Jan	CAHN
----	-------------------	-----	---------	-----	--------------	-----	------

SUGAMMADEX SODIUM

SOLUTION; INTRAVENOUS

BRIDION

	ORGANON SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jan	CPOT
+		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015	Jan	CPOT

SULFAMETHOXAZOLE

TABLET; ORAL

SULFAMETHOXAZOLE

@ AUROLIFE PHARMA LLC	500MG	A085844	001		Feb	CAHN
-----------------------	-------	---------	-----	--	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

BACTRIM

@ SUN PHARM INDS

200MG/5ML; 40MG/5ML

N017560 001

Jun CAHN

BACTRIM PEDIATRIC

@ SUN PHARM INDS

200MG/5ML; 40MG/5ML

N017560 002

Jun CAHN

TABLET; ORAL

BACTRIM

AB SUN PHARM INDS

400MG; 80MG

N017377 001

Mar CAHN

BACTRIM DS

AB + SUN PHARM INDS

800MG; 160MG

N017377 002

Mar CAHN

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB SUN PHARM INDS

800MG; 160MG

A071017 001 Aug 25, 1986

Mar CAHN

SULFASALAZINE

TABLET; ORAL

SULFASALAZINE

@ SUN PHARM INDS

500MG

A089590 001

Oct 19, 1987

Mar CAHN

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE

@ AUROLIFE PHARMA LLC

500MG

A085628 001

Feb CAHN

SULINDAC

TABLET; ORAL

SULINDAC

AB SUN PHARM INDS

150MG

A072050 001

Apr 17, 1991

Mar CAHN

AB

200MG

A072051 001

Apr 17, 1991

Mar CAHN

SUMATRIPTAN

SPRAY; NASAL

IMITREX

AB + GLAXOSMITHKLINE

5MG/SPRAY

N020626 001

Aug 26, 1997

Feb CFTG

AB +

20MG/SPRAY

N020626 003

Aug 26, 1997

Feb CFTG

SUMATRIPTAN

AB LANNETT

5MG/SPRAY

A204841 001

Feb 19, 2016

Feb NEWA

AB

20MG/SPRAY

A204841 002

Feb 19, 2016

Feb NEWA

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

AP EUROHLTH INTL SARL

EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML)

A079123 001

Feb 06, 2009

Jun CAHN

POWDER; INHALATION

ONZETRA XSAIL

+ AVANIR PHARMS

EQ 11MG BASE

N206099 001

Jan 27, 2016

Jan NEWA

SOLUTION; SUBCUTANEOUS

ZEMBRACE SYMTOUCH

DR REDDYS LABS LTD

EQ 3MG BASE/0.5ML (EQ 3MG
BASE/0.5ML)

N208223 001

Jan 28, 2016

Jan NEWA

TACROLIMUS

OINTMENT; TOPICAL

PROTOPIC

AB + LEO PHARMA AS

0.03%

N050777 001

Dec 08, 2000

Jun CAHN

AB +

0.1%

N050777 002

Dec 08, 2000

Jun CAHN

TAMOXIFEN CITRATE

SOLUTION; ORAL

SOLTAMOX

MIDATECH PHARMA US

EQ 10MG BASE/5ML

N021807 001

Oct 29, 2005

Jan CAHN

TABLET; ORAL

TAMOXIFEN CITRATE

@ ACTAVIS LABS FL INC

EQ 10MG BASE

A076179 001

Feb 20, 2003

Jan DISC

TABLET;ORAL

TAMOXIFEN CITRATE

@	EQ 20MG BASE	A076179	002	Feb 20, 2003	Jan DISC
---	--------------	---------	-----	--------------	----------

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INTRAVENOUS

ULTRA-TECHNEKOW FM

+	MALLINKRODT NUCLEAR	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014	Jan CAHN
@		0.25-3 CI/GENERATOR	N017243	002		Jan CAHN

TEGASEROD MALEATE

TABLET;ORAL

ZELNORM

@	US WORLDMEDS LLC	EQ 2MG BASE	N021200	001	Jul 24, 2002	Jan CAHN
@		EQ 6MG BASE	N021200	002	Jul 24, 2002	Jan CAHN

TELITHROMYCIN

TABLET;ORAL

KETEK

@	SANOVI AVENTIS US	300MG	N021144	002	Feb 09, 2005	Mar DISC
@		400MG	N021144	001	Apr 01, 2004	Mar DISC

TELMISARTAN

TABLET;ORAL

TELMISARTAN

AB	HETERO LABS LTD V	20MG	A205901	001	Apr 22, 2016	Apr NEWA
AB		40MG	A205901	002	Apr 22, 2016	Apr NEWA
AB		80MG	A205901	003	Apr 22, 2016	Apr NEWA

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

AB	AMNEAL PHARMS	7.5MG	A203482	001	May 23, 2016	May NEWA
AB		15MG	A203482	002	May 23, 2016	May NEWA
AB		22.5MG	A203482	003	May 23, 2016	May NEWA
AB		30MG	A203482	004	May 23, 2016	May NEWA
AB	SUN PHARM INDS	7.5MG	A078581	001	Sep 08, 2009	Mar CAHN
@		15MG	A071174	001	Jul 10, 1986	Mar CAHN
AB		22.5MG	A071175	002	Sep 14, 2009	Mar CAHN
@		30MG	A071175	001	Jul 10, 1986	Mar CAHN

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

>A>	AB	AMERIGEN PHARMS LTD	5MG	A203490	001	Jul 13, 2016	Jul NEWA
>A>	AB		20MG	A203490	002	Jul 13, 2016	Jul NEWA
>A>	AB		100MG	A203490	003	Jul 13, 2016	Jul NEWA
>A>	AB		140MG	A203490	004	Jul 13, 2016	Jul NEWA
>A>	AB		180MG	A203490	005	Jul 13, 2016	Jul NEWA
>A>	AB		250MG	A203490	006	Jul 13, 2016	Jul NEWA
	AB	IDT AUSTRALIA LTD	5MG	A206413	001	Apr 12, 2016	Mar NEWA
	AB		20MG	A206413	002	Apr 12, 2016	Mar NEWA
	AB		100MG	A206413	003	Apr 12, 2016	Mar NEWA
	AB		140MG	A206413	004	Apr 12, 2016	Mar NEWA
	AB		180MG	A206413	005	Apr 12, 2016	Mar NEWA
	AB		250MG	A206413	006	Apr 12, 2016	Mar NEWA
	AB	KREMERS URBAN PHARMS	5MG	A203898	001	Feb 10, 2016	Jan NEWA
	AB		20MG	A203898	002	Feb 10, 2016	Jan NEWA
	AB		100MG	A203898	003	Feb 10, 2016	Jan NEWA
	AB		140MG	A203898	004	Feb 10, 2016	Jan NEWA
	AB		180MG	A203898	005	Feb 10, 2016	Jan NEWA
	AB		250MG	A203898	006	Feb 10, 2016	Jan NEWA
	AB	LOTUS PHARM CO LTD	5MG	A206309	001	Apr 27, 2016	Apr NEWA
	AB		20MG	A206309	002	Apr 27, 2016	Apr NEWA
	AB		100MG	A206309	003	Apr 27, 2016	Apr NEWA
	AB		140MG	A206309	004	Apr 27, 2016	Apr NEWA
	AB		180MG	A206309	005	Apr 27, 2016	Apr NEWA
	AB		250MG	A206309	006	Apr 27, 2016	Apr NEWA
	AB	MYLAN PHARMS INC	5MG	A205227	001	Jun 29, 2016	Jun NEWA
	AB		20MG	A205227	002	Jun 29, 2016	Jun NEWA
	AB		100MG	A205227	003	Jun 29, 2016	Jun NEWA
	AB		140MG	A205227	004	Jun 29, 2016	Jun NEWA
	AB		180MG	A205227	005	Jun 29, 2016	Jun NEWA

	CAPSULE;ORAL						
	TEMOZOLOMIDE						
AB		250MG	A205227	006	Jun 29, 2016	Jun	NEWA
	<u>TERBUTALINE SULFATE</u>						
	INJECTABLE;INJECTION						
	TERBUTALINE SULFATE						
AP	+	AMPHASTAR PHARMS INC 1MG/ML	A076770	001	Apr 23, 2004	Jun	CAHN
AP	+	EUROHLTH INTL SARL 1MG/ML	A076770	001	Apr 23, 2004	Apr	CAHN
	TABLET;ORAL						
	TERBUTALINE SULFATE						
	@	IMPAX LABS 2.5MG	A075877	001	Jun 26, 2001	Mar	DISC
	@	LANNETT 5MG	A075877	002	Jun 26, 2001	Mar	DISC
		LANNETT 2.5MG	A077152	001	Mar 25, 2005	Mar	CTEC
		5MG	A077152	002	Mar 25, 2005	Mar	CTEC
	<u>TESTOSTERONE</u>						
	FILM, EXTENDED RELEASE;TRANSDERMAL						
	ANDRODERM						
	+	ALLERGAN SALES LLC 2MG/24HR	N020489	003	Oct 20, 2011	Mar	CAHN
	@	2.5MG/24HR	N020489	001	Sep 29, 1995	Mar	CAHN
	+	4MG/24HR	N020489	004	Oct 20, 2011	Mar	CAHN
	@	5MG/24HR	N020489	002	May 02, 1997	Mar	CAHN
	GEL, METERED;NASAL						
	NATESTO						
		AYTU BIOSCIENCE INC 5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jun	CAHN
	PELLET;IMPLANTATION						
	TESTOPEL						
	+	AUXILIUM PHARMS INC 75MG	A080911	001		Mar	CAHN
	TABLET, EXTENDED RELEASE;BUCCAL						
	STRIANT						
	+	AUXILIUM PHARMS INC 30MG	N021543	001	Jun 19, 2003	Mar	CAHN
	<u>TESTOSTERONE CYPIONATE</u>						
	INJECTABLE;INJECTION						
	TESTOSTERONE CYPIONATE						
AO		EUROHLTH INTL SARL 100MG/ML	A090387	001	Jul 15, 2010	Jun	CAHN
AO		200MG/ML	A090387	002	Jul 15, 2010	Jun	CAHN
	<u>TETRABENAZINE</u>						
	TABLET;ORAL						
	TETRABENAZINE						
AB		HETERO LABS LTD V 12.5MG	A204574	001	Feb 03, 2016	Jan	NEWA
AB		25MG	A204574	002	Feb 03, 2016	Jan	NEWA
	<u>TETRACAINE HYDROCHLORIDE</u>						
	SOLUTION;OPHTHALMIC						
	TETRACAINE HYDROCHLORIDE						
	+	ALCON RES LTD 0.5%	N208135	001	Feb 29, 2016	Feb	NEWA
	<u>TETRACYCLINE HYDROCHLORIDE</u>						
	CAPSULE;ORAL						
	TETRACYCLINE HYDROCHLORIDE						
AB		CHARTWELL CIENCA 250MG	A062752	001	Aug 12, 1988	Apr	CMFD
AB		500MG	A062752	002	Aug 12, 1988	Apr	CMFD
	@	SUN PHARM INDS 250MG	A060736	001		Mar	CAHN
	@	500MG	A060736	002		Mar	CAHN
	<u>THEOPHYLLINE</u>						
	CAPSULE, EXTENDED RELEASE;ORAL						
	THEO-24						
>D>		AUXILIUM PHARMS INC 200MG	A087943	001	Aug 22, 1983	Jul	CAHN
		200MG	A087943	001	Aug 22, 1983	Mar	CAHN
>D>		300MG	A087944	001	Aug 22, 1983	Jul	CAHN
		300MG	A087944	001	Aug 22, 1983	Mar	CAHN
	+	400MG	A081034	001	Feb 28, 1992	Mar	CAHN
>A>		AUXILIUM PHARMS LLC 200MG	A087943	001	Aug 22, 1983	Jul	CAHN
>A>		300MG	A087944	001	Aug 22, 1983	Jul	CAHN
	SOLUTION, ELIXIR;ORAL						
	ELIXOPHYLLIN						
	+	NOSTRUM LABS INC 80MG/15ML	A085186	001		Jan	CAHN

<u>TABLET, EXTENDED RELEASE;ORAL</u>							
THEOCHRON							
AB	NOSTRUM LABS INC	100MG	A088320	001	Feb 21, 1985	Jan	CAHN
AB		200MG	A088321	001	Feb 21, 1985	Jan	CAHN
	@	300MG	A087400	002	Jan 11, 1983	Jan	CAHN
THEOPHYLLINE							
AB	MYLAN IRELAND LTD	400MG	A040560	003	Apr 21, 2006	Jan	CAHN
AB	+	600MG	A040560	002	Apr 21, 2006	Jan	CAHN
<u>THIORIDAZINE HYDROCHLORIDE</u>							
TABLET;ORAL							
THIORIDAZINE HYDROCHLORIDE							
AB	SUN PHARM INDS	10MG	A089953	004	Aug 01, 1986	Mar	CAHN
	@	15MG	A088461	001	Nov 18, 1983	Mar	CAHN
AB		25MG	A089953	003	Aug 01, 1986	Mar	CAHN
AB		50MG	A089953	002	Aug 01, 1986	Mar	CAHN
AB		100MG	A089953	001	Oct 07, 1988	Mar	CAHN
	@	150MG	A088737	001	Sep 26, 1984	Mar	CAHN
	@	200MG	A088738	001	Oct 16, 1984	Mar	CAHN
<u>THIOTHIXENE</u>							
CAPSULE;ORAL							
THIOTHIXENE							
	@ SANDOZ	1MG	A071610	001	Jun 24, 1987	Mar	DISC
	@	2MG	A071570	001	Jun 24, 1987	Mar	DISC
	@	5MG	A071529	001	Jun 24, 1987	Mar	DISC
	@	10MG	A071530	001	Jun 24, 1987	Mar	DISC
<u>TINIDAZOLE</u>							
TABLET;ORAL							
TINIDAZOLE							
BX	UNIQUE PHARM LABS	250MG	A202489	001	Oct 09, 2013	Apr	CTEC
BX		500MG	A202489	002	Oct 09, 2013	Apr	CTEC
<u>TOBRAMYCIN SULFATE</u>							
INJECTABLE;INJECTION							
TOBRAMYCIN SULFATE							
AP	CLARIS	EQ 40MG BASE/ML	A206965	001	Jul 01, 2016	Jun	NEWA
<u>TOFACITINIB CITRATE</u>							
TABLET, EXTENDED RELEASE;ORAL							
XELJANZ XR							
+	PFIZER INC	EQ 11MG BASE	N208246	001	Feb 23, 2016	Feb	NEWA
<u>TOLAZAMIDE</u>							
TABLET;ORAL							
TOLAZAMIDE							
	@ SUN PHARM INDS	100MG	A071357	001	Jul 16, 1987	Mar	CAHN
	@	250MG	A071358	001	Jul 16, 1987	Mar	CAHN
	@	500MG	A071359	001	Jul 16, 1987	Mar	CAHN
<u>TOLMETIN SODIUM</u>							
CAPSULE;ORAL							
TOLMETIN SODIUM							
	@ SUN PHARM INDS	EQ 400MG BASE	A073311	001	Nov 27, 1991	Mar	CAHN
TABLET;ORAL							
TOLMETIN SODIUM							
AB	SUN PHARM INDS	EQ 200MG BASE	A073310	001	Nov 27, 1991	Mar	CAHN
<u>TOPIRAMATE</u>							
TABLET;ORAL							
TOPIRAMATE							
	@ ACTAVIS TOTOWA	25MG	A078637	001	Feb 27, 2013	Apr	DISC
AB		25MG	A078637	001	Feb 27, 2013	Jan	CAHN
	@	50MG	A078637	002	Feb 27, 2013	Apr	DISC
AB		50MG	A078637	002	Feb 27, 2013	Jan	CAHN
	@	100MG	A078637	003	Feb 27, 2013	Apr	DISC
AB		100MG	A078637	003	Feb 27, 2013	Jan	CAHN
	@	200MG	A078637	004	Feb 27, 2013	Apr	DISC
AB		200MG	A078637	004	Feb 27, 2013	Jan	CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB	ACI HEALTHCARE LTD	50MG	A202075	001	Nov 28, 2011	Mar	CAHN
AB	SUN PHARM INDS	50MG	A076100	001	Jun 20, 2002	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

ULTRAM ER

AB1	+ VALEANT PHARMS	100MG	N021692	001	Sep 08, 2005	Mar	CAHN
AB1		200MG	N021692	002	Sep 08, 2005	Mar	CAHN
AB1		300MG	N021692	003	Sep 08, 2005	Mar	CAHN

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

AP	AKORN	100MG/ML	A206634	001	Jun 09, 2016	May	NEWA
AP	AUROBINDO PHARMA LTD	100MG/ML	A205035	001	Jan 14, 2016	Jan	NEWA
AP	NORTH CREEK PHARMS	100MG/ML	A202755	001	Feb 25, 2016	Feb	NEWA

TABLET; ORAL

TRANEXAMIC ACID

>A>	@ AMERIGEN PHARMS LTD	650MG	A203256	001	Jul 25, 2016	Jul	DISC
>A>	AB	650MG	A203256	001	Jul 25, 2016	Jul	NEWA

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

	@ AUROLIFE PHARMA LLC	50MG	A072484	001	Apr 30, 1990	Feb	CAHN
AB	SUN PHARM INDS	50MG	A073137	002	Mar 24, 1993	Mar	CAHN
AB		100MG	A073137	001	Mar 24, 1993	Mar	CAHN
AB		150MG	A073137	003	Dec 22, 1995	Mar	CAHN

TRETINOIN

CREAM; TOPICAL

TRETINOIN

>A>	+ ALLERGAN SALES LLC	0.0375%	A090098	001	Mar 22, 2010	Jul	CAHN
>A>		0.075%	A202209	001	Oct 11, 2012	Jul	CAHN
>D>	AB ELAN PHARMA INTL LTD	0.025%	A075264	001	Dec 24, 1998	Jul	CAHN
	AB	0.025%	A075264	001	Dec 24, 1998	Feb	CAHN
>D>	AB1	0.05%	A075265	001	Dec 24, 1998	Jul	CAHN
	AB1	0.05%	A075265	001	Dec 24, 1998	Feb	CAHN
>D>	AB	0.1%	A075213	001	Dec 24, 1998	Jul	CAHN
	AB	0.1%	A075213	001	Dec 24, 1998	Feb	CAHN
>A>	AB PERRIGO PHARMA INTL	0.025%	A075264	001	Dec 24, 1998	Jul	CAHN
>A>	AB1	0.05%	A075265	001	Dec 24, 1998	Jul	CAHN
>A>	AB	0.1%	A075213	001	Dec 24, 1998	Jul	CAHN
>D>	+ WATSON LABS INC	0.0375%	A090098	001	Mar 22, 2010	Jul	CAHN
>D>		0.075%	A202209	001	Oct 11, 2012	Jul	CAHN

GEL; TOPICAL

TRETINOIN

>D>	AB ELAN PHARMA INTL LTD	0.01%	A075589	001	Jun 11, 2002	Jul	CAHN
	AB	0.01%	A075589	001	Jun 11, 2002	Feb	CAHN
>D>	AB	0.025%	A075529	001	Feb 22, 2000	Jul	CAHN
	AB	0.025%	A075529	001	Feb 22, 2000	Feb	CAHN
>A>	AB PERRIGO PHARMA INTL	0.01%	A075589	001	Jun 11, 2002	Jul	CAHN
>A>	AB	0.025%	A075529	001	Feb 22, 2000	Jul	CAHN

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

>A>	AT GLENMARK PHARMS LTD	0.1%	A207117	001	Aug 05, 2016	Jul	NEWA
-----	------------------------	------	---------	-----	--------------	-----	------

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	TELIGENT PHARMA INC	0.025%	A204608	001	Jul 07, 2016	Jun	NEWA
AT		0.1%	A204606	001	Jul 07, 2016	Jun	NEWA

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

>A>	AT GLENMARK PHARMS LTD	0.5%	A206379	001	Jul 22, 2016	Jul	NEWA
	AT TELIGENT PHARMA INC	0.1%	A205373	001	May 13, 2016	May	NEWA

PASTE; DENTAL

TRIAMCINOLONE ACETONIDE

>A>	AT VERSAPHARM INC	0.1%	A206312	001	Aug 11, 2016	Jul	NEWA
-----	-------------------	------	---------	-----	--------------	-----	------

		SPRAY; TOPICAL							
		KENALOG							
>A>	AT	+	RANBAXY LABS LTD	0.147MG/GM	N012104	001		Jul	CAHN
>D>	AT	+	SUN PHARM INDS LTD	0.147MG/GM	N012104	001		Jul	CAHN
		<u>TRIMETHOBENZAMIDE HYDROCHLORIDE</u>							
		CAPSULE; ORAL							
		TRIMETHOBENZAMIDE HYDROCHLORIDE							
AB			SUN PHARM INDS	300MG	A076570	001	Aug 28, 2003	Mar	CAHN
		<u>TRIMETHOPRIM</u>							
		TABLET; ORAL							
		TRIMETHOPRIM							
		@	SUN PHARM INDS	100MG	A070494	001	Jan 22, 1986	Jun	CAHN
		@		200MG	A070495	001	Sep 24, 1986	Mar	CAHN
		<u>TRIMETHOPRIM HYDROCHLORIDE</u>							
		SOLUTION; ORAL							
		PRIMSOL							
		+	AYTU BIOSCIENCE INC	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Jun	CAHN
		@	AYTU PHARMS	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995	Jun	CMS2
		@		EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995	Jan	CAHN
		+		EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Jan	CAHN
		<u>TRIMIPRAMINE MALEATE</u>							
		CAPSULE; ORAL							
		TRIMIPRAMINE MALEATE							
AB			CROSSMEDIKA SA	EQ 25MG BASE	A208127	001	Apr 15, 2016	Apr	NEWA
AB				EQ 50MG BASE	A208127	002	Apr 15, 2016	Apr	NEWA
AB				EQ 100MG BASE	A208127	003	Apr 15, 2016	Apr	NEWA
		<u>TRIPTORELIN PAMOATE</u>							
		INJECTABLE; INTRAMUSCULAR							
		TRELSTAR							
		+	ALLERGAN SALES LLC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000	Apr	CAHN
		+		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001	Apr	CAHN
		+		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010	Apr	CAHN
		<u>TROSPIUM CHLORIDE</u>							
		CAPSULE, EXTENDED RELEASE; ORAL							
		TROSPIUM CHLORIDE							
		@	SANDOZ INC	60MG	A091635	001	Apr 29, 2015	Apr	DISC
		<u>UNOPROSTONE ISOPROPYL</u>							
		SOLUTION/DROPS; OPHTHALMIC							
		RESCULA							
		@	R-TECH UENO LTD	0.15%	N021214	001	Aug 03, 2000	Mar	DISC
		@	SUCAMPO PHARMA LLC	0.15%	N021214	001	Aug 03, 2000	Mar	CAHN
		<u>URSODIOL</u>							
		CAPSULE; ORAL							
		ACTIGALL							
		@	ALLERGAN SALES LLC	150MG	N019594	001	Dec 31, 1987	Mar	CAHN
AB		+		300MG	N019594	002	Dec 31, 1987	Mar	CAHN
		<u>VALGANCICLOVIR HYDROCHLORIDE</u>							
		FOR SOLUTION; ORAL							
		VALCYTE							
>D>		+	HOFFMANN LA ROCHE	50MG/ML	N022257	001	Aug 28, 2009	Jul	CFTG
>A>	AB	+		50MG/ML	N022257	001	Aug 28, 2009	Jul	CFTG
>A>			VALGANCICLOVIR HYDROCHLORIDE						
>A>	AB		ACTAVIS LABS FL INC	50MG/ML	A205220	001	Jul 18, 2016	Jul	NEWA
		TABLET; ORAL							
		VALGANCICLOVIR HYDROCHLORIDE							
AB			AUROBINDO PHARMA LTD	EQ 450MG BASE	A204750	001	Mar 31, 2016	Mar	NEWA
AB			HETERO LABS LTD V	EQ 450MG BASE	A205166	001	Mar 18, 2016	Mar	NEWA

VINORELBINE TARTRATEINJECTABLE; INJECTION
VINORELBINE TARTRATE

AP	EUROHLTH INTL SARL	EQ 10MG BASE/ML	A076461	001	Dec 11, 2003	Apr	CAHN
----	--------------------	-----------------	---------	-----	--------------	-----	------

VORICONAZOLEFOR SUSPENSION; ORAL
VORICONAZOLE

AB	AMNEAL PHARMS	200MG/5ML	A205034	001	Apr 13, 2016	Mar	NEWA
AB	NOVEL LABS INC	200MG/5ML	A206799	001	May 31, 2016	May	NEWA

INJECTABLE; IV (INFUSION)
VORICONAZOLE

AP	ALVOGEN INC	200MG/VIAL	A206398	001	Mar 23, 2016	Mar	NEWA
----	-------------	------------	---------	-----	--------------	-----	------

TABLET; ORAL

VORICONAZOLE

AB	AJANTA PHARMA LTD	50MG	A206181	001	May 24, 2016	May	NEWA	
AB		200MG	A206181	002	May 24, 2016	May	NEWA	
AB	APPCO PHARMA LLC	50MG	A206762	001	May 24, 2016	May	NEWA	
AB		200MG	A206762	002	May 24, 2016	May	NEWA	
AB	AUROBINDO PHARMA LTD	50MG	A206837	001	Jan 22, 2016	Jan	NEWA	
AB		200MG	A206837	002	Jan 22, 2016	Jan	NEWA	
AB	NOVEL LABS INC	50MG	A207371	001	May 24, 2016	May	NEWA	
AB		200MG	A207371	002	May 24, 2016	May	NEWA	
>A>	AB	PRINSTON INC	50MG	A206654	001	Aug 08, 2016	Jul	NEWA
>A>	AB		200MG	A206654	002	Aug 08, 2016	Jul	NEWA
AB	ZYDUS PHARMS USA INC	50MG	A206747	001	May 24, 2016	May	NEWA	
AB		200MG	A206747	002	May 24, 2016	May	NEWA	

VORTIOXETINE HYDROBROMIDE

TABLET; ORAL

TRINTELLIX

	TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013	Jun	CTNA
		EQ 10MG BASE	N204447	002	Sep 30, 2013	Jun	CTNA
		EQ 15MG BASE	N204447	003	Sep 30, 2013	Jun	CTNA
	+	EQ 20MG BASE	N204447	004	Sep 30, 2013	Jun	CTNA

XENON XE-133

GAS; INHALATION

XENON XE 133

	LANTHEUS MEDCL	20mCi/VIAL	N017284	002		Feb	CTEC
	MALLINKRODT NUCLEAR	10mCi/VIAL	N018327	001	Mar 09, 1982	Feb	CMFD
		20mCi/VIAL	N018327	002	Mar 09, 1982	Feb	CMFD

ZOLMITRIPTAN

TABLET; ORAL

ZOLMITRIPTAN

AB	AJANTA PHARMA LTD	2.5MG	A204041	001	May 20, 2016	May	NEWA
AB		5MG	A204041	002	May 20, 2016	May	NEWA
AB	AUROBINDO PHARMA LTD	2.5MG	A207021	001	May 11, 2016	Apr	NEWA
AB		5MG	A207021	002	May 11, 2016	Apr	NEWA

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

	@ SUN PHARM INDS	5MG	A077288	001	Apr 23, 2007	Mar	CAHN
	@	10MG	A077288	002	Apr 23, 2007	Mar	CAHN

TABLET; SUBLINGUAL

EDLUAR

>D>	MEDA PHARMS	5MG	N021997	001	Mar 13, 2009	Jul	CFTG	
>A>	AB	5MG	N021997	001	Mar 13, 2009	Jul	CFTG	
>D>	+	10MG	N021997	002	Mar 13, 2009	Jul	CFTG	
>A>	AB	10MG	N021997	002	Mar 13, 2009	Jul	CFTG	
	ZOLPIDEM TARTRATE							
>A>	AB	MYLAN PHARMS INC	5MG	A202657	001	Aug 08, 2016	Jul	NEWA
>A>	AB		10MG	A202657	002	Aug 08, 2016	Jul	NEWA
>A>	AB	PAR FORM	5MG	A201509	001	Aug 01, 2016	Jul	NEWA
>A>	AB		10MG	A201509	002	Aug 01, 2016	Jul	NEWA

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

AB	SUNOVION PHARMS INC	25MG	N020789	003	Aug 22, 2003	Feb	CAHN
AB		50MG	N020789	002	Aug 22, 2003	Feb	CAHN
AB	+	100MG	N020789	001	Mar 27, 2000	Feb	CAHN
	ZONISAMIDE						
AB	BIONPHARMA INC	25MG	A077813	001	Aug 16, 2006	Jan	CAHN
AB		50MG	A077813	002	Aug 16, 2006	Jan	CAHN
AB		100MG	A077813	003	Aug 16, 2006	Jan	CAHN
	@ SUN PHARM INDS	25MG	A077635	001	Dec 22, 2005	Mar	CAHN
	@	50MG	A077635	002	Dec 22, 2005	Mar	CAHN
	@	100MG	A077635	003	Dec 22, 2005	Mar	CAHN

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

EXCEDRIN (MIGRAINE)

+	GLAXOSMITHKLINE CONS	250MG; 250MG; 65MG	N020802	001	Jan 14, 1998	Feb	CAHN
---	----------------------	--------------------	---------	-----	--------------	-----	------

BUDESONIDE

SPRAY, METERED; NASAL

BUDESONIDE

	APOTEX INC	0.032MG/SPRAY	A078949	002	Nov 20, 2015	Apr	NEWA
--	------------	---------------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

	BIONPHARMA INC	5MG	N022429	001	Jul 23, 2009	Jan	CAHN
--	----------------	-----	---------	-----	--------------	-----	------

+		10MG	N022429	004	Jul 23, 2009	Jan	CAHN
---	--	------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	BIONPHARMA INC	5MG	N022429	003	Jul 23, 2009	Jan	CAHN
--	----------------	-----	---------	-----	--------------	-----	------

+		10MG	N022429	002	Jul 23, 2009	Jan	CAHN
---	--	------	---------	-----	--------------	-----	------

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@	CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008	Apr	DISC
---	---------------	---------	---------	-----	--------------	-----	------

	NOSTRUM LABS INC	5MG/5ML	A091327	001	Oct 17, 2011	Mar	CAHN
--	------------------	---------	---------	-----	--------------	-----	------

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@	CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008	Apr	DISC
---	---------------	---------	---------	-----	--------------	-----	------

	NOSTRUM LABS INC	5MG/5ML	A091327	002	Oct 17, 2011	Mar	CAHN
--	------------------	---------	---------	-----	--------------	-----	------

TABLET, CHEWABLE; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	NOVEL LABS INC	5MG	A206793	001	Mar 08, 2016	Feb	NEWA
--	----------------	-----	---------	-----	--------------	-----	------

		10MG	A206793	002	Mar 08, 2016	Feb	NEWA
--	--	------	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE

SPONGE; TOPICAL

CHLORHEXIDINE GLUCONATE

+	BECTON DICKINSON	4%	A072525	001	Oct 24, 1989	Jun	CRLD
---	------------------	----	---------	-----	--------------	-----	------

PHARMASEAL SCRUB CARE

@	CAREFUSION	4%	N019793	001	Dec 02, 1988	Jun	DISC
---	------------	----	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP ONE-STEP

+	BECTON DICKINSON CO	2%; 70% (3ML)	N020832	001	Jul 14, 2000	May	CAHN
---	---------------------	---------------	---------	-----	--------------	-----	------

+		2%; 70% (10.5ML)	N020832	004	Aug 20, 2003	May	CAHN
---	--	------------------	---------	-----	--------------	-----	------

+		2%; 70% (26ML)	N020832	006	Nov 21, 2006	May	CAHN
---	--	----------------	---------	-----	--------------	-----	------

CHLORAPREP ONE-STEP FREPP

+	BECTON DICKINSON CO	2%; 70% (1.5ML)	N020832	003	Apr 26, 2002	May	CAHN
---	---------------------	-----------------	---------	-----	--------------	-----	------

CHLORAPREP WITH TINT

+	BECTON DICKINSON CO	2%; 70% (26ML)	N020832	002	May 03, 2005	May	CAHN
---	---------------------	----------------	---------	-----	--------------	-----	------

+		2%; 70% (10.5ML)	N020832	005	Apr 03, 2006	May	CAHN
---	--	------------------	---------	-----	--------------	-----	------

+		2%; 70% (3ML)	N020832	007	Oct 10, 2006	May	CAHN
---	--	---------------	---------	-----	--------------	-----	------

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+	BECTON DICKINSON CO	2%; 70% (0.67ML)	N021555	001	Oct 07, 2002	May	CAHN
---	---------------------	------------------	---------	-----	--------------	-----	------

CHLORAPREP SINGLE SWABSTICK

+	BECTON DICKINSON CO	2%; 70% (1.75ML)	N021555	002	May 10, 2005	May	CAHN
---	---------------------	------------------	---------	-----	--------------	-----	------

CHLORAPREP TRIPLE SWABSTICK

+	BECTON DICKINSON CO	2%; 70% (5.25ML)	N021555	003	Jun 10, 2009	May	CAHN
---	---------------------	------------------	---------	-----	--------------	-----	------

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

@	AUROLIFE PHARMA LLC	12MG	A070797	001	Aug 12, 1988	Feb	CAHN
---	---------------------	------	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

	BIONPHARMA INC	25MG; EQ 200MG FREE ACID AND	A090397	001	Nov 22, 2010	Jan	CAHN
--	----------------	------------------------------	---------	-----	--------------	-----	------

POTASSIUM SALT

FAMOTIDINETABLET; ORAL
FAMOTIDINE

AUROBINDO PHARMA LTD	10MG	A206531	001	Apr 26, 2016	Apr	NEWA
	20MG	A206531	002	Apr 26, 2016	Apr	NEWA

FLUTICASONE PROPIONATESPRAY, METERED; NASAL
FLUTICASONE PROPIONATE

>A>	APOTEX INC	0.05MG/SPRAY	A208150	001	Feb 29, 2016	Jul	CAHN
>D>	APOTEX TECHNOLOGIES	0.05MG/SPRAY	A208150	001	Feb 29, 2016	Jul	CAHN
		0.05MG/SPRAY	A208150	001	Feb 29, 2016	Feb	NEWA
	ROXANE	0.05MG/SPRAY	A207957	001	May 26, 2016	May	NEWA

IBUPROFENCAPSULE; ORAL
IBUPROFEN

BIONPHARMA INC	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009	Jan	CAHN
PURACAP PHARM LLC	EQ 200MG FREE ACID AND POTASSIUM SALT	A206568	001	Jun 21, 2016	Jun	NEWA

MIDOL LIQUID GELS

+ BIONPHARMA INC	200MG	N021472	001	Oct 18, 2002	Jan	CAHN
------------------	-------	---------	-----	--------------	-----	------

TABLET; ORAL

IBUPROFEN

STRIDES PHARMA	200MG	A079129	001	Mar 28, 2011	May	CAHN
	200MG	A091355	001	Apr 04, 2011	May	CAHN
@ SUN PHARM INDS	200MG	A070493	001	Dec 24, 1985	Mar	CAHN
@	200MG	A070908	001	Sep 26, 1986	Mar	CAHN
@	200MG	A071462	001	Oct 02, 1986	Mar	CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

MYLAN PHARMS INC	15MG	A203187	001	Jun 01, 2016	May	NEWA
------------------	------	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE; ORAL

LANSOPRAZOLE

DEXCEL PHARMA	15MG	N208025	001	Jun 07, 2016	Jun	NEWA
---------------	------	---------	-----	--------------	-----	------

LEVONORGESTREL

TABLET; ORAL

HER STYLE

NOVAST LABS LTD	1.5MG	A207976	001	Mar 11, 2016	Feb	NEWA
-----------------	-------	---------	-----	--------------	-----	------

LEVONORGESTREL

GLENMARK PHARMS LTD	1.5MG	A207044	001	Mar 25, 2016	Mar	NEWA
---------------------	-------	---------	-----	--------------	-----	------

+ PERRIGO R AND D	0.75MG	A090740	001	Dec 30, 2010	Apr	CRLD
-------------------	--------	---------	-----	--------------	-----	------

@ WATSON LABS	0.75MG	A078665	001	Aug 28, 2009	Apr	DISC
---------------	--------	---------	-----	--------------	-----	------

PLAN B

@ TEVA BRANDED PHARM	0.75MG	N021045	002	Aug 24, 2006	Apr	DISC
----------------------	--------	---------	-----	--------------	-----	------

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

LOPERAMIDE HYDROCHLORIDE

BIONPHARMA INC	1MG	N021855	001	Aug 04, 2005	Jan	CAHN
----------------	-----	---------	-----	--------------	-----	------

+	2MG	N021855	002	Aug 04, 2005	Jan	CAHN
---	-----	---------	-----	--------------	-----	------

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

MONISTAT 3 COMBINATION PACK

+ MEDTECH PRODUCTS	2%, 200MG	N020670	002	Apr 16, 1996	Mar	CMS1
--------------------	-----------	---------	-----	--------------	-----	------

NAPROXEN SODIUM

CAPSULE; ORAL

NAPROXEN SODIUM

+ BIONPHARMA INC	EQ 200MG BASE	N021920	001	Feb 17, 2006	Mar	CAHN
------------------	---------------	---------	-----	--------------	-----	------

TABLET; ORAL

NAPROXEN SODIUM

AUROBINDO PHARMA LTD	EQ 200MG BASE	A205497	001	Mar 18, 2016	Mar	NEWA
----------------------	---------------	---------	-----	--------------	-----	------

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

ACTAVIS LABS NY INC EQ 2MG BASE
EQ 4MG BASEA204794 001 May 10, 2016 Apr NEWA
A204833 001 Feb 26, 2016 Feb NEWAOMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

>A> OMEPRAZOLE AND SODIUM BICARBONATE
>A> ACTAVIS ELIZABETH 20MG;1.1GM
>A> PAR PHARM 20MG;1.1GM
>A> PERRIGO R AND D 20MG;1.1GMA204137 001 Jul 15, 2016 Jul NEWA
A201946 001 Jul 15, 2016 Jul NEWA
A201361 001 Jul 15, 2016 Jul NEWAOXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

+ ALLERGAN SALES LLC 3.9MG/24HR

N202211 001 Jan 25, 2013 Jan CAHN

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

MISSION PHARMACAL CO 65MG/ML

A206211 001 Mar 24, 2016 Mar NEWA

TABLET;ORAL

THYRO-BLOCK

@ MEDA PHARMS 130MG

N018307 001 May CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

STRIDES PHARMA EQ 75MG BASE

A201745 001 Feb 29, 2012 May CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 07 JULY 2016

NO JULY 2016 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JULY 2016 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001	9242986	Dec 08, 2029	DS DP			
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	6028222	Aug 05, 2017	DP		PED	Jan 11, 2017
	6028222*PED	Feb 05, 2018				
	6992218	Jun 06, 2021	DP			
	6992218*PED	Dec 06, 2021				
	>A> 9399012	Sep 11, 2031	U-1882			
	>A> 9399012*PED	Mar 11, 2032				
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	9327028	Jul 21, 2031	U-1839			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	8747894	May 08, 2032	DP U-1373			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	8747894	May 08, 2032	DP U-1373			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	9333195	Jul 07, 2020	DP U-1263			
<u>ADAPALENE - DIFFERIN</u>						
N 020380 001					>A> RTO	Jul 08, 2019
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8809305	Dec 23, 2022	U-1078			
	>A> 9381179	Mar 12, 2023	U-1078			
	>A> 9387187	Mar 12, 2023	U-1078			
<u>AFATINIB DIMALEATE - GILOTRIFF</u>						
N 201292 001	8426586	Oct 10, 2029	DS		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTRIFF</u>						
N 201292 002	8426586	Oct 10, 2029	DS		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTRIFF</u>						
N 201292 003	8426586	Oct 10, 2029	DS		I-730	Apr 15, 2019
	RE43431	Jan 22, 2022	DS		ODE	Apr 15, 2023
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	8978966	Jan 13, 2032	DP		NPP	Apr 28, 2019
	9216260	Jun 28, 2031	DP			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001	9365514	Mar 04, 2032	DP		ODE	Dec 11, 2022
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003					M-177	Apr 05, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414	001				M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414	002				M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	001				M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	002				M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	003				M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	004				M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	005				M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	006				M-177	Apr 05, 2019
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081	001				NP	May 10, 2019
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	001	8709491	Jun 28, 2032	DP		
		8840924	Jun 05, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	002	8709491	Jun 28, 2032	DP		
		8840924	Jun 05, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	003	8709491	Jun 28, 2032	DP		
		8840924	Jun 05, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	004	8709491	Jun 28, 2032	DP		
		8840924	Jun 05, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	005	8709491	Jun 28, 2032	DP		
		8840924	Jun 05, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	006	8709491	Jun 28, 2032	DP		
		8840924	Jun 05, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	9326945	Feb 24, 2031	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	9326945	Feb 24, 2031	DP			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001	9359302	Sep 25, 2022	DS DP U-1859			
	>A> 9387182	Dec 25, 2023				U-1529
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002	9359302	Sep 25, 2022	DS DP U-1859			
	>A> 9387182	Dec 25, 2023				U-1529
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003	9359302	Sep 25, 2022	DS DP U-1859			
	>A> 9387182	Dec 25, 2023				U-1529
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 004	9359302	Sep 25, 2022	DS DP U-1859			
	>A> 9387182	Dec 25, 2023				U-1529
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 005	9359302	Sep 25, 2022	DS DP U-1859			
	>A> 9387182	Dec 25, 2023				U-1529
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 006	9359302	Sep 25, 2022	DS DP U-1859			
	>A> 9387182	Dec 25, 2023				U-1529
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021713 001	>A> 9387182	Dec 25, 2023				U-1529
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 002	>A> 9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	>A> 9387182	Dec 25, 2023				U-1529
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 003	>A> 9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	>A> 9387182	Dec 25, 2023				U-1529
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 004	>A> 9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	>A> 9387182	Dec 25, 2023				U-1529
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 005	>A> 9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	>A> 9387182	Dec 25, 2023				U-1529
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 001					PC	Nov 28, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 002					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 003					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200156 004					>A> PC	Nov 28, 2016
<u>ASPIRIN - ASPIRIN</u>						
N 203697 001	9216150	Sep 29, 2032	DP			
	9226892	Sep 29, 2032		U-1731		
	9226892	Sep 29, 2032		U-1732		
	9226892	Sep 29, 2032		U-1733		
	9351984	Dec 19, 2021	DP			
<u>AVANAFIL - STENDRA</u>						
N 202276 001	6656935	Apr 27, 2025	DS DP	U-155		
<u>AVANAFIL - STENDRA</u>						
N 202276 002	6656935	Apr 27, 2025	DS DP	U-155		
<u>AVANAFIL - STENDRA</u>						
N 202276 003	6656935	Apr 27, 2025	DS DP	U-155		
<u>AXITINIB - INLYTA</u>						
N 202324 001	6534524	Apr 29, 2025	DS DP			
<u>AXITINIB - INLYTA</u>						
N 202324 002	6534524	Apr 29, 2025	DS DP			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	9265725	Dec 08, 2027	DP			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	9259428	Jun 13, 2023		U-644		
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	9169238	Feb 04, 2030	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	9169238	Feb 04, 2030	DP			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	9192616	Aug 02, 2026		U-1229		
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9265831	Jan 28, 2031	DP			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	9364485	Aug 31, 2030	DP	U-1858	NDF	Feb 05, 2019
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	9241918	Mar 16, 2025	DP	U-1814		
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	9216183	Jan 15, 2023		U-1487		
	9226931	Jan 15, 2023		U-1799		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BOCEPREVIR - VICTRELIS</u>						
N 202258 001	RE43298	Dec 22, 2024	DS DP U-1128			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021262 001	9295641	Jul 10, 2021	U-1833			
	9295641*PED	Jan 10, 2022				
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	9295641	Jul 10, 2021	U-1833			
	9295641*PED	Jan 10, 2022				
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BROMFENAC SODIUM - BROMSITE</u>						
N 206911 001	8778999	Sep 03, 2029	DP U-1834		NP	Apr 08, 2019
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9192576	Apr 30, 2032	DP U-976			
<u>BUDESONIDE - ENTOCORT EC</u>						
N 021324 001					M-178 NPP	Apr 29, 2019 Apr 29, 2019
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9320716	Jun 09, 2020	DP U-1325			
<u>BUPRENORPHINE HYDROCHLORIDE - PROBUPHINE</u>						
N 204442 001	>A> 7736665	Apr 25, 2024	U-1878		NP	May 26, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	>A> 8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	>A> 8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	>A> 8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	>A> 8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	9259421	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	9248123	Jan 13, 2032	U-1808			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	6582727	Aug 22, 2020	DP		NP	Jun 17, 2019
	8207149	Apr 25, 2028	U-1871			
	8361488	Jul 19, 2028	DP			
	8426391	Aug 27, 2028	DP U-1872			
	8778373	Apr 25, 2028	U-1873			
	8906410	Feb 02, 2027	DP			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					I-733	May 20, 2019
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					I-733	May 20, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	001				I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	002				I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	003				I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	004				I-735	May 20, 2019
<u>CANGRELOR - KENGREAL</u>						
N 204958	001	9295687	Jul 10, 2035	DP		
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714	001	7417042	Jul 20, 2026	DS DP	I-722	Jan 21, 2019
		8129346	Apr 14, 2025	U-1260	I-723	Jan 21, 2019
<u>CEFIXIME - SUPRAX</u>						
N 202091	001	9233112	Dec 14, 2028	DP U-1676		
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327	001				NPP	May 27, 2019
					NPP	May 27, 2019
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327	002				NPP	May 27, 2019
					NPP	May 27, 2019
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829	001	9320740	Mar 14, 2034	DP		
<u>CERITINIB - ZYKADIA</u>						
N 205755	001	9309229	Jan 18, 2032	DS DP		
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750	001				NCE	Mar 17, 2020
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750	002				NCE	Mar 17, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688	001	>A> 9375405	Sep 22, 2026	DP		
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688	002	>A> 9375405	Sep 22, 2026	DP		
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688	003	>A> 9375405	Sep 22, 2026	DP		
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986	001	9233068	Dec 11, 2029	DP	NP	Dec 10, 2018
<u>CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL</u>						
N 208251	001	8932610	Mar 24, 2030	DP U-1578	NC	Apr 29, 2019
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537	001	9345714	Sep 13, 2022	DP U-1578		
		>A> 9402805	Sep 13, 2022	DP U-1578		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537 001	9345714	Sep 13, 2022	DP U-1578			
	>A> 9402805	Sep 13, 2022	DP U-1578			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7803788	Feb 02, 2022		U-257		
	9296769	Aug 15, 2032	DS DP U-257			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001					ODE	Nov 10, 2022
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					ODE	Mar 11, 2023
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					ODE	Mar 11, 2023
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 001	9375410	Nov 14, 2023		U-1088		
	>A> 9399025	Nov 14, 2023	DP U-979			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 002	>A> 9375410	Nov 14, 2023		U-1088		
	>A> 9399025	Nov 14, 2023	DP U-979			
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	9248191	Aug 27, 2024		U-1479		
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	9233077	Jun 17, 2034	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	9233077	Jun 17, 2034	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	9233956	May 04, 2029		U-1811	M-170	Nov 20, 2018
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	9233956	May 04, 2029		U-1811	M-170	Nov 20, 2018
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001					D-161 D-162 I-726 I-727	Feb 05, 2019 Feb 05, 2019 Feb 05, 2019 Feb 05, 2019
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002					D-161 D-162 I-726 I-727	Feb 05, 2019 Feb 05, 2019 Feb 05, 2019 Feb 05, 2019
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001					D-154	Jan 20, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPSONE - ACZONE</u>						
N 207154 001	5863560	Sep 11, 2016	DP		NS	Feb 24, 2019
	6060085	Sep 11, 2016	U-124			
	6620435	Sep 11, 2016	DP			
	9161926	Nov 18, 2033	DP			
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572 002 >A>	9138456	Nov 23, 2030	DP			
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	8492386	Sep 04, 2032	U-1840		D-163	Apr 22, 2019
	8685984	Sep 04, 2032	U-1840			
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001					>A> NCE	Dec 19, 2019
<u>DEFERASIROX - JADENU</u>						
N 206910 001	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 002	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 003	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001					NCE	Mar 30, 2021
					ODE	Mar 30, 2023
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	9283178	Oct 20, 2020	U-1205			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N 050818 001	8450287	Dec 19, 2027	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	9233103	Mar 05, 2032	U-1805		>A> NPP	Jul 08, 2019
	9238029	Jan 17, 2026	DP		>A> NPP	Jul 08, 2019
					>A> NPP	Jul 08, 2019
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	9233103	Mar 05, 2032	U-1805		>A> NPP	Jul 08, 2019
	9238029	Jan 17, 2026	DP		>A> NPP	Jul 08, 2019
					>A> NPP	Jul 08, 2019
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001 >A>	6328994	May 17, 2019	DP			
>A>	6328994*PED	Nov 17, 2019				
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6462058*PED	Dec 15, 2020				
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
	7399485	May 26, 2018	DP			
	7399485*PED	Nov 26, 2018				
	7431942	May 17, 2019	DP			
	7431942*PED	Nov 17, 2019				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8784885	Oct 15, 2023	DP			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	8871273*PED	Jul 11, 2028				
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9238029	Jan 17, 2026	DP			
	9241910	Mar 10, 2029	DP			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9220784	Oct 17, 2027		U-1488		
	9339551	Oct 17, 2027		U-1488		
	9339552	Oct 17, 2027	DP	U-1488		
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003	9308195	Sep 30, 2033	DP			
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 001					PC	Dec 04, 2016
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 002					PC	Dec 04, 2016
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 003					PC	Dec 04, 2016
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 002	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 003	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	8513299	Sep 07, 2030		U-620		
	9107898	May 01, 2028		U-620		
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	8513299	Sep 07, 2030		U-620		
	9107898	May 01, 2028		U-620		
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	9241946	Apr 05, 2022		U-1063		
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431 003					PC	Nov 19, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431	005				PC	Nov 15, 2016
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795	007	6958161	Dec 15, 2022	DP U-918		
		8715724	Feb 03, 2028	DP		
		9295652	Oct 23, 2034	DP U-918		
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795	008	6958161	Dec 15, 2022	DP U-918		
		8715724	Feb 03, 2028	DP		
		9295652	Oct 23, 2034	DP U-918		
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567	001	9302009	Oct 24, 2030	DP		
<u>ELBASVIR; GRAZOPREVIR - ZEPATIER</u>						
N 208261	001	7973040	Jul 24, 2029	DS DP U-1813	NCE	Jan 28, 2021
		8871759	May 04, 2031	DS DP U-1813		
<u>ELUXADOLINE - VIBERZI</u>						
N 206940	001	9364489	Jul 07, 2028	U-1709		
<u>ELUXADOLINE - VIBERZI</u>						
N 206940	002	9364489	Jul 07, 2028	U-1709		
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629	001	>A> 8551957	Oct 14, 2029	DP U-1651	M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629	002	>A> 8551957	Oct 14, 2029	DP U-1651	M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073	001	7407955	May 02, 2025	DS DP		
		>A> 8551957	Oct 14, 2029	DP U-1651		
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073	002	7407955	May 02, 2025	DS DP		
		>A> 8551957	Oct 14, 2029	DP U-1651		
		8673927	May 04, 2027	DP U-1652		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111	001				>A> M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111	002				>A> M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111	003				>A> M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111	004				>A> M-174	Mar 18, 2019
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351	001	5814639	Sep 29, 2015	DS DP	NCE	Nov 05, 2020
		5814639*PED	Mar 29, 2016			
		5914331	Jul 02, 2017	DS		
		5914331*PED	Jan 02, 2018			
		6642245	Nov 04, 2020	U-257		
		6642245*PED	May 04, 2021			
		6703396	Mar 09, 2021	DS DP		
		6703396*PED	Sep 09, 2021			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	6838464	Feb 26, 2021	DS DP			
	7067522	Dec 20, 2019	DS DP			
	7125879	Aug 09, 2022	DS DP		U-257	
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022			U-257	
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
	8754065	Aug 15, 2032	DS DP		U-257	
	9296769	Aug 15, 2032	DS DP		U-257	
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	5814639	Sep 29, 2015	DS DP	Y	NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020			U-257	
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022			U-257	
	8754065	Aug 15, 2032	DS DP		U-257	
	9296769	Aug 15, 2032	DS DP		U-257	
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6043230	Jul 25, 2017			U-248	
	6043230	Jul 25, 2017			U-541	
	6043230	Jul 25, 2017			U-1170	
	6043230	Jul 25, 2017			U-1259	
	6043230*PED	Jan 25, 2018				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS		U-248	
	5922695	Jul 25, 2017	DS		U-541	
	5922695	Jul 25, 2017	DS		U-1170	
	5922695	Jul 25, 2017	DS		U-1259	
	5935946	Jul 25, 2017	DS DP		U-248	
	5935946	Jul 25, 2017	DS DP		U-541	
	5935946	Jul 25, 2017	DS DP		U-1170	
	5935946	Jul 25, 2017	DS DP		U-1259	
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP		U-248	
	5977089	Jul 25, 2017	DS DP		U-541	
	5977089	Jul 25, 2017	DS DP		U-1170	
	5977089	Jul 25, 2017	DS DP		U-1259	
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017			U-248	
	6043230	Jul 25, 2017			U-541	
	6043230	Jul 25, 2017			U-1170	
	6043230	Jul 25, 2017			U-1259	
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020			U-248	
	6642245	Nov 04, 2020			U-541	
	6642245	Nov 04, 2020			U-1170	
	6642245	Nov 04, 2020			U-1259	
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS		U-248	
	5922695	Jul 25, 2017	DS		U-541	
	5922695	Jul 25, 2017	DS		U-1170	
	5922695	Jul 25, 2017	DS		U-1259	
	5935946	Jul 25, 2017	DS DP		U-248	
	5935946	Jul 25, 2017	DS DP		U-541	
	5935946	Jul 25, 2017	DS DP		U-1170	
	5935946	Jul 25, 2017	DS DP		U-1259	
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP		U-248	
	5977089	Jul 25, 2017	DS DP		U-541	
	5977089	Jul 25, 2017	DS DP		U-1170	
	5977089	Jul 25, 2017	DS DP		U-1259	
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017			U-248	
	6043230	Jul 25, 2017			U-541	
	6043230	Jul 25, 2017			U-1170	
	6043230	Jul 25, 2017			U-1259	
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020			U-248	
	6642245	Nov 04, 2020			U-541	
	6642245	Nov 04, 2020			U-1170	
	6642245	Nov 04, 2020			U-1259	
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS		U-248	
	5922695	Jul 25, 2017	DS		U-541	
	5922695	Jul 25, 2017	DS		U-1170	
	5922695	Jul 25, 2017	DS		U-1259	
	5935946	Jul 25, 2017	DS DP		U-248	
	5935946	Jul 25, 2017	DS DP		U-541	
	5935946	Jul 25, 2017	DS DP		U-1170	
	5935946	Jul 25, 2017	DS DP		U-1259	
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP		U-248	
	5977089	Jul 25, 2017	DS DP		U-541	
	5977089	Jul 25, 2017	DS DP		U-1170	
	5977089	Jul 25, 2017	DS DP		U-1259	
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017			U-248	
	6043230	Jul 25, 2017			U-541	
	6043230	Jul 25, 2017			U-1170	
	6043230	Jul 25, 2017			U-1259	
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020			U-248	
	6642245	Nov 04, 2020			U-541	
	6642245	Nov 04, 2020			U-1170	
	6642245	Nov 04, 2020			U-1259	
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035	U-1829			
	9295657	Mar 13, 2035	U-1830			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001	9295657	Mar 13, 2035	U-1829			
<u>EPINEPHRINE - EPINEPHRINE</u>						
N 205029 001	9283197	Aug 15, 2034	DP U-1828			
	9283197	Aug 15, 2034	DP U-1829			
	9283197	Aug 15, 2034	DP U-1830			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6469182	Jun 16, 2019	U-1096		I-721	Jan 28, 2019
	6469182	Jun 16, 2019	U-1812		ODE	Jan 28, 2023
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001					D-164	May 20, 2019
					>A> M-181	Jun 01, 2019
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002					D-164	May 20, 2019
					>A> M-181	Jun 01, 2019
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003					D-164	May 20, 2019
					>A> M-181	Jun 01, 2019
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER</u>						
N 205703 001	6310094	Jan 12, 2021	DP			
	6310094*PED	Jul 12, 2021				
	6528540	Jan 12, 2021	DP			
	6528540*PED	Jul 12, 2021				
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 205703 002	6310094	Jan 12, 2021	DP			
	6310094*PED	Jul 12, 2021				
	6528540	Jan 12, 2021	DP			
	6528540*PED	Jul 12, 2021				
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	>A> 6369085	May 25, 2018	DS DP U-1509			
	>A> 6369085	May 25, 2018	DS DP U-1875			
	>A> 6369085*PED	Nov 25, 2018				
	>A> 6428810	Nov 03, 2019	DP U-1509			
	>A> 6428810	Nov 03, 2019	DP U-1874			
	>A> 6428810*PED	May 03, 2020				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	9220698	Mar 10, 2031		U-1781		
	9345695	May 31, 2022	DP			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	9345695	May 31, 2022	DP			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	9238076	Apr 15, 2024	DP U-412			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	5424286	Dec 01, 2016	U-1108			
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
	8216180	Jan 12, 2028	DP	Y		
	8329648	Aug 18, 2026	U-1313			
	8431685	Apr 13, 2025	DP U-412			
	8439864	Mar 25, 2028	DP	Y		
	8461105	Apr 13, 2025	DP U-412			
	8906851	Aug 18, 2026	U-1313			
	9238076	Apr 15, 2024	DP U-412			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 005	9314447	May 31, 2033	DP U-1447			
	9314447	May 31, 2033	DP U-1448			
<u>FENTANYL - SUBSYS</u>						
N 202788 001	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	9241935	Jan 25, 2027	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	9364656	Sep 30, 2031	U-736			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001 >A>	9376505	Oct 20, 2023	DS DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001 >A>	9387191	Jul 21, 2030	DP			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	8586551	Jul 15, 2023	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	5808146	Nov 09, 2016	DS		NCE	May 27, 2021
	>A> 9387266	Nov 28, 2026	U-1879			
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N 022051 001	9320862	Nov 06, 2024	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	9333310	Oct 02, 2027	DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	8324266	May 28, 2030	U-1841		NP	Apr 25, 2019
	8703806	May 28, 2030	U-1841			
	8808713	May 28, 2030	DP U-1841			
	8815258	Mar 17, 2031	U-1841			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002					D-155	Feb 01, 2019
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	6774122	Jan 09, 2021	U-596		I-725	Feb 19, 2019
	6774122	Jan 09, 2021	U-1826			
	6774122*PED	Jul 09, 2021				
	7456160	Jan 09, 2021	U-596			
	7456160	Jan 09, 2021	U-1826			
	7456160*PED	Jul 09, 2021				
	8329680	Jan 09, 2021	U-596			
	8329680	Jan 09, 2021	U-1826			
	8329680*PED	Jul 09, 2021				
	8466139	Jan 09, 2021	U-596			
	8466139	Jan 09, 2021	U-1826			
	8466139*PED	Jul 09, 2021				
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002					I-731	Apr 27, 2019
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006	5980864	Nov 09, 2021	DS DP U-1119			
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	>A> 9402874	Aug 19, 2030	U-441			
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 001					PC	Jul 27, 2016
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 002					PC	Apr 25, 2016
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 003					PC	Apr 25, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLYCEROL PHENYL BUTYRATE - RAVICTI</u>						
N 203284 001	5968979	Jul 28, 2018	DS DP U-1378			
	9254278	Mar 09, 2032	U-1816			
	9326966	Mar 09, 2032	U-1816			
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001	6582678	Apr 24, 2018	DP			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	6582678	Apr 24, 2018	DP			
	6878721	Feb 25, 2025	DS DP U-1773			
<u>GRANISETRON - SANCUSO</u>						
N 022198 001	7608282	Jan 22, 2025	DP U-1011			
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183 001					NP	Nov 06, 2018
<u>HYDROCODONE BITARTRATE - ZOXYDRO ER</u>						
N 202880 001	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOXYDRO ER</u>						
N 202880 002	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOXYDRO ER</u>						
N 202880 003	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOXYDRO ER</u>						
N 202880 004	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOXYDRO ER</u>						
N 202880 005	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOXYDRO ER</u>						
N 202880 006	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9289391	Oct 30, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9289391	Oct 30, 2021	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	9296753	Oct 30, 2033	DS DP		D-165 I-729 I-736 I-737 ODE ODE	May 06, 2019 Mar 04, 2019 May 06, 2019 May 06, 2019 Mar 04, 2023 May 06, 2023
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	9295639	Sep 30, 2029	U-1756			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001					NCE	Jul 26, 2017
<u>LLOPERIDONE - FANAPT</u>						
N 022192 001					M-180	May 26, 2019
<u>LLOPERIDONE - FANAPT</u>						
N 022192 002					M-180	May 26, 2019
<u>LLOPERIDONE - FANAPT</u>						
N 022192 003					M-180	May 26, 2019
<u>LLOPERIDONE - FANAPT</u>						
N 022192 004					M-180	May 26, 2019
<u>LLOPERIDONE - FANAPT</u>						
N 022192 005					M-180	May 26, 2019
<u>LLOPERIDONE - FANAPT</u>						
N 022192 006					M-180	May 26, 2019
<u>LLOPERIDONE - FANAPT</u>						
N 022192 007					M-180	May 26, 2019
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 001					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 002					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	RE43932 RE43932*PED	Jul 16, 2018 Jan 16, 2019	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	>A> 6958335	Dec 19, 2021	U-791			
	>A> 6958335	Dec 19, 2021	U-1883			
	>A> 6958335*PED	Jun 19, 2022				
	7544799	Jul 16, 2018	DS DP	Y		
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	>A> 6958335	Dec 19, 2021	U-791			
	>A> 6958335	Dec 19, 2021	U-1883			
	>A> 6958335*PED	Jun 19, 2022				
	7544799	Jul 16, 2018	DS DP	Y		
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	6878721	Feb 25, 2025	DS DP U-1168			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	7410656	Oct 10, 2020	U-1222			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	7410656	Oct 10, 2020	U-1222			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	9265893	Sep 23, 2032	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	9265893	Sep 23, 2032	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u>						
N 021536 002	9265893	Sep 23, 2032	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
	9345750	May 18, 2031	DP U-1855			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
<u>INSULIN HUMAN - HUMULIN R</u>						
N 018780 004	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	>A> 9393372	Jul 04, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
>A>	9393372	Jul 04, 2029	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
>A>	9393372	Jul 04, 2029	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
>A>	9393372	Jul 04, 2029	DP			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	9339497	Jun 12, 2033	U-1848		ODE	Oct 22, 2022
	9364473	Jun 12, 2033	U-1856			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	9216969	Nov 08, 2026	DS DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	9233117	Mar 13, 2034	U-1631			
	9233118	Mar 13, 2034	U-1631			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 001	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 002	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 003	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	9216167	May 28, 2024	U-1800			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIIDRIA</u>						
N 205388 001	9278101	Jul 30, 2023	U-1518			
>A>	9399040	Jul 30, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004	9339504	Jul 02, 2028	DP U-1596			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	9284342	Sep 13, 2030	DS DP U-1470		D-158 D-159 D-160	Feb 12, 2019 Feb 12, 2019 Feb 12, 2019
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001					I-734	May 13, 2019
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002					I-734	May 13, 2019
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029		U-1801		
	8283369	Nov 26, 2028		U-1802		
	8283369	Nov 26, 2028		U-1804		
	8357713	Nov 26, 2028	DP	U-1801		
	8357713	Nov 26, 2028	DP	U-1802		
	8357713	Nov 26, 2028	DP	U-1803		
	8546436	Feb 29, 2032	DS DP			
	8546437	Apr 29, 2029		U-1803		
	9216179	Aug 02, 2030		U-1806		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	9283282	Oct 28, 2018	DS DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	9339489	Mar 14, 2034	DP	U-1850		
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	9339489	Mar 14, 2034	DP	U-1850		
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	9339489	Mar 14, 2034	DP	U-1850		
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114 001	9358338	Apr 27, 2035		U-1870		
	9370622	Sep 28, 2035		U-1870		
<u>LIFITEGRAST - XIIDRA</u>						
N 208073 001	>A> 7314938	Mar 10, 2025	DS DP		>A> NCE	Jul 11, 2021
	>A> 7745460	Nov 05, 2024	DS DP	U-1880		
	>A> 7790743	Nov 05, 2024		U-1880		
	>A> 7928122	Nov 05, 2024	DS DP			
	>A> 8084047	May 17, 2026	DS DP			
	>A> 8168655	May 09, 2029		U-1880		
	>A> 8367701	Apr 15, 2029	DP	U-1880		
	>A> 8592450	May 17, 2026		U-1880		
	>A> 8927574	Nov 12, 2030	DP			
	>A> 9085553	Jul 25, 2033	DP			
	>A> 9216174	Nov 05, 2024	DP			
	>A> 9353088	Oct 21, 2030	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	7407955	May 02, 2025	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	6303661	Apr 24, 2017	U-802			
	6340475	Sep 19, 2016	DP U-1852			
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6890898	Feb 02, 2019	U-803			
	7078381	Feb 02, 2019	U-803			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-803			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	6303661	Apr 24, 2017	U-802			
	6340475	Sep 19, 2016	DP U-1852			
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6890898	Feb 02, 2019	U-803			
	7078381	Feb 02, 2019	U-803			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-803			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	9265893	Sep 23, 2032	DP		M-176	Apr 22, 2019
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	>A> 8475414	Dec 28, 2030	DP U-1881		>A> NCE	Jul 27, 2021
	>A> 8882721	Jun 28, 2031	DP			
	>A> 8915888	Jun 08, 2030	DP U-1881			
	>A> 9072836	Mar 15, 2032	DP			
	>A> 9084853	Oct 05, 2031	DP			
	>A> 9308329	Dec 28, 2030	DP U-1881			
	>A> RE45313	Jul 12, 2020	DS DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	>A> 8475414	Dec 28, 2030	DP U-1881		>A> NCE	Jul 27, 2021
	>A> 8882721	Jun 28, 2031	DP			
	>A> 8915888	Jun 08, 2030	DP U-1881			
	>A> 9072836	Mar 15, 2032	DP			
	>A> 9084853	Oct 05, 2031	DP			
	>A> 9308329	Dec 28, 2030	DP U-1881			
	>A> RE45313	Jul 12, 2020	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001					>A> NCE	Jun 27, 2017
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	9370629	May 20, 2024	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	5900488	Jul 05, 2017	DS DP U-540			
	9199977	Sep 06, 2033	DS DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9259423	May 23, 2031			U-1822	
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9259423	May 23, 2031			U-1822	
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9259423	May 23, 2031			U-1822	
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9259423	May 23, 2031			U-1822	
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9259423	May 23, 2031			U-1822	
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	9265762	May 29, 2027	DP U-1820			
<u>MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR</u>						
N 202317 001	>A> 9382191	Mar 07, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MEGESTROL ACETATE - MEGESTROL ACETATE</u>						
A 203139	001				PC	Jan 24, 2016
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155	001	8410077	Mar 13, 2029	DP	ODE	Mar 10, 2023
		9200088	Mar 13, 2029	DP		
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029	001	9233184	Aug 01, 2027	DP		
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029	002	9233184	Aug 01, 2027	DP		
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664	001				PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664	002				PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842	001	9320714	Feb 03, 2029	DP		
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842	002	9320714	Feb 03, 2029	DP		
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678	001	>A> 9339472	Jul 13, 2025	DP	M-175	Apr 05, 2019
		RE44186	Jul 31, 2023	DS DP U-1097		
		RE44186	Jul 31, 2023	DS DP U-1838		
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678	002	RE44186	Jul 31, 2023	DS DP U-1097	M-175	Apr 05, 2019
		RE44186	Jul 31, 2023	DS DP U-1838		
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678	003	RE44186	Jul 31, 2023	DS DP U-1097	M-175	Apr 05, 2019
		RE44186	Jul 31, 2023	DS DP U-1838		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044	001	7326708	Nov 24, 2026	DS DP U-802		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044	002	7326708	Nov 24, 2026	DS DP U-802		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270	001	7326708	Nov 24, 2026	DS DP U-1227		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270	002	7326708	Nov 24, 2026	DS DP U-1227		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270	003	7326708	Nov 24, 2026	DS DP U-1227		
<u>METHOTREXATE - OTREXUP</u>						
N 204824	006	6746429	Apr 12, 2020	DP		
		8021335	Oct 04, 2026	DP		
		8480631	Mar 19, 2030	DP		
		8562564	Jan 24, 2026	DP		
		8579865	Mar 19, 2030	DP		
		8945063	Mar 19, 2030	DP		
		RE44846	Aug 10, 2019	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP			
	8945063	Mar 19, 2030	DP			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP			
	8945063	Mar 19, 2030	DP			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 001					ODE	Apr 08, 2023
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271 001	>A> 6559158	Nov 03, 2017	U-1185		>A> NP	Jul 19, 2019
	>A> 8420663	Sep 30, 2029	U-1185			
	>A> 8524276	Mar 10, 2031	DP			
	>A> 8956651	Mar 10, 2031	DP			
	>A> 9180125	Sep 30, 2029	DP U-1185			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	>A> 7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	>A> 7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	>A> 7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	>A> 7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	>A> 7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	>A> 7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	>A> 7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	9278105	May 12, 2031	U-282			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	6346532	Mar 27, 2022	DS DP			
	RE44872	Nov 04, 2023	U-1527			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	6346532	Mar 27, 2022	DS DP			
	RE44872	Nov 04, 2023	U-1527			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 001	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 002	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 003	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 004	7955619	Aug 12, 2028	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	9238108	Jan 22, 2027	DP			
	9278182	Feb 01, 2026	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 001	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 002	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 003	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NEBIVOLOL HYDROCHLORIDE; VALSARTAN - BYVALSON</u>						
N 206302 001	7803838	Aug 29, 2026	DP		NC	Jun 03, 2019
	7838552	Oct 04, 2027	U-185			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	9271975	Sep 09, 2031	U-528			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 005	9364564	Dec 26, 2027	DP			
<u>NITISINONE - ORFADIN</u>						
N 206356 001	>A> 9301932	Feb 28, 2033	DP U-1836			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	9265911	Jan 06, 2031	DP U-1824			
	9265911*PED	Jul 06, 2031				
	9279794	Feb 19, 2034	DP U-1823			
	9279794*PED	Aug 19, 2034				
	9295802	Jan 06, 2031	DP U-1226			
	9295802*PED	Jul 06, 2031				
<u>NITROGLYCERIN - GONITRO</u>						
N 208424 001	9101592	Mar 11, 2032	DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 001	7138390	Nov 16, 2022	DS DP		NCE	May 27, 2021
	8058267	Feb 21, 2022	U-1854		ODE	May 27, 2023
	8377916	Feb 21, 2022	U-1854			
	9238673	Jun 17, 2033	DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 002	7138390	Nov 16, 2022	DS DP		NCE	May 27, 2021
	8058267	Feb 21, 2022	U-1854		ODE	May 27, 2023
	8377916	Feb 21, 2022	U-1854			
	9238673	Jun 17, 2033	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001					M-173	Mar 18, 2019
<u>OMEGA-3-ACID ETHYL ESTERS TYPE A - OMTRYG</u>						
N 204977 001					NCE	Apr 23, 2019
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2017	DP		NCE	May 05, 2019
	5948818	May 13, 2017	DP			
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N 022056 001	5900424	May 04, 2016	DS U-864			
	5900424	May 04, 2016	DS U-1817			
	6428810	Nov 03, 2019	DP U-864			
	6428810	Nov 03, 2019	DP U-1817			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N 022056 002	5900424	May 04, 2016	DS U-864			
	5900424	May 04, 2016	DS U-1817			
	6428810	Nov 03, 2019	DP U-864			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	5840737	Jul 15, 2016	U-588			
	6489346	Jul 15, 2016	DP U-588	Y		
	6645988	Jul 15, 2016	DP	Y		
	6699885	Jul 15, 2016	U-588	Y		
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-588			
	RE45198	Jul 15, 2016	U-588			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	5840737	Jul 15, 2016	U-623			
	5840737	Jul 15, 2016	U-624			
	6489346	Jul 15, 2016	DP U-623	Y		
	6489346	Jul 15, 2016	DP U-624	Y		
	6645988	Jul 15, 2016	DP	Y		
	6699885	Jul 15, 2016	U-623	Y		
	6699885	Jul 15, 2016	U-624	Y		
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
	RE45198	Jul 15, 2016	U-623			
	RE45198	Jul 15, 2016	U-624			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 001	7399772	Jul 15, 2016	U-588			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 002	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001					ODE	Nov 13, 2022
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002					ODE	Nov 13, 2022
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	9259388	Nov 06, 2029	U-1644			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	>A> 7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	>A> 7771707	Mar 24, 2025	DP			
	>A> 8449909	Mar 24, 2025	DP			
	>A> 8557291	Mar 21, 2025	DP			
	>A> 8758813	Jun 10, 2025	U-1556			
	>A> 8840928	Jul 07, 2023	DP U-1556			
	>A> 9044398	Jul 07, 2023	DP			
	>A> 9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	>A> 7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	>A> 7771707	Mar 24, 2025	DP			
	>A> 8449909	Mar 24, 2025	DP			
	>A> 8557291	Mar 21, 2025	DP			
	>A> 8758813	Jun 10, 2025	U-1556			
	>A> 8840928	Jul 07, 2023	DP U-1556			
	>A> 9044398	Jul 07, 2023	DP			
	>A> 9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	>A> 7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	>A> 7771707	Mar 24, 2025	DP			
	>A> 8449909	Mar 24, 2025	DP			
	>A> 8557291	Mar 21, 2025	DP			
	>A> 8758813	Jun 10, 2025	U-1556			
	>A> 8840928	Jul 07, 2023	DP U-1556			
	>A> 9044398	Jul 07, 2023	DP			
	>A> 9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	>A> 7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	>A> 7771707	Mar 24, 2025	DP			
	>A> 8449909	Mar 24, 2025	DP			
	>A> 8557291	Mar 21, 2025	DP			
	>A> 8758813	Jun 10, 2025	U-1556			
	>A> 8840928	Jul 07, 2023	DP U-1556			
	>A> 9044398	Jul 07, 2023	DP			
	>A> 9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	>A> 7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	>A> 7771707	Mar 24, 2025	DP			
	>A> 8449909	Mar 24, 2025	DP			
	>A> 8557291	Mar 21, 2025	DP			
	>A> 8758813	Jun 10, 2025	U-1556			
	>A> 8840928	Jul 07, 2023	DP U-1556			
	>A> 9044398	Jul 07, 2023	DP			
	>A> 9248195	Jul 07, 2023	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE - KOVANAZE</u>						
N 208032 001	>A> 6413499	Mar 20, 2020	U-1876		NC	Jun 29, 2019
	>A> 8580282	Apr 02, 2030	DP U-1876			
	>A> 9308191	Apr 02, 2030	DP U-1876			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9066980	Jan 30, 2024	DP U-528			
	9066980*PED	Jul 30, 2024				
	9125905	Jan 30, 2024	DP			
	9125905*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
<u>PAROXETINE MESYLATE - PEKEVA</u>						
N 021299 001	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEKEVA</u>						
N 021299 002	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEKEVA</u>						
N 021299 003	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEKEVA</u>						
N 021299 004	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	7598271	May 04, 2025	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
	8772497	May 16, 2026	DS			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	>A> 8658205	Jun 18, 2019	DP			
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159 001					NPP	Mar 18, 2019
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	6756393	Mar 06, 2021	DS DP		NCE	Apr 29, 2021
	6815458	Mar 06, 2021	DS DP U-1843			
	7115634	Oct 06, 2021	DS DP			
	7601740	Jun 17, 2027	DS DP			
	7659285	Aug 24, 2026			U-1844	
	7732615	Jun 03, 2028	DS DP			
	7858789	Dec 13, 2020	DS DP			
	7923564	Sep 26, 2025	DS DP			
	8110574	Dec 13, 2020	DS DP			
	8618130	Jan 15, 2024			U-1845	
	8921393	Jan 15, 2024			U-1846	
	9296694	Mar 06, 2021	DS DP			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9358297	Jun 24, 2031	DP U-1454			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A 202206 004					PC	May 18, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A 202206	006				PC	Jan 01, 2017
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307	001	5288726	Apr 14, 2017	DS DP U-991	>A> M-182	Jul 12, 2019
		5288726*PED	Oct 14, 2017		>A> PED	Jan 12, 2020
		8404703	Jan 02, 2023	U-1381		
		8404703*PED	Jul 02, 2023			
		8569325	Jan 02, 2023	U-1381		
		8569325*PED	Jul 02, 2023			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307	002	5288726	Apr 14, 2017	DS DP U-991	>A> M-182	Jul 12, 2019
		5288726*PED	Oct 14, 2017		>A> PED	Jan 12, 2020
		8404703	Jan 02, 2023	U-1381		
		8404703*PED	Jul 02, 2023			
		8569325	Jan 02, 2023	U-1381		
		8569325*PED	Jul 02, 2023			
<u>PROPOFOL - PROPOFOL</u>						
A 205307	001				PC	Feb 24, 2016
<u>REGADENOSON - LEXISCAN</u>						
N 022161	001	9289446	Jun 22, 2019	DP U-116		
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA</u>						
N 203324	001				NP	Apr 15, 2019
					ODE	Apr 15, 2023
					>A> ODE	Jul 15, 2023
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA VISCOUS IN DEXTRAN 20%</u>						
N 203324	002				NP	Apr 15, 2019
					ODE	Apr 15, 2023
					>A> ODE	Jul 15, 2023
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361	001	9271968	Feb 27, 2026	DP		
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554	001	9271968	Feb 27, 2026	DP		
<u>RIVAROXABAN - XARELTO</u>						
N 022406	001	7157456	Aug 28, 2024	DS DP U-1301		
		7157456	Aug 28, 2024	DS DP U-1302		
<u>RIVAROXABAN - XARELTO</u>						
N 022406	002	7157456	Aug 28, 2024	DS DP U-1301		
		7157456	Aug 28, 2024	DS DP U-1302		
<u>RIVAROXABAN - XARELTO</u>						
N 022406	003	7157456	Aug 28, 2024	DS DP U-1301		
		7157456	Aug 28, 2024	DS DP U-1302		
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533	006	7828787	Oct 18, 2025	DP		
		7857802	Nov 28, 2026	DP		
		8118802	May 18, 2023	DP		
		8162915	May 23, 2024	DP		
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533	007	7828787	Oct 18, 2025	DP		
		7857802	Nov 28, 2026	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 007	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 001					>A> PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 002					>A> PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 003					>A> PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 004					>A> PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 002	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 003	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004	6858618	Dec 17, 2021	U-618		I-732	May 27, 2019
	6858618	Dec 17, 2021	U-1032		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 005					ODE	May 27, 2023
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 001	9216178	Nov 01, 2032	DP			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 002	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	9216178	Nov 01, 2032	DP			
	RE43797	Nov 17, 2024	U-1590			
	RE43797*PED	May 17, 2025				
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001	RE44186	Jul 31, 2023	DS DP U-995		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1837			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002	RE44186	Jul 31, 2023	DS DP U-995		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1837			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 001	9095509	Dec 06, 2030	DP			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 002	9095509	Dec 06, 2030	DP			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9353103	Jul 28, 2026	U-1467		M-171 M-179	Feb 26, 2019 May 20, 2019
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	7326708	Nov 24, 2026	DS DP U-802			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9284342	Sep 13, 2030	DS DP U-1470			
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	>A> 7964580	Mar 26, 2029	DS DP U-1470		NCE	Jun 28, 2021
	>A> 8334270	Mar 21, 2028	DS DP U-1470			
	>A> 8575135	Nov 16, 2032	DS DP U-1470			
	>A> 8580765	Mar 21, 2028	DS DP U-1470			
	>A> 8618076	Dec 11, 2030	DS DP U-1470			
	>A> 8633309	Mar 26, 2029	DS DP U-1470			
	>A> 8735372	Mar 21, 2028	U-1470			
	>A> 8889159	Mar 26, 2029	DP U-1470			
	>A> 8921341	Nov 16, 2032	DS DP U-1470			
	>A> 8940718	Nov 16, 2032	DS DP U-1470			
	>A> 9085573	Mar 21, 2028	DS DP U-1470			
	>A> 9284342	Sep 13, 2030	DS DP U-1470			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001					I-728	Mar 31, 2019
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	9272137	Sep 07, 2027	DP			
	9327114	Oct 08, 2032	DP U-1328			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	6715485	Mar 03, 2020	DP			
	7975690	Aug 18, 2025	DP U-1809			
	8047202	Jul 02, 2023	DP			
	8327844	Oct 03, 2023	U-1809			
	8550073	Oct 22, 2029	DP			
	8555877	Mar 03, 2020	DP			
	8590530	Sep 15, 2025	DP U-1809			
	8875704	Apr 07, 2028	DP U-1809			
	8899229	Aug 18, 2030	DP			
	8978647	Dec 06, 2030	DP			
	9108015	Sep 15, 2025	DP			
	9119932	Apr 23, 2024	DP			
<u>T AFLUPROST - ZIOPTAN</u>						
N 202514 001	5886035	Dec 18, 2022	DS DP U-778			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2020	DS DP U-1320			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	9289586	Feb 26, 2027	U-1390			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	9295675	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	9295675	Feb 11, 2034	DP U-1531			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6525060	Dec 02, 2019	DS DP U-1171			
	6525060	Dec 02, 2019	DS DP U-1860			
	6525060	Dec 02, 2019	DS DP U-1862			
	6525060	Dec 02, 2019	DS DP U-1863			
	7250419	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1860			
	7250419	Dec 02, 2019	DS DP U-1864			
	7250419	Dec 02, 2019	DS DP U-1865			
	7250419	Dec 02, 2019	DS DP U-1866			
	7250419	Dec 02, 2019	DS DP U-1867			
	7265124	Jul 09, 2021	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1860			
	7265124	Jul 09, 2021	DS DP U-1868			
	7265124	Jul 09, 2021	DS DP U-1869			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	>A> 6525060	Dec 02, 2019	DS DP U-1171			
	>A> 6525060	Dec 02, 2019	DS DP U-1860			
	>A> 6525060	Dec 02, 2019	DS DP U-1862			
	>A> 6525060	Dec 02, 2019	DS DP U-1863			
	7250419	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1860			
	7250419	Dec 02, 2019	DS DP U-1864			
	7250419	Dec 02, 2019	DS DP U-1865			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	7250419	Dec 02, 2019	DS DP U-1866			
	7250419	Dec 02, 2019	DS DP U-1867			
	7265124	Jul 09, 2021	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1860			
	7265124	Jul 09, 2021	DS DP U-1868			
	7265124	Jul 09, 2021	DS DP U-1869			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	9254328	Mar 13, 2026	DP			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 001	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 001	6770660	Jun 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 002	6770660	Jun 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 003	6770660	Jun 01, 2023	U-1444			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	6956027	Mar 25, 2023	DS		NCE	Nov 06, 2017
	6956041	Dec 08, 2020	DP			
	7091208	Dec 08, 2020	U-247			
	7265221	Dec 08, 2020	DS			
	7301023	May 23, 2022	DS			
	RE41783	Dec 08, 2020	DS			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	9339507	Mar 10, 2028	DP			
	9358240	May 05, 2028	U-1849			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	>A> 9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	>A> 9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	>A> 9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	>A> 9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	9283233	Apr 13, 2030	U-1821			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	9333310	Oct 02, 2027	DP		M-172	Feb 24, 2019
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	9333310	Oct 02, 2027	DP			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001					ODE	Dec 11, 2022
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	RE42353	Jun 27, 2022	DS DP			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	RE42353	Jun 27, 2022	DS DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 001	9375478	Jan 30, 2035		U-1857		
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030		U-1835	ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030		U-1835	ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030		U-1835	ODE	Apr 11, 2023
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388 001	9278961	Dec 15, 2028		U-1825		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	9227946	Jun 15, 2027		U-1668		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	9227946	Jun 15, 2027		U-1668		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	9227946	Jun 15, 2027		U-1668		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	9227946	Jun 15, 2027		U-1668		
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 001					PC	Sep 18, 2016
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 002					PC	Sep 18, 2016
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	9265720	May 13, 2030		U-674		
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	9265720	May 13, 2030		U-674		
<u>ZOLPIDEM TARTRATE - ZOLPIMIST</u>						
N 022196 001	8236285	Aug 07, 2032	DS DP	U-70		

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 36th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>